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Gliomas present a significant clinical burden.  In 2008, there were 22,000 new 
cases of brain and nervous system cancers in adults. The five-year survival rate is 
markedly poor with only 35% of diagnosed patients surviving. Nearly 20% of the tumors 
were glioblastoma exhibiting an invasive phenotype that has even poorer prognosis. This 
results in malignant glioma being the second leading cause of cancer death in middle 
aged adults. Primary malignant brain tumors are also the second leading cause of cancer 
death in adolescents. Surgical resection has poor outcomes, and chemotherapy and local 
therapy do not significantly affect survival.  There is an urgent need to develop 
alternative, more effective therapy for glioma and enhance current treatments for better 
prognosis. 
The primary reason for poor outcomes for glioma after therapy is their invasive 
nature which, when combined with the need to minimize amount of normal tissue 
damaged to preserve neural function, almost always leads to incomplete resection.  While 
the standard chemotherapy with temozolomide has enhanced clinical options, this is a 
cytotoxic agent whose ability to be effective is hampered by invasive tumor fronts being 
surrounded by normal brain tissue, complicating dosing, delivery and effectiveness.  
Therefore it would be useful if there were effective ‘anti-invasive’ agents that 
limit the migration of tumor away from the primary site.  This ability would enhance the 
outcomes of surgical resection, and make chemotherapy and radiation more likely to 
succeed due to the proximity of tumor regions without risking damage to normal brain.  
Unfortunately, while there are several candidate cytotoxic agents such as temozolomide, 
BCNU, and doxorubicin, currently there are no effective anti-invasive agents for glioma 
in the clinic.  If an effective anti-invasive agent were identified, we hypothesize that a 
combinatorial therapy, with an anti-invasive agent that limits the aggressive invasion of 
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glioma and an effective cytotoxic agent delivered preferentially to tumors would 
significantly increase the success of treatment. 
To test this hypothesis, we proposed to identify an anti-invasive, but not cytotoxic 
agent by using in vitro screening methods. Further, we encapsulated this compound in 
order to passively target brain tumor to test the efficacy of the compound in vivo. Lastly, 
we determined if use of an anti-invasive agent will enhance the efficacy of current 
chemotherapeutic compounds in vivo.  
 In all, this thesis encompasses work surrounding the invasion of glioma. Through 
determination of a compound that will halt invasion in a glioblastoma model without 
causing cytotoxicity (Chapter 2) we identified a compound, Imipramine Blue. Then, 
using liposomes and in vitro and in vivo invasion quantification methods we show that 
this compound halts invasion and can assist the efficacy of doxorubicin to enhance 
survival (Chapter 3). In Chapter 4, we co-encapsulated IB and doxorubicin in a single 
nanoparticle and showed again, enhanced survival but with a disadvantage in survival 
time. Last, in Chapter 5, we performed a series of experiments, and, along with 
information from collaborators, determined a plausible mechanism of action of 
Imipramine Blue through binding of NADPH Oxidase 4. This thesis offers a new method 
of treatment and validation of the hypothesis that halting invasion can, in fact, enhance 






1.1 Brain cancers: types and treatments 
Brain tumors only affect a small proportion of the adult population, however, the 
most malignant form, glioblastoma, has such poor prognosis that they are a significant 
clinical problem. The incidence of brain tumors is about 14 in every 100,000 people in 
the United States [1]. This is a relatively low proportion when compared to more 
common cancers, such as breast (124 out of 100,000 women) [2] and prostate (166 per 
100,000 men) [3]. However, the success of treatment of these latter cancers is much 
better than that seen with brain tumors. The 5-year survival rate after brain tumor 
diagnosis is around 35%, as compared to an average 5-year survival rate in breast cancer 
of 89% and prostate of nearly 100%. This progress is due to several reasons: 1. There is 
more funding given yearly to development of new treatments and changes to current 
clinical treatments and therefore 2. There is more research going into how these cancers 
grow and develop. 3. Many of these non-central nervous system tumors share 
commonalities of treatment that are not shared by brain tumors [4, 5].  
Brain tumors are different from other cancers treatment and progression-wise due 
to the environment in which these tumors grow, how they interact with the host 
environment, and the types of cells from which they develop [6]. For these reasons, brain 
tumors present a unique and difficult challenge for cancer researchers and neurologists 
alike. This has led to failure of treatments commonly used with other cancers when brain 
tumor treatment is attempted. Hence, it is difficult to advance treatment and survival in 
this regard. In the following introduction, I will discuss the types of brain tumors and the 
specific difficulties involved in treatment of the most malignant of these: glioblastoma 
(GBM). Next, I will highlight the attributes of glioblastoma with an in depth look at 
cancer cell invasion with a focus on clinical implications of invasion and methodology 
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for studying this phenomenon. Next, I will discuss particular mechanisms involved in 
glioma cell invasion and migration with a focus on those relevant to the dissertation 
work.  From this, I will move onto a discussion of the types of compounds currently 
available as anti-invasive agents preclinically and clinically. Last, I will describe 
nanocarriers and how they can and are used to assist in delivery of compounds for cancer. 
In all, we will see that development of agents for brain tumors specifically to halt 
invasion is a necessary entity and a possible paradigm shift in the battle against this 
deadly disease. 
1.1.1 Types of primary brain tumors 
Brain tumors most often develop from glial cells in the brain and hence, are 
termed “gliomas”. More specifically, the majority of brain tumors in adults originate 
from astrocytes, leading to the subtype term astrocytoma. There are differing grades of 
tumors but, unlike non-central nervous system tumors, brain tumors are not staged 
because they do not metastasize outside of the brain. Grade I and II brain tumors tend to 
be easier to treat while Grade III and IV are more deadly. Grade I (pilocytic 
astrocytoma), Grade II (astrocytoma), Grade III (anaplastic astrocytoma) and grade IV 
(glioblastoma) tumors are defined by the degree of abnormality of the nuclei and 
involvement of anatomical features [7, 8]. Glioblastoma, the most common form of 
primary brain tumor, is the most deadly because it exhibits all of these features resulting 
in extremely rare survival after diagnosis. 
1.1.2 Anatomy of GBM  
The anatomy of glioblastoma has been well-studied and contains many particular 
attributes that account for the ineffective treatment of the disease. In 1938 Hans Scherer 
identified key features that were apparent in glioblastoma, which were henceforth named 
Scherer’s structures, and include: 1) perivascular invasion, 2) perineuronal satellitosis, 3) 
subpial spread, and 4) white matter tract invasion [9]. These structures are optimized by 
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the glioma for diffuse spread of disease. The reasons for this pattern of formation have 
been partially attributed to protein preference, chemokine gradients, fluid flow patterns, 
and cell-cell interactions through a variety of studies [10-15]. However, there has yet to 
be a compound that can combat this type of tumor development. More recently, a more 
microscopic view of glioblastoma development has revealed particular sub structures in 
the tumor bulk known as pseudopalisading necrosis [16]. This distinguishing feature 
results from the growth of small groups of cells resulting in hypoxia (low oxygen levels) 
and cell death at the center, followed by migration away from this site. This is later 
followed by induction of growth factors and angiogenesis as the tumor cells survive, 
selecting for the most invasive and malignant cancer cells [17]. These regions can be seen 
throughout the tumor bulk as well as in the invading fronts. 
1.1.3 Treatment of Glioblastoma 
Current treatment of glioblastoma (GBM) is difficult and results in high 
recurrence rates. Upon display of symptoms of a brain tumor (seizure, chronic headache, 
loss of consciousness, loss of motor/sensory function) a patient will undergo MRI for 
detection of the tumor. This is followed by a host of treatments to remove the bulk of the 
tumor if possible [18]. Patients are then monitored for recurrence. This is standard 
protocol for treatment of glioma regardless of grade [19]. This line of treatment can often 
lead to decreased quality of life. Last, if tumor recurs, there are last line treatments given 
after which there is no ability to treat further. The treatment of glioma is varied 
depending on grade, but this discussion will focus on the treatment of the most aggressive 
form: glioblastoma (GBM). 
1.1.3.1 Clinical treatments 
Clinically there have been many changes in the treatment approaches to GBM, 
but there have not been any major advances in the survival of these patients [19-21]. The 
common treatment after detection has several components including: 1. Surgical 
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resection of tumor from the primary site, 2. Lining of the primary site with carmustine 
wafers designed to kill cells in the close proximity 3. Metronomic oral temozolmide 
chemotherapy and 4. Radiotherapy to the brain. As mentioned previously, in the case of 




Figure 1.1: Current treatment paradigm for glioblastoma including resection, 
radiation and chemotherapy with temozolomide, a DNA alkylating agent. After this 
treatment fails, anti-angiogenics are given to halt glioma growth and eventually lead to 
recurrence. 
 
Surgical Resection is the removal of the tumor from the primary site by a skilled 
neurosurgeon. The general procedure involves craniotomy followed by suction of tumor 
from the site. Though there are experimental imaging agents, such as optically visible 
fluorescent dyes coupled with intravital magnetic resonance imaging of the brain for 
guidance and assessment of accuracy and completion, this is not an exact science [19, 22-
24]. The skill of the neurosurgeon is vital to success and speaking with neurosurgeons 










communications]. Once the tumor is removed, surgeons often remove extra tissue 
between 2-10 mm of the border in an attempt to remove any extraneous cancer cells [25].   
Local chemotherapy is applied in the resection site after removal of the bulk in 
the form of Poly (lactic-co-glycolic acid)-BCNU wafers that slowly degrade and release 
the chemotherapeutic BCNU (Carmustine®) into the resection site [26].  This technology 
has been reported to yield a slight increase in survival times, as opposed to leaving the 
tumor site empty, however, it still does not allow adequate decrease in recurrence. Use of 
this BCNU wafer has become less commonplace due to both cost-benefit analysis and 
preference of use by surgeons [27, 28]. Since development in the 1990’s, many 
alternative therapies have been developed pre-clinically to fill the site of resection, but 
thus far there is not a better option for local chemotherapy [29].  However, stereotactic 
radiosurgery (SRS) is being used clinically with some success in reducing regrowth of 
tumor and is a viable replacement after bulk resection [25, 30]. 
Systemic Chemotherapy in the form of orally delivered temozolomide (TMZ) is 
given metronomically to patients post-surgery (as well as to those bearing non-surgically 
accessible tumors). Findings in the New England Journal of Medicine in 2005 showed 
that coupling of this treatment with current resection and radiotherapy yields a significant 
increase in survival time compared to resection alone [31]. Other chemotherapeutics have 
been tried but are unsuccessful in the clinic. Most promising of which, in animal studies, 
is liposomal Doxorubicin (Doxil ®, Caelyx®), however, clinical studies using free 
Doxorubicin have tainted use of this product in brain tumor patients due to toxicity [32]. 
Temozolomide (TMZ) is a DNA-alkylating agent which acts to induce apoptosis in 
cancer cells through randomly quieting genes in an epigenetic manner. Though effective 
overall, many patients are resistant to TMZ due to upregulation or overactivity of the 
gene methyl-guanine-methyl-transferase (MGMT), which acts to undo the methylation 
performed by TMZ thus reducing its effect [33]. Patients are often screened for 
overactivity of this gene after resection to determine use of this drug [34]. Another 
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problem with TMZ is the side effects from the oral delivery [35], however, this effect has 
been reduced due to the metronomic on/off scheduling of the treatment. TMZ has 
benefits reported in pre-clinical research, showing inhibition of invasion of glioma cells, 
though there are contradictory reports citing TMZ as a cause of far-distant metastases in 
the brain [36, 37]. These discrepancies are likely due to the response of different tumor 
models and patients to the compound and resistances therein. 
Radiotherapy involves the use of gamma-irradiation in order to induce cell death 
through DNA damage. This therapy is used in over 50% of all cancer patients at some 
point during treatment and has been in use in cancer for almost a century [38]. In brain 
tumors, this treatment works by sending gamma rays through to the site of the tumor to 
directly damage DNA, but in longer-lasting effects, create free radicals which can go on 
to cause further damage [39, 40]. Radiation therapy involves not just radiation of the 
tumor, as would be desirable, but irradiation of an area which can include both tumor 
tissue and healthy brain tissue. This treatment can, therefore, be difficult on a patient with 
neurological detriments reported after treatment [41]. Radiation can result in death of 
large amounts of the tumor, however, recent discoveries suggest that radiation may 
actually be causing side effects which can aid in recurrence. For example, research in rats 
has shown that irradiating the mammary fat pad prior to injection of non-malignant 
pancreatic cancer cells causes them to have a more malignant phenotype leading to 
invasion [42]. Additionally, glioma cells exposed to radiation in vitro show increased 
invasion post treatment, indicating enhanced malignancy of disease [43]. Further, 
radiation leads to many side effects associated with cancer malignancy and disease 
progression, including the creation of free radical species, degradation of the extracellular 
matrix, inflammation and immune cell recruitment, and increased blood flow to the area 
[40, 44, 45].  
Anti-angiogenic therapy has traveled a bumpy road in the past ten years since its 
advent. Most therapeutics were designed as monoclonal antibodies against Vascular 
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Endothelial Growth Factor (VEGF), this drug acts by scavenging VEGF and preventing 
the tumor from promoting angiogenesis through endothelial cell recruitment and tube 
formation [46]. The most common agent, bevacizumab (Avastin ®), was first successful 
in colorectal cancer yielding phenomenal results which led to clinical trials in many other 
cancers [47, 48]. However, a growing body of evidence suggests that for many cancers, 
including those of the brain, bevacizumab is actually detrimental to the ability to “cure” 
the disease [49]. This has been attributed to later effects occurring from loss of 
vasculature. Therefore, there has been a move towards normalization of tumor 
vasculature in place of complete removal to prevent these effects [50]. Thus, in brain 
tumor treatment, use of these compounds is only used after other treatments have failed 
repeatedly to prolong life. 
1.1.3.2 Experimental treatments 
Many experimental treatments involve combinations of many existing FDA-
approved drugs for both brain cancer and other forms of cancer [51-54]. To date, none of 
these combinations has been stronger at halting the progression of disease better than the 
currently implemented therapy. In the clinical trial setting, there has been a push for 
novel cancer prevention agents (EGCG, antioxidants, curcumin), novel anti-invasive 
agents (Marimastat®), and novel inhibitors of specifically active proteins (EGFR, Src, 
PDGF) [55-58]. Cancer preventive agents range in activity, including simple antioxidants 
which act to scavenge free radicals from areas of potential tumor initiation, more 
advanced compounds which may have antioxidant activity, and compounds that work 
downstream of antioxidant induced changes (e.g. NFκB activation) [59]. These 
compounds are difficult to move to market because they are “preventive” in nature and 
thus, if not included in dietary needs, could be difficult to both study clinically and 




1.1.4 Physiology of GBM  
Hanahan and Weinberg defined the hallmarks of cancer ten years ago and recently 
offered a revised version to account for the ever growing list of implicated biological 
changes that contribute to progression of disease [60, 61]. Like all cancers, brain cancer 
cells are defined by the many malignant characteristics inherent to the disease, including 
an unedited proliferative capacity, a resistance to inhibitory and apoptotic signaling 
mechanisms, and a self-sufficiency in growth factors. Furthermore, there are attributes 
that involve the interaction of the cells with their environment including inflammation, 
angiogenesis, and invasion. Outside of the hallmarks of cancer typically applied to the 
disease there are other commonly recurring themes in glioblastoma such as hypoxia, 
extracellular matrix properties (e.g. stiffness), and stromal cell interactions which can 
progress the disease [61, 62].  Further, these properties all affect the development and 
implementation of therapeutics.  
1.1.4.1 Cell growth and death 
The ability of tumor cells to proliferate unendingly is a vital step in their growth 
and malignancy. Further, cancer cells have the ability to evade apoptosis through 
ignoring death signals (e.g. TRAIL ligand binding, caspase activation), but also through 
self-sufficiency of growth signals (e.g. EGF, PDGF, VEGF) [63]. These changes are the 
primary targets of many anti-tumor agents. Taxanes inhibit cell division. Anthracyclines, 
alkylating agents, and radiation induce DNA damage leading to apoptosis. Growth 
receptor inhibitors inhibit self-sustaining growth and can lead to apoptosis.  Death 
receptor inducers directly trigger apoptotic signaling [64]. While the other classes are 
universally used, the receptor targeted molecules are highly specialized and often, the 
efficacy of these compounds can be pre-screened based on inherent tumor mutations 




1.1.4.2 Inflammatory microenvironment 
Recently, the hallmarks of cancer were amended to include inflammation and 
interactions with the host immune system as part of the disease progression [66]. In 
cancer, the immune microenvironment plays an important role in the ability of the disease 
to persist and invade. In systemic cancers, this is vital for metastasis and proliferation. It 
is proposed that the cancer actually acts to train T-cells in the immune system creating an 
immunoprivileged microenvironment in which the cancer can persist. In the brain, an 
already immunoprivileged organ, this is particularly striking as immune cells infiltrate 
and assist in development of disease [67]. There has been evidence of T-cell infiltration 
into glioma from systemic circulation as well as macrophage and dendritic cell homing 
[68]. Further, the inflammatory microenvironment of the brain is highly activated during 
glioma progression. Reactive astrocytes and microglia can be found throughout the tumor 
bulk. These reactive glial cells have been implicated in enhancing secretion of many 
chemokines and growth factors that lead to a more invasive tumor phenotype. Astrocytes 
are involved in crosstalk with tumor cells that, through an uPAR mediated mechanism, 
causes increased secretion of matrix metalloproteinases [69]. Microglia are known to 
secrete CXCL12 and EGF, which can cause increased tumor cell proliferation, 
angiogenesis, invasion and reduced apoptosis [70, 71]. In all of these cases, the glial cells 
are initiating inflammatory responses to the tumor and thereby can increase its 
malignancy. This response causes difficulties when translating in vitro or preclinical 
study results to in vivo or human neoplasms. 
1.1.4.3 Sustained angiogenesis 
Angiogenesis is a hallmark of the most malignant forms of brain cancer and is 
nicely reviewed in [72]. As a tumor develops the individual cells begin to proliferate at a 
high rate, until eventually, there is not enough nutrient supply to sustain the cells. At this 
point, the cells either die via necrosis, leading to the trademark necrotic cores of solid 
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tumors and the pseudopalisading necrosis of glioblastoma, or they begin to recruit blood 
supply [72]. This can either happen through co-option of nearby blood vessels or through 
neo-angiogenesis by tumor cells [73]. The angiogenesis resulting from endothelial cell 
recruitment through growth factors such as VEGF or angiopoetin results in sustained 
angiogenesis. These factors are highly expressed in glioblastoma [74]. This process is 
similar to that seen during wound healing and development, and thus, is highly 
disorganized and leads to the altered vasculogenic state of tumor as compared to healthy 
tissue. This disorganization is advantageous for targeting and will be discussed further in 
the nanocarrier delivery section. There have been many therapeutics aimed at inhibiting 
angiogenesis and thereby starving the tumor of nutrients [75]. However, more recently, 
the idea of ablating the vasculature has met high criticism because of the ensuing tissue 
invasion and increased malignancy of tumors once this treatment has occurred [49, 76]. 
Further, once the vasculature has been removed, systemic delivery to the tumor is lost as 
the primary conduits are gone. Therefore, there has been a recent push from the tumor 
angiogenesis community to move more towards a model of vasculature normalization 
and away from eradication [50]. In this way, it is proposed that delivery of 
chemotherapeutic agents can be more steadily delivered and the tumor almost maintained 
in a quiescent state, as opposed to enhancing the invasive potential. 
1.1.4.4 Tissue invasion 
Complementary to angiogenesis is invasion of cancer cells into healthy tissue. 
Without invasion, it would be difficult for cancer cells to recruit and allow formation of 
blood vessels [77]. In glioblastoma, the histopathalogical feature of pseudopalisading 
necrosis is a result of a multistep process whereby cancer cells proliferate, necrose, 
invade, and then secrete blood vessel recruitment factors [16]. Invasion will be discussed 




1.1.5 Animal models of glioblastoma 
There is no consensus on the appropriate model for glioblastoma in the literature 
[78-81]. However, there are certain attributes and factors that must be taken into account 
when deciding on the appropriate model. The choice depends largely on the application 
and outcome measures desired. The models fall into several categories. There are 
implantable, or injected models, and inducible, or external stimulus driven models; 
xenograft, human tumor in an immunocompromised animal, or syngeneic, where species 
are the same for tumor and host; and orthotopic, within the brain, and flank models which 
are location dependent. These categories are not mutually exclusive and the cost and 
benefits along with examples of each are listed in Table 1.1.  
 




Model Benefits Drawbacks Examples
Xenograft
Human model, derived 
from patient GBM
Immunocompromised




Intact immune system, 
efficient gliomagenesis,
invasive
Rodent derivation, C6, 9L, RT2, GL261
Implantable
Consistent growth and 
location, efficient 
gliomagenesis
Quick growing, don’t 




Better mimic normal 
tumor development
Wait time can be long 
and varied, inconsistent 









with human GBM 
features
Only occurs in dogs and 
non-human primates, 
logistically difficult
Canine GBM in 
Boxers
Orthotopic
Tumor grows in its 
normal environment
Tumor size is limited, 
imaging in the head is 
difficult
Any implantable or 
inducible model
Flank
Imaging is simple, tumor 
can grow to human-size







1.1.5.1 Selection of a model of glioblastoma 
The difficulty in selecting a model is to determine how closely they resemble the 
human form of glioblastoma and how closely they mimic the genetic make-up of human 
glioblastoma. Further, it is important to know what attribute of glioblastoma you are 
interested in testing be it invasion, angiogenesis, or proliferation. Several of the most 
common models are highlighted in Table 1.2 with their derivations. The most widely 
used model of GBM for testing is U87MG. This is a human derived cell line from a 
female patient in 1966 [83]. This cell line is popular for its invasive phenotype in vitro 
however, upon cortical implantation in nude mice, it is not very invasive. Further, as with 
all xenograft, human models of glioma, the immune system must be compromised in the 
animal and this can affect outcomes of experiments. Rodent models of glioma are 
generally created through induction of tumor by chemical means (BCNU) or viral 
infection (RSV) followed by maintenance in culture [78]. These models have the 
appropriate immune respsonse to cancer which can aid in its development, and they are 
also more robust in vivo due to minimization of tumor rejection by the host. Further, 
many of these models show invasive phenotypes to varying degrees including RT2, 
GL261, and C6. Newer models of glioblastoma involve development of genetically 
engineered mice (GEM), in which an oncogene can be turned on and a tumor will begin 
to develop [79, 81]. These models more closely resemble the development and 
progression of glioma in humans (unlike the implantation models which grow very 












1.1.5.2 Tumor visualization methods 
The ability to visualize the tumor once growing in an animal model is of high importance 
because it can dictate the type of information and measures used in a single study. This 
can weigh heavily on model selection depending on the scope of the research. There are 
two main categories of techniques that include in vivo live imaging and ex vivo 
postmortem imaging that can be used for analysis. The former is a newer category that 
can include a large range of techniques and use of different imaging agents nicely 
reviewed in [86]. The latter is more straightforward and involves mostly histological 
analyses or specific tumor cell identification methodology.   








Rat, virus induced 
cell line
Immune response, angiogenesis, 
invasion
Chemotherapy, resection, 
radiation, gene therapy, 
immune therapy
RT2
Rat, virus induced 
cell line































Invasive (with Scherer’s structures), 
heterogeneous cell population, 
primary cells, angiogenesis







Invasion, development of disease, 






Live Imaging has the ability to give you more within subject information 
throughout an experiment. With decreasing cost of methods and increasing abundance of 
molecular imaging agents available these techniques are becoming more commonplace. 
Optical Imaging through near infrared or bioluminescent imaging allows low resolution 
detection of molecules and tumor cells [86]. This is particularly useful in biodistribution 
studies to detect clearance and general organ distribution over time of new therapeutics 
[87, 88]. Further, this technique can be used for tracking of tumor growth and has been 
used with U87MG and 9L models of glioblastoma in vivo in survival studies, yielding 
more information as to the growth kinetics and response to treatment [89, 90]. This 
technique has been used to detect MMP levels, EGFR expression and cell death via 
Annexin V staining in separate experiments resulting in increased information after 
treatment and in development of tumor models [91-93]. Computed Tomography (CT) and 
the higher resolution microCT are often used to determine the angiogenic state of the 
tumor as it grows and in response to treatment [94]. In particular, with angiogenesis 
research, this technique has been important in understanding the leakiness of vasculature 
live when formerly this was a postmortem analysis.   
Postmortem analysis primarily involves removal of the brain containing tumor 
and subsequent immunohistological methods for tumor definition. This can be followed 
or supplemented with a variety of staining techniques for particular proteins or advanced 
image analysis methods for determination of tumor morphology and characteristics. [95] 
offers a good review of many of these techniques and they will be discussed for invasion 
in particular in section 1.2.  
1.2 Invasion of glioblastoma 
As aforementioned, glioblastoma invasion is a significant attribute of the disease. 
There are particular patterns in the brain by which GBM cells invade which have already 
been highlighted. Further, the invasion of glioblastoma is intricately linked with other 
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attributes of its malignancy including angiogenesis. In this section we will look in depth 
at how invasion is determined clinically and explored experimentally. 
1.2.1 Invasion in a clinical context 
Brain tumor invasion is the single most important attribute for failure of therapy 
in the clinic. The first documentation of invasion in glioblastoma patients dates back to 
the 1800’s, however, only recently, has a significant effort been put forth to try and 
observe the invasive front of tumors [9]. With MRI scans, it has been possible to 
determine the course of treatment based on contralateral involvement and extent of 
invasion. Through recent use of diffusion tensor imaging, the degree of invasion can be 
more distinctly seen, as determined by the anisotropy of proton relaxation rates [96]. This 
is preliminarily being used to better assess the borders for radiation treatment [97]. In 
most cases though, tumors are resected as usual and the degree of invasive potential is 
determined by the degree of differentiation of the cells histologically [7]. Where invasion 
comes into play more is in the response to treatment in the clinic and recurrence as multi 
focal tumors arise. 
1.2.1.1 Failure of first-line treatment 
The first line of treatment involves surgical resection, followed by rounds of 
radiation therapy and chemotherapy with temozolomide [98]. This treatment fails in the 
majority of cases, and this is largely due to the invasive characteristics of the 
glioblastoma. Resection is limited by surgical experience and availability of equipment 
such as MRI for intraoperative monitoring of tumor removal [24]. Though many 
intraoperative imaging agents are in preclinical stages to enhance tumor borders and aid 
in tumor removal, most surgeons still rely on the feel of the tissue and MRI to determine 
tumor edges [99]. This technique still results in the inability to remove the entire tumor 
due to the invasion of cells into the healthy brain. Similarly, due to the invasion of cells, 
radiotherapy will miss many of the tumor cells in the brain in order to prevent damage to 
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healthy tissue. Chemotherapy is delivered systemically and enters the tumor via the blood 
vessels and thus is limited by diffusion through the tumor [100, 101]. This means that 
often chemotherapeutics cannot reach invading cells and thus do not kill them.  
1.2.1.2 Induction of invasion by treatment 
It has been purported that all of the methods of treatment of glioma can lead to 
invasion of tumor cells into healthy tissue in some animal of human case. These changes 
have been proven to various degrees but it is difficult to determine what is attributable to 
the treatment versus progression of the tumor after longer survival in the patient. The 
most direct links with invasion and treatment are between radiation therapy and anti-
angiogenic therapy [43, 49]. In other cases, resection has been shown to increase 
malignancy of tumors through a stem cell proliferation effect termed repopulation [102]. 
Chemotherapy causes a large range of alterations in malignancy of cancer cells [20]. 
However, the degree to which this process is accelerated as opposed to tumors that are 
untreated is unknown due to survival effects.  
Radiation is closely linked with increasing tumor invasion in several different 
types of tumors in vitro and in vivo including glioma, breast cancer, and prostate cancer 
[103]. This effect is highly pronounced and appears to have to do with both low radiation 
levels to the tumor cells themselves and through effects on the surrounding tumor stroma 
that can lead to increased invasion. Using human breast carcinoma cells, it was seen that 
irradiating the injection area before injecting the tumor cells enhanced the invasion and 
metastasis of the cells upon implantation [104]. Further, it has been shown that irradiation 
causes activation of fibroblasts in the tumor area which enhances the invasive potential of 
prostate cancer cells through cell-cell interactions [42]. In glioma, in vitro studies have 
indicated increased invasion when low-dose radiation is applied in culture in both 
U87MG and C6 tumor model [43, 105-107]. Last, radiation therapy in glioblastoma is 
rarely contained to just the tumor due to the ill-defined borders and desire to reach all 
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invasive cells. This can lead to priming of the stroma and area around the tumor yielding 
increased invasion [42]. Radiation also acts to activate astrocytes and microglia which 
could also enhance the invasive potential of the tumor [105].  
Anti-angiogenic treatment as previously alluded to, yields enhanced invasion in 
many tumor types. Each year, new evidence correlating anti-angiogenic therapy with 
enhanced tumor invasion surfaces, bringing the usefulness of treatments such as sunitinib 
and bevacizumab into question [108]. Though there have been effects in many different 
cancer types, in glioma this effect is particularly pronounced. Used as a last line of 
treatment in glioblastoma because it extends life by a few months, the invasiveness of the 
tumor into the brain is apparent postmortem. It is thought that the invasion is enhanced 
due to the removal of blood supply, yielding increased hypoxia in the regions of high 
proliferation [46]. This effect results in a lot of cell death and necrosis, but also causes 
switching on of many pro-invasive factors that will yield increased migration away from 
the tumor site [46, 77]. This change can also be seen after treatment with 
chemotherapeutics that affect blood vessels, but it’s not as enhanced as with the anti-
angiogenics [109, 110]. 
With chemotherapeutics, it has been observed that treatment of brain tumors can 
lead to far-distant metastases in humans and animal models. This can be due to the 
increase in invasion accorded to the reduced blood supply; however, it is often attributed 
to the clonal selection that can result from treatment [111, 112]. It is known that glioma 
stem cells, a subpopulation of highly proliferative and invasive tumor cells, show 
resistance to apoptosis induced by etoposide, camptothecin, cisplatin, temozolomide, 
doxorubicin, vincristine, and methotrexate at doses that are toxic to comparable non-stem 
cell populations [113]. This is also highlighted by the tenacity of cancer stem cells to 
establish tumors. It is known that through implantation of a single cancer stem cell, a 
tumor will establish and grow to normal proportions, hence highlighting the particularly 
dangerous nature of leaving these cells behind after treatment [114]. Further, these cells 
18 
 
are commonly localized to the invasive front of tumors and along blood and lymphatic 
vessels of solid tumors during their development indicating an association with these 
tumor elements [115]. The ability of chemotherapy to actually induce invasion is thought 
to be largely through this selection mechanism of the most deadly of the cancer cells. 
Therefore, though the effect is slightly delayed as compared to the anti-angiogenic 
treatment, the results are the same in the long run. 
The last area of treatment and its effects on invasion is more controversial. The 
surgical removal of brain tumors is necessary due to the immense pressure increases 
within the brain and the ensuing symptoms. It is known that in the most invasive brain 
tumors, resection does not remove the entire tumor, which is why this treatment is 
coupled with radiation and chemotherapy. However, the degree to which resection 
actually aids in the invasive and proliferative potential of the tumor cells left behind is 
speculative. Models have been developed explaining the recurrence of tumors in the 
resection site post surgery indicating an increased propensity to proliferate and resist 
cytotoxicity of this population [98, 116]. However, this effect could be due to the fact that 
the tumor cells left behind are often the invasive cancer stem cells which have tumor 
generating potential. One observation that does occur only after resection is the presence 
of metastasized tumors outside of the central nervous system [30]. Several case studies 
have been documented with patients showing metastasis in the cervical lymph nodes, the 
draining lymph nodes from the brain vasculature, and in other regions of the body [117-
119]. It is highly unusual for brain tumor cells to be found metastasized outside of the 
brain and the reasons for this are largely not understood.  In recent studies it is thought to 
be due to the large blood brain barrier disruption that occurs during surgery as the tumor 
is dissected away leaving hemorrhaging blood vessels where tumor cells can enter. This 
is a largely unstudied area though, as it is a rare occurrence and therefore there are few to 
no hypotheses. Regardless, the invasion of glioma cells is closely connected with the 
success and future outcomes of treatments.    
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1.2.2 Methods for measuring invasion in vivo 
Methods for measuring invasion in vivo are only recently moving into the clinical 
setting. The development of advanced MRI methods such as diffusion tensor imaging is 
the primary method that can be used to visualize invasive fronts in tumors. This is now 
being used clinically to reassess the tumor margins for subsequent radiotherapy to 
prevent unnecessary damage and invasive side effects. Other than this methodology, 
invasion is only really observed after or during treatment using MRI for after recurrence. 
The development of methods for assessing this attribute of tumors is only now gaining 
focus in the clinic in a pre-treatment sense.  
In animal models, measuring invasion is becoming a more common part of 
survival studies and drug response monitoring. The use of diffusion tensor imaging is a 
possible technique, though size limitations in rats makes this type of imaging difficult as 
the induction of gradients through the brain are necessary [96, 120]. More common is the 
use of stably transfected cell lines to monitor invasion live and postmortem for 
assessment of tumor invasion and treatment response [84, 121, 122].  
Postmortem analysis involves the use of marked cell lines for antibody detection 
and simple distinction from the surrounding brain by reporter genes such as green 
fluorescent protein or lacZ for β-gal activation and pigment change. Though cancer cells 
can be distinguished from surrounding brain, these methods make imaging analysis for 
tumor size and structure simpler and assist the untrained eye in examining the tumor.  
Similar stable transfections have been successful for in vivo analysis of tumor cell 
invasion, though many imaging modalities are still limited by resolution and signal 
detection. Use of MRI detectable nanocarriers such as ferromagnetic dendrimers and iron 
oxide nanocarriers is possible for tracking of cells in the brain though the signal quickly 
declines as the cells proliferate thus diluting the cytosolic agent[123]. To counteract this 
problem, cells have been stably transfected to overexpress ferritin light and heavy chain 
which will act to sequester iron in the cytosol and create an endongenous T2 enhancement 
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on MRI. This technique has been successful with C6 glioblastoma [123, 124]. Other 
methods for determination of glioma invasion in vivo are limited by the resolution of the 
imaging modalities including bioluminescent imaging via endogenous luciferase 
reporters [125].  
Other methods exist to try to understand the invasive molecular profile of the 
tumor in vivo in experimental animal techniques. This can be an indirect measure of 
invasion and has been successful in detecting the changes in matrix metalloproteinase 
expression, chemokine secretion, and common markers of invasive and malignant 
phenotype such as EGFR and uPAR [123, 126]. This result can be achieved through 
stable transfection resulting in switching on of a fluorescent of bioluminescent marker but 
can also be delivered systemically. For instance, MMP-cleavable fluorescent probes have 
been developed that will only give off signal if there is specific MMP activity in the 
tumor [126, 127].   In this way, it is possible to determine how an experimental 
compound can affect the phenotype of the tumor without actually seeing the 
micromorphology of the tumor.  However, there is the limitation of having to know a 
particular function of a tested compound or treatment and how the target molecule affects 
both the reporter and the tumor phenotype. This validation generally involves 
postmortem analysis in addition to the in vivo live imaging. Further, at this time, these 
methods are highly experimental and can become very expensive when compared to 
more traditional histological techniques. 
1.2.3  Methods to determine invasion in vitro 
Since invasion can be difficult to determine in vivo in a reproducible, high 
throughput way, many assays have been developed to examine this phenomenon in vitro. 
In this way compounds can be screened as anti-invasive agents and cell morphology can 
be examined in a more controlled environment. The evolution of these types of assays 
has moved from 2-dimensional migration assays based on wound healing to 3- 
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dimensional invasion assays consisting of tissue culture insert assays. More recently, use 
of organotypic brain slices has become popular as the movement of cells along structures 
in the brain can be observed and mimics white matter tract invasion in vivo.  
Early models for cell migration include the wound healing scratch assay and the 
agarose spot assay. Scratch assays are popular for fibroblast migration due to the ability 
to mimic a wound through a monolayer of cells. In this way, the distance of closing of the 
wound can be examined over time and inhibitors of such migration can be assessed [128]. 
This assay has fallen out of popularity in the cancer literature primarily due to the 
inherent differences in how cancer cells invade and how healthy cell types migrate. The 
spot assay and agarose spot assay is still in use with some modifications. The general 
principle is that cells are plate in a spot (either in 2D or within an agarose gel) and the 
radiation outward of cells as they migrate into the gel is measured. Many studies are 
using this technique with tumor spheroids to assess invasion though agarose is being 
substituted with naturally occurring extracellular matrix proteins such as collagen and 
laminin to better mimic the degradation necessary for cell movement [129]. Currently, 
primary glioblastoma cells are embedded in matrices and can be both assessed for 
invasion and stained for various markers to determine degree of malignancy for screening 
of drug resistance, mutations, and transformation [130]. 
The Boyden Chamber Assay is the most popular of the invasion assays with 
over 1200 hits in PubMed as of 2011. This assay involves the use of a tissue culture insert 
insert with a permeable membrane that will allow cells to pass through. Cells migrate 
through the pores and into the lower chamber where they can be quantified through 
imaging or collection and counting. This assay is very powerful for its adaptability and 
thus has been used with a variety of ECM protein coatings, many different chemokines, 
with combinations of cells, and in 2D and 3D gels [131, 132]. Modifications of this 
chamber have also been used for assessment of permeability of endothelial cells layers, 
interstitial flow examination for lymphatic homing, and live imaging of cell invasion 
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[133, 134]. Further, the commercial availability of a variety of sizes, coatings, and 
quantification methods has made these assays the most popular choice of cell invasion 
and migration experimentalists.  
Organotypic brain slices are sections of rodent brains that can be maintained in a 
tissue culture environment for testing of compounds against a more structurally relevant 
tumor invasion mode [135]. These systems offer the benefit of a more clinically relevant 
ECM and cell type microenvironment for the cancer cells to interact with and migrate 
along. They have successfully been used with certain MMP inhibitors to assess degree of 
inhibition of invasion [136]. Further, they are often used to determine the changes 
afforded to glioma cells through siRNA mediated inhibition of particular genes. They 
offer the advantage of in vivo systems of being able to view in real time the progression 
of disease in a more approachable clinical manner without the limitations of imaging and 
drug delivery [137]. Further, a single animal can be used for screening of multiple 
compounds or constructs thus minimizing need for large animal numbers. These systems 
do have drawbacks though. For one, they can be difficult to work with and must be 
equilibrated in culture for 6-8 weeks after initial explants. Because of this, many of the 
cell types will die and the actual slice, though beginning as thick as 800µm, will flatten to 
an almost 2-dimensional substrate. Therefore, many of the conclusions that can be drawn 
from these systems are not directly relatable to the in vivo environment however they do 
offer a nice alternative for particular applications. All of these invasion assays are 
summarized in Table 1.3. 
Newer invasion assays have been largely modifications of these pre-existing 
assays and mostly focus on increasing throughput or enhancing in vivo translatability. 
Examples include use of microarray type 3D printing arrays for testing of compounds on 
clinically relevant ECM substrates, use of perfusion chambers for the organotypic brain 
slices to enhance cell-cell interaction capabilities, and development of live cell migration 
acquisition systems that monitor cell movement across a plate tracking velocities and 
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persistence [128, 138]. Further, microfluidics chambers for migration studies are highly 
desirable due to the ability to create and maintain specific chemokine gradients and 
integration of the aforementioned attributes such as three dimensionality, high throughput 
screening and clinical relevance [139-142].  
 
Table 1.3: Common invasion and migration assays used in cancer research. Adapted 
from [128, 131, 132] 
 
  
Assay Benefits Drawbacks Example
Agarose spot assay
Imageable, 3D, adaptable 
to other matrices























1.3 Mechanisms of brain tumor invasion 
1.3.1 Cellular aspects of invasion 
Invasion is a hallmark of brain tumor progression and is the result of a 
coordinated effort of many intracellular events. A cell is stimulated to invade through 
many extracellular and intracellular cues resulting from itself, surrounding cells, and the 
microenvironment. The stimulation of migration is attributed to chemokine gradients and 
signaling, structural cues such as matrix stiffness and fiber alignment, and cell-cell 
signaling from the surrounding environment [15, 143]. These characteristics of invasion 
stimulation are more difficult to control as they involve alteration of the tumor 
microenvironment. Therefore, much of anti-invasive therapy development has focused on 
individual cells. For a cell to invade, it needs to be able to alter its connections with the 
microenvironment through changes in adhesions and matrix composition, and then alter 
its cytoskeleton to adequately propel forward [144].  
1.3.1.1  Adhesion 
Cells maintain adhesion to both the extracellular matrix (ECM) and other cells 
through receptor binding. Adhesion is necessary for most cells’ survival and upon 
detachment they will undergo anoikis. However, cancer cells are able to detach from 
matrices and cell layers without any effects on viability. A cell maintains binding through 
interaction of focal adhesions which link the actin cytoskeleton to the cell membrane. 
These adhesions further interact with a host of different regulatory molecules including 
integrins, Src, and focal adhesion kinase (FAK) to maintain binding and regulate cell 
changes [12, 138, 145]. These complexes can contain many different components and 
therefore, their disassembly and assembly is of vital importance to the dynamics of cell 
movement and is regulated upstream by Rho-GTPase signaling, and Src kinase through 
interactions with FAK. In addition, FAK can recruit cytoskeletal proteins and activate 
RhoGTPases creating a more activated structure and integrating the adhesion process 
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with cellular cytoskeleton assembly [146]. Src kinase also acts to activate and assemble 
many of these complex proteins to through homology binding and integration. In cancer, 
both FAK and Src have been extensively studied. It is known that FAK is highly 
overexpressed in almost every type of cancer including brain and the degree to which 
FAK is overexpressed correlates with degree of malignancy in breast, colon, and brain 
cancer [147]. Src activity is also correlated with degree of malignancy in a host of 
cancers and has further effects than just those on focal adhesions including cytoskeletal 
assembly, inflammatory response, and MMP secretion and thus is a highly desirable 
target for many novel therapeutics [56, 148].  
1.3.1.2  Matrix degradation 
In order to move through the matrix, cancer cells often need to manipulate the 
host environment. This can often be avoided by changing route which leads to formation 
of many of the typical glioma invasion structures mentioned earlier based on cell 
preferences. However, more often, cancer cells prefer to degrade and alter the 
environment in which they are growing through degradation of the matrix around them 
[149]. The most common culprits in matrix alterations are the matrix metalloproteinases 
(MMPs) which are a class of zinc dependent proteases that degrade a variety of 
membrane proteins including collagen and gelatin [150]. These proteins are highly 
upregulated in all cancers, and in brain tumors, MMP-2 and MMP-9, the two gelatinases 
are overexpressed most universally in tumors [151-153]. These enzymes can also be 
induced by a variety of intracellular and extracellular signaling mechanisms and cell-cell 
interactions with normal glial cells [69]. Other matrix degradatory enzymes such as 
hyaluronidases (degrades hyaluronan) and cathepsin B (degrades laminin) are 
overexpressed by glioma [154, 155]. Further, glioma cells express and secrete a host of 
ECM constituents to rebuild the matrix for enhanced motility.  A full review of the 
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interaction of glioma cells with the ECM and its components can be found in [15, 145, 
151, 156].  
1.3.1.3 Cytoskeleton rearrangement 
Along with adhesion assembly and disassembly is the rearrangement of the 
cytoskeleton. For the cell to protrude forward there must be a large degree of actin 
polymerization and depolymerization leading to movement of the cell body. Further, the 
use of myosin to contract the cell as it moves is vital to movement. Last, microtubules 
and intermediate filaments act to maintain the cell structure internally and hold the 
organelles in place [157]. Therefore, compounds, such as Cytochalasin D or Paclitaxel 
that disrupt any of these components can have a large effect on both cell viability and 
motility. However, many of these compounds are not specific to cancer cells and thus can 
have toxic side effects on any motile cells. 
1.3.2 Actin and invasion 
Actin is an essential component of cell morphology and motility and as such, is 
one of the most well-studied molecules in cells. The role of actin in cancer is largely as a 
facilitator of cell motility and therefore, therapies that inhibit its ability to structurally 
change can also inhibit invasion.  
1.3.2.1 Types of actin structures involved in cell migration 
For a cell to migrate, alteration of the actin cytoskeleton is vital. There are many 
different structures that a cell can adopt to move through the ECM and invade including 
filopodia (one dimension), lamellipodia (two dimensions), and in cancers, three 
dimensional structures called invadopodia [158]. This is a highly specialized structure in 
cancer cells that is most commonly seen in invading cells. These 3D structures have three 
primary functions: intracellular signlaling, actin reorganization, and membrane 
trafficking [159]. These functions assist in the ability to protrude into the extracellular 
space by alteration in focal adhesions, actin filaments, and secretion of matrix proteases. 
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The development of these structures is regulated by primarily by RhoGTPases and Src 
kinase, however other intracellular signaling proteins such as PI3K and NFκB can initiate 
formation and secretion of the proteases [160]. In some cell types, a more specialized 
actin structure will form called a podosome. The podosome has the same functionality as 
the invadopodia but is characterized by a ring of focal adhesions surrounding a core of 
actin filaments [159]. These structures are seen most commonly in healthy cells that have 
been transformed with constituitively active Src kinase and transformation with Src 
kinase is the only requirement for development of podosome structures [148]. 
1.3.2.2   Regulation of actin polymerization and depolymerization 
Actin polymerization is one of the oldest studied fields in biochemistry and cell 
biology. Actin consists of monomer units (G-actin) which are activated with ATP. These 
monomers assemble into long filaments of actin (F-actin) which will make up the higher 
order actin structures seen in podosomes, invadopodia, and stress fibers. Actin 
polymerization and depolymerization is essential to the dynamic motility of cells. Actin 
provides the fibers along which myosin can contract the cell to propel movement forward 
and also yield pathways along which intracellular molecules can be transported. There 
are a host of factors that regulate the process of actin polymerization including actin 
binding proteins (ABP), the rho GTPases, and other signaling proteins.  
Actin binding proteins include a large range of molecules from adhesion 
complexes, to kinases, to polymerization facilitators. There are many great reviews of 
actin binding proteins including [161] which covers the various types in general, and 
[162] which gives more detail about their specific function in cancer progression. In 
brief, molecules that tend to promote or speed the ability of actin to polymerize and 
depolymerize are upregulated in cancer and those that cause stability of the filaments are 
downregulated. This is complicated by proteins that have roles in both functions, such as 
the profilin proteins, which bind G-actin monomers and can sequester them inhibiting 
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polymerization or activate them and enhance polymerization [163]. However, this rule 
holds true for most of the more black and white proteins such as the gelsolins which 
severs actin filaments (downregulated) and Arp2/3 which is responsible for nucleation of 
actin filaments (upregulated) [160, 164].  
1.3.2.3 Upstream regulators of actin structures 
The Rho GTPases are the most well-studied of the upstream regulators of actin 
polymerization and cell motility. There are three types of Rho GTPases: Rho, Rac, and 
Cdc42 which are implicated in formation of F-actin is which act by activating 
polymerization of the actin filaments in a process termed “treadmilling.” [158] In turn, 
the cell becomes more motile with the ability to push forward with lamellipodia and 
filopodia to yield bulk migration through ECM. Other proteins, such as scinderin and 
profilin act as actin regulators by cutting filaments and capping polymerizing ends. Since 
cells may need to alter their cytoskeletal arrangement at any moment, a baseline level of 
free actin (G-actin) is pooled in the cytoplasm [165]. Upon activation by the Rho 
GTPases, these monomers polymerize to form the filamentous F-actin.  The ratio of G-
actin to F-actin in the cytoplasm regulates the amount of mRNA available to be translated 
to these proteins [166]. Like the actin protein, actin mRNA is kept in stores in the 
cytoplasm for translation upon a drop in G-actin in the cell. When G-actin levels are too 
high, these mRNA stores are degraded leading to a consistent reserve of actin mRNA in 
the cell. Further, this yields a concise feedback loop where actin controls its own 
translation. If a drug had the ability to affect any part of this feedback loop by inhibiting 
actin polymerization the amount of actin mRNA would also decrease leading to an 
inability of the cell to adequately mobilize [167].  
1.3.3 NADPH Oxidases in cell migration 
NADPH Oxidases (Nox) are a class of proteins that are responsible for the generation 
of reactive oxygen species (ROS). When cells are in distress, ROS are produced to enable 
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a host of downstream signaling effects which lead to rallying of the cells survival system 
causing migration, angiogenesis, and resistance to apoptosis. This activation is often 
caused by extracellular events such as inflammatory responses or injury, however cancer 
cells use this system to their advantage to enable survival. Hence, this system, though not 
as mainstream as other cancer signaling systems and receptors, is important to the 
progression of disease [168]. 
1.3.3.1  Types of NADPH Oxidases 
There are six Nox proteins: Nox1, Nox2, Nox3, Nox4, Nox5, and Duox1/Duox2 
that function to produce ROS in all cells. Activity of the Noxes is regulated by both 
expression level changes, and activation by extracellular signals such as PDGF, TGF-β, 
or angiotensin, as well as intracellular proteins via complex formation and 
phosphorylation. Nox1-3 are activated by cytosolic subunit regulation including p22phoz, 
p47 and p67 among other variable proteins [169]. Nox4 activation is not fully 
understood, and Nox5 and the Duox’s are regulated by calcium ion concentrations. All 
Nox family members yield superoxide O2
·- and H2O2 which can lead to downstream 
signaling events [168]. Though all family members function in this same way, they are 
differentiated by the intracellular localization leading to compartmentalization of the 
ROS that they produce [170]. The ROS react with proteins nearby to alter their function 
and based on which membrane the Nox proteins are located in they will react with 
different proteins. Regardless, all Nox proteins are necessary for normal physiological 
function. Therefore dysregulation or mutation in the Nox proteins leads to a variety of 
diseases including immune disorders, Alzheimer’s, hypertension, atherosclerosis and 
cancer [171, 172]. The specific function of Nox family members in disease is nicely 





1.3.3.2. Subcellular localization of Nox Family Proteins 
Nox proteins are always associated with membranes but may be located on any 
membrane throughout the cell. This includes the endoplasmic reticulum where they help 
to regulate protein translation, the nucleus, where regulation of transcription events can 
occur, the mitochondria, for metabolism, the cell membrane, for intracellular signaling, 
and on small endosomes for secretion of proteins. Each Nox protein has been localized to 
each place for a variety of functionalities. A detailed description of the locations and 
functions of each protein can be found in [170].  Further, the various Nox proteins have 
different splice variants. Nox4, for instance, has five known splice variants: two of which 
localize to the endoplasmic reticulum (4A, 4B), two that localize to the nucleus (4D, 4E) 
and one that remains in the cytoplasm (4C), likely interacting with endosomes[175].  
1.3.3.3.  Nox family proteins in cancer 
Downstream targets of the Nox family proteins include many common players in 
cancer progression. This is due to the activation of these proteins by the reactive oxygen 
species. Similar alterations occur during inflammation and this is one key in the growing 
evidence that chronic inflammation can result in development of cancer. ROS resulting 
from all Nox proteins and their ability to enable cancer progression and invasion is nicely 
reviewed in [176]. In short, ROS lead to a variety of downstream signaling effects 
involving protein kinase C (PKC), protein tyrosine phosphatases (PTPs), and mitogen-
activated protein kinase (MAPK) that can enable a host of phenotypic changes in cells 
leading to malignant transformation. Further, through activation of NFkB and other 
proteins, transcriptional level alterations result and cause longer-lasting effects in cells 
[177]. In all, ROS can lead to induction of every aspect of cell invasion outlined above. 
Looking at one particular Nox protein, Nox4, which has been shown to increased 
expression and activity in gliomas, all of these changes are apparent. In fact, it was seen 
that Nox4 is the most overexpressed of the Nox family proteins in these types of tumors 
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and that this expression correlates with tumor grade [178]. Further, Nox4 knockdown 
results in decreased chemoresistance and proliferation yielding a less malignant tumor. 
Similarly, in studies with cancer cells and Src-transformed 3T3 fibroblasts, Nox4 was 
found to be essential for the formation of invadopodia and MMP secretion at these sites 
[179]. Thus, it is apparent that Nox proteins are important to the invasive phenotype and 
malignancy of cancer in general, and that Nox4 may specifically be an important protein 
in glioma.  
1.4 Molecules that stop invasion 
 
1.4.1 The clinical landscape 
There has been an explosion in potential anti-invasive compounds in the past 5 
years and many of them are summarized in Table 1.4. These compounds are repurposed 
chemotherapeutics, targeted therapeutics, or chemopreventive agents. For instance, the 
use of EGCG (green tea) in conjunction with temozolomide against the U87MG model of 
glioblastoma has shown promise in extending survival in mice [180]. EGCG has been 
shown to reduce reactive oxygen species and has been heralded as a chemopreventive 
agent for some time along with acai and lycopene[58]. However, most experimental and 
more traditional anti-invasives have focused on the ability of compounds to inhibit matrix 
metalloproteinases (MMPs) and thus limiting invasive progress of cancer cells[55]. One 
such compound, Marimastat ®, an MMP-2 inhibitor, was developed and showed 
promise, however in clinical trials, was unsuccessful in enhancing outcomes after 
treatment in glioblastoma [181, 182].  Since then, MMP inhibitors are still popularly 
pursued, though growing evidence suggests that assumptions as to the subtypes involved 
in glioblastoma progression and invasion must be altered [183, 184].  
More recently, there has been a shift in the development of novel drugs to that of 
more personalized therapy. In these cases, specific receptors and signaling molecules are 
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targeted for inhibition in order to kill cancer cells. Treatment can be modified to the 
individual cancer type and patient which is advantageous in reducing side effects. They 
work often by relying on receptor addiction of the cancer cells meaning if the receptor 
becomes useless through blocking, the cancer cell will almost go through withdrawal and 
can die [185, 186]. However, this is not known to occur with all potential targets and it is 
always possible that pathways will be rerouted to compensate.  This type of treatment 
often has a side effect of halting invasion of cancer cells though more commonly 
treatment leads to cell death. A recent review highlights many of these compounds and 
their potential anti-invasive effects based on the target molecule for which they were 
developed [187].  However, the exact anti-invasive effects are unknown for most of these 
compounds based on lack of in depth studies of invasion opting instead for survival and 
tumor growth measures.  
Most of the targets of this type of therapy are receptor tyrosine kinases (RTKs) 
which, upon activation by a ligand, will change conformation and phosphorylate 
intracellular signaling proteins leading to downstream events [188]. In cancer, these 
receptors are often mutated to be constituitively active and thus require no growth factors 
to function. A cancer cell can actually become “addicted” to this activation and so by 
turning it off, the cell will die. This phenomenon and the genes that are privy to it are 
reviewed in [186]. Inhibitors of RTKs are most often antibodies due to the high 
specificity. The more notable RTK inhibitors are Herceptin® (against EGFR), Avastin® 
(against VEGF), and Tarceva® (against PDGFR). These are all used clinically for 
different types of cancers and have been thought to have possible anti-invasive effects 
due to their signaling pathways involving targets for invasion [187]. However, there is 
insufficient evidence to tie their effects to halting glioma invasion and as aforementioned, 
in vivo, Avastin causes glioma invasion[189]. EGFR inhibition is particularly exciting 
due to the overexpression or mutation of EGFR in >60% of glioblastomas and alteration 
of glioblastoma to express EGFRvIII causes a more invasive phenotype of cells in vitro 
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[190]. However, these compounds are expensive and difficult to work with. Further, their 
actual role in invasion prevention is yet to be seen due to the far-reaching effects of the 
involved pathways. 
Inhibitors of downstream proteins such as Src-kinase have shown promise in 
inhibiting tumor growth and progression [56]. Based on the ability of Src to increase all 
attributes of an invasive phenotype including cytoskeletal remodeling, MMP secretion, 
and adhesion disassembly, it was tested for anti-invasive activity. This treatment 
inhibited invasion in brain, prostate and breast cancers while also inhibiting growth, 
angiogenesis and proliferation.   
 
Table 1.4: Molecules showing or predicted to have anti-invasive activity in glioma  
 
 
Inhibitor Binds Inhibits Status
Erlotonib/gefitinib/lapatinib EGFR growth, invasion Phase II/III
Dasatinib/imatinib/tandutinib PDGFR growth, invasion, angiogenesis Phase II
AZD4547 FGFR growth, invasion Phase I
XL184 Met growth, angiogenesis, metastasis Phase I
WP-1034/LLL12 JAK-STAT growth, invasion, angiogenesis Phase I/II
Perifosine AKT growth, invasion Phase I/II
BEZ235/XL765 PI3K growth, invasion, proliferation Phase I
Sunitinib Tyr Kin Growth, angiogenesis, invasion Phase I
TLN-4601 Ras Growth, invasion, proliferation Phase I
Sorafenib Raf Growth, invasion, proliferation Phase II
WX-671 uPA Invasion, proliferation Phase II
PD169316 MAPK Growth, invasion, proliferation Preclinical
AP120009 TGF-β Growth, invasion, proliferation Preclinical
Everolimus/rapamycin mTOR Growth, invasion proliferation Phase I/II
Dasatinib Src Growth invasion proliferation Phase I
Marimastat MMP-2 invasion Phase II
AMD3100 CXCR4 Growth Phase II
Geldanamycin Hsp90 Survival, growth, migration Preclinical
EGCG ROS Growth, invasion, angiogenesis Preclinical
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1.4.2  Experimental methods 
Other treatments to halt invasion involve genetic interventions using DNA, 
siRNA, and microRNA delivery via a host of transfection methods [191, 192]. These 
therapies are all in animal phases at the moment, largely due to the invasive nature of the 
interventions and the difficulties in the past twenty years with gene therapy in clinical 
trials. The advantage to these interventions is the ability to directly target specific genes 
necessary for glioma invasion without need for design of a novel drug and determination 
of a particular target. However, like all compounds, there are delivery issues associated 
with these treatments as well as possible unforeseen side effects.  
1.5 Nanocarriers for drug delivery in cancer 
Upon design of novel compounds and in development of the therapeutics, there is 
often difficulty in modulating delivery. There is a desire to target the tumor without 
causing adverse side effects to the rest of the body. Often, drugs will fail from in vitro to 
in vivo translation due to poor pharmacokinetics and pharmacodynamics that lead to poor 
outcomes of anti-tumor effect. Lastly, once the drugs arrive at the site, there may be 
difficulties in cell uptake and monitoring effect at the site. To overcome these obstacles, 
nano-sized carriers have been developed to aid in providing reliable and tunable delivery 
and activity profiles regardless of the compound being delivered.  
Nanocarrier is a term generally applied to submicron sized particles in cancer, are 
primarily used as drug delivery vehicles. They have a close history with 
chemotherapeutics as many of the early developed nanocarriers were for encapsulation of 
these types of drugs [193, 194]. This is mainly due to the great advantages afforded by 
encapsulating chemotherapeutics. Namely, reduction in cytotoxicity is afforded through 
use of nanocarriers through the ability of these to selectively accumulate at tumor sites 
with reduced toxicity to non-target organs [195, 196]. Second is the ability to modify 
these types of particles with targeting agents to enhance accumulation at organ sites 
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further [197]. Lastly, there is the advantage of delivering multiple compounds or agents 
into a single particle to overcome drug resistance, image the efficacy of delivery and drug 
activity. However, though these are advantages to nanocarriers in general, each type of 
particle comes with specific advantages and limitations and thus selection of a type to use 
specifically for cancer requires balancing on these factors.  
1.5.1 Types of nanocarriers 
There are many types of nanocarriers that have been successfully synthesized and 
used in cancer models [198, 199]. Some of the more popular nanocarriers are highlighted 
in Table 1.5. These variants fall into a few classes of nanocarriers based on the material 
and method by which they are synthesized which alters the pharmacodynamics and 
pharmacokinetics in vivo. For instance, polymeric nanocarriers are useful because of the 
well-characterized and tunable degradation rates and thus drug release profiles. 
Liposomal nanocarriers offer advantages of dual encapsulation based on hydrophobicity 
of drugs and use of naturally occurring materials reducing immune response. Other 
compounds, such as dendrimers, which are based on conjugation of drugs as opposed to 
encapsulation are useful for delivery of both drugs and genetic material.  
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Further, the FDA approval status for many of these nanocarriers is important in 
moving molecular delivery systems to clinic. Beginning with a more novel drug delivery 
vehicle, such as carbon nanotubes, with less information about toxicology, will delay 
translation of a new anti-cancer therapy. In this regard, liposomes are a useful nanocarrier 
as there exist many FDA approved formulations already clinically used for various 
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Table 1.6: FDA-Approved liposomal formulations of drugs and their indications.  
 
 
1.5.2 Use of nanocarriers in cancer 
As malignant brain tumors develop, they begin to create new blood vessels 
through a process called angiogenesis. Cancer angiogenesis is similar to angiogenesis 
seen during development except that it is less controlled and precise [72]. These blood 
vessels have many marked features including blind ends, erratic size and connections, 
and most significantly, large gaps in the endothelial lining. This last feature is important 
because it signifies that larger molecules can enter the tumor effectively bypassing the 
blood brain barrier (Figure 1.2). In fact, tumor vasculature can have intercellular gaps as 
large as 2 µm which is large enough for passive accumulation of 100-200nm particles 
into the tumor interstitium [200].  
Drug Clinical Use
Doxorubicin (Doxil ®) Kaposi’s sarcoma
Daunorubicin (Daunoxome ®) Kaposi’s sarcoma
Amphotericin B (Ambisome ®) Antifungal
Amikasin (MiKasome ®) Antibiotic




Figure 1.2: Enhanced Permeability and Retention Effect. Gaps in neovasculature 
allow liposomal accumulation in the tumor but not in healthy organs. Once there, 




Liposomes are 50-200nm nanocarriers that are composed of phospholipids and 
cholesterol in order to make a semi-fluid lipid bilayer that mimics the cell bilayer. These 
nanocarriers have been used to successfully deliver many drugs including lipophilic 
compounds [201]. In fact, liposomes are particularly useful for lipophilic drug derivatives 
due to the ability to trap the compounds within the bilayer. This leads to decreased 
leakiness through the membrane and enhanced loading capabilities. Though liposomes 
are often drawn as a single lipid bilayer, they are in fact several bilayer stacked together 
which can yield enhanced entrapment. 
The size of liposomes allows for passive accumulation in tumors while avoiding 
other major organs such as heart and lung and possible side effects [202]. When a solid 
tumor reaches a size of 2mm diffusion from surrounding blood vessels becomes limited 
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leading to areas of hypoxia and nutrient deficiency [16]. This impetus leads to 
development of vasculature within the tumor via recruitment of endothelial cells and 
secretion of angiogenic factors [203]. These blood vessels are poorly defined as are 
vessels during development, however, rearrangement and trimming never occurs. This 
leads to disorganized vessels with large gaps in the endothelial lining. These gaps may be 
as large as 800nm which is appropriate for extravasation of liposomes into the tumor 
interstitium where they can act on tumor cells [200]. Further, once there, they remain in 
the tumor for some time owing to the poor drainage out of the tumor due to heightened 
blood pooling and pressure build-up. This effect is known as enhaced permeability and 
retention (EPR) and is a phenomenon that is advantageous when using nanocarriers 
[204]. Further, PEGylated liposomes have altered clearance routes from small molecule 
drugs resulting in prolonged circulation times allowing adequate time to accumulate 
through multiple passes through the vasculature [205]. Therefore, this type of nanocarrier 
offers benefits of long-circulation and slow clearance along with tumor targeting to 
deliver compounds in order to halt invasion. 
1.6 Summary 
Overall, brain tumors present a difficult clinical problem due to their invasive 
nature. In the same vein, invasion is a highly complex and well-regulated process 
utilized by cancer cells to survive and grow. There is a need for novel anti-invasive 
compounds, ways in which to analyze their ability to halt invasion in vivo, and a simple 
way to deliver the novel compound without extensive testing. Therefore, in the 
dissertation that follows, we have selected a novel compound and used liposomal 
nanoparticles to deliver it in vivo. Further, the compound was studied for anti-invasive 
activity and paired with common chemotherapy (Doxorubicin) to enhance survival in an 







Work done in conjunction with: Michael Y Bonner, Levi K Fried, Jack L Arbiser who 
synthesized the novel compounds. 
2.1 Summary 
Glioma is a significant clinical problem with treatments both failing and causing 
invasion of cells. There are currently no compounds that have shown reproducible 
clinical success at halting glioblastoma invasion in humans. Current therapeutics take aim 
at growth factors and matrix metalloproteinases but there are none that only inhibit the 
invasion of the cells, without effects on the environment or viability of the tumor. Such a 
compound could be integrated with current treatment and result in increased survival in 
patients. In this study, two classes of novel compounds, honokiol derivatives (HDs) and 
triphenylmethane dyes (TPMs) are examined with a rat invasive astrocytoma cell line, 
RT2. Cytotoxicity is assessed at a range of concentrations, followed by invasion 
inhibition below cytoxic doses to determine lead compounds. Last, the compounds are 
tested at anti-invasive doses in healthy astrocytes to assess cancer specificity. This 
analysis leads to a single compound, Imipramine Blue, which shows invasion inhibition 
below cytotoxic doses and does not lead to astrocyte toxicity. This compound is 
interesting for further study in glioma therapy. 
2.2 Introduction 
Glioblastoma is the deadliest and most common primary brain cancer. Though 
many compounds are used against glioblastoma, many of these are nonspecific and the 
primary desired effect is cytotoxicity. This strategy has not changed much in the past 
decades, with treatment moving from resection alone, to resection coupled with anti-
tumor treatments such as radiation therapy and chemotherapy with temozolomide [206]. 
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This treatment regimen has only modestly increased the survival time in patients. The 
primary reason for failure of these treatments is the invasive nature of the disease [6]. 
Hence, we propose to find a novel compound that will halt glioma invasion specifically at 
non-cytotoxic doses. In this way, we hope to find a new molecule that can be integrated 
with other anti-tumor therapies to yield a new paradigm in treatment. 
Honokiol is a compound derived from the magnolia tree and is an ancient herbal 
remedy. It has been shown to inhibit growth and progression of multiple types of cancer 
including melanoma, prostate and colon cancers [207-210]. Through these studies it was 
also determined that honokiol works via modulation of NFkB activity though the direct 
target is still unknown. NFkB is highly overactive in cancers with constituitive activation 
in 75% of cancers [211, 212]. This is particularly dangerous because NFkB acts as a 
transcription factor, regulating the machinery responsible for invasion and metastasis of 
cancer cells including actin regulatory elements, cell adhesion proteins such as integrins 
and focal adhesion kinases, and secretion of matrix metalloproteinases [213]. The 
upregulation of these factors all contributes to the migration of cancer cells. In particular, 
these attributes are necessary for the invasion of glioblastoma into the surrounding brain. 
Hence, the class of honokiol derivatives is tested for their possible anti-invasive activity. 
Triphenylmethanes (TPM) are a class of compounds modeled after 
triphenyliodide (TPI) and thought to have NADPH Oxidase (Nox) antagonistic activity 
[214]. They were explored in the early 1990’s as chemopreventive agents though not 
pursued extensively [215]. The Nox family of proteins is generally active in cancers 
leading to enhanced presence of reactive oxygen species in the tumor cells and stroma. 
This leads to activation of a host of intracellular pathways including Src kinase, 
p38/MAPK, and NFkB which can lead to downstream cytoskeletal rearrangement as well 
as directly activating matrix metalloproteinases (MMPs) [213, 216]. Triphenylmethane 
compounds such as TPI have previously been seen to inhibit invadopodia formation, 
inflammatory response, and cancer cell migration in vitro [179]. Therefore, this class of 
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compounds was of interest for development of novel therapeutics against glioma 
invasion. 
We show here data from a screen of novel compounds from the triphenylmethane 
and honokiol classes of drugs. These are all novel compounds save for honokiol, and all 
show anti-tumor activity to some extent. The compounds were synthesized through 
simple methods to yield derivatives of the original two compounds and thus are divided 
into Triphenylmethanes (TPMs) and honokiol derivatives (HDs). We test the compounds 
against the rat astrocytoma invasive cell line RT2 and against healthy primary rat 
astrocytes for toxicity and invasion screening [84]. It was determined through this screen 
that the best anti-invasive agent at non-cytotoxic doses to astrocytes or RT2 is 
Imipramine Blue, a novel triphenylmethane compound.  
2.3 Methods 
2.3.1 Compounds 
Compounds were synthesized according to previous publications and assessed by 
NMR to confirm the structure (data not shown). All compounds were extracted in the 
final step using ethanol and then dried for use in experiments. Stock solutions in 100% 
ethanol Triphenylmethanes) or DMSO (honokiol derivatives) were made to minimize 
exposure of cells to the carriers (100x solutions). 
2.3.2 Cell Culture 
RT2 glioma cells were a generous gift from Helen Fillmore (Virginia 
Commonwealth University).  The cell line was maintained in Dulbecco’s Modified 
Eagle’s Medium (Mediatech) supplemented with 10% Fetal Bovine Serum, 1% 
Penicillin/Streptomycin, 1% Non-Essential Amino Acids (Gibco), and 1% L-glutamine. 
Astrocytes were harvested from P0 rat pups as described in [217]. Cells were maintained 
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in DMEM/F12 media supplemented with 10% FBS and 1% P/S. Astrocytes used were 
passage 3. 
2.3.3 Cytotoxicity testing against RT2 glioma 
Cells were seeded in 96 well plates at a density of 100,000 cells/ml in serum 
containing media. After overnight attachment, media was exchanged with serum free 
media containing the compounds at varying doses (0.5, 5, 25µM) or the carrier alone. 
Cells were continuously incubated with the compounds and readings were taken using the 
Dojindo cell counting kit 8 (CCK8) at 0h, 24h, 48h, and 72h. Experiments were repeated 
two times with triplicate samples. Absorbance readings from the kit were normalized to 
the control samples (carrier only) and reported as normalized viability. 
2.3.4 Cytotoxicity testing against astrocytes 
Cells were seeded in 24 well plates at a density of 100,000 cells/ml in serum 
containing media. After overnight attachment, media was exchanged with serum free 
media containing the compounds at the cytotoxic dose seen in RT2 to determine 
specificity or the carrier alone. Cells were continuously incubated with the compounds 
and readings were taken using the Dojindo cell counting kit 8 (CCK8) at 0h, 24h, 48h, 
and 72h. Experiments were repeated 2 times with triplicate samples. Absorbance readings 
from the kit were normalized to the control samples (carrier only) and reported as 
normalized viability. 
2.3.5 Invasion assays against RT2 glioma 
For invasion assays, chambers were coated with basement membrane extract 
(BME, 0.5 mg/ml) and cells were starved with serum free medium overnight. Cells were 
plated at 1E6 cells/ml in top of the Millipore insert. After 2 hours, serum containing 
medium was placed in bottom well, drug was added to the top well, and cells were 
allowed to invade for 48 hours. Wells were washed with PBS, incubated with Cell 
Dissociation Solution (Trevigen) and Calcein AM then assessed at 485/590 and 
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normalized to control well  which had either ethanol for the TPMs or DMSO for the HDs 
(normalized RT2 invasion).  
 
Figure 2.1: Honokiol derivatives These compounds represent several of the honokiol-























Figure 2.2: Triphenylmethane dyes Representative compounds of the triphenylmethane 
dye class. All compounds have the signature diphenyl structure attached to a central 






2.4.1 Honokiol derivatives and Triphenylmethanes have low cytotoxicity  
Through testing of the compounds shown in Figure 2.1 and 2.2 at several doses, 
we determined the dose at which each compound was cytotoxic against the RT2 tumor 
cells. Figure 2 shows the cytotoxicity at the dose at cytotoxic (Figure 2.3) and below 
cytotoxic (Figure 2.4) doses against the cells for each class of compounds. Many of the 
compounds showed significant anti tumor activity against RT2 glioma and thus would be 
good candidates for novel anti-tumor compounds. However, we were interested in the 




























Figure 2.3: Cytotoxicity in RT2 glioma at high doses. (A) Honokiol derivatives and 
(B) Triphenylmethanes dyes. Some compounds showed no cytotoxicity at any dose (up to 
25µM), but others were cytotoxic at doses of 5µM. Viability readings at 48 h were 
compared to initial readings before drug application. *p<0.05 in t-tests as compared to 
control. 
 
Figure 2.4: Cytotoxicity in RT2 glioma low doses. (A) Honokiol derivatives and (B) 
Triphenylmethane dyes. Viability readings 48 h awere compared to initial readings before 
drug application. There were no significant differences from control. The dose range was 
between 0.5 and 5 µM for non-cytotoxic effects. These doses were used for testing of 






2.4.2 Several compounds showed anti-invasive activity against RT2 glioma 
Using the dose below cytotoxic dose to prevent confounding cell death effects, we 
explored the anti-invasive potential of these compounds (Figure 2.5). Through this assay, 
there were several significant results for compounds including that seen with honokiol, 
carbazole blue, and Imipramine Blue. These compounds inhibited invasion to below 50% 
at 5µM dose for 48 hours.   
 
Figure 2.5: Invasion inhibition of RT2 glioma.  A) Honokiol derivatives and B) 
Triphenylmethane dyes in Boyden chamber assay with basement membrane extract 
coating after 48 h. Only three compounds showed anti-invasive effect that was significant 
in these screenings. *p<0.05 with t-test as compared to control. 
 
2.4.3 Several compounds were toxic to astrocytes 
Astrocytes were selected as a control cell type for the RT2 astrocytoma to 
determine if there would be any side effects in vivo. The cells were incubated with the 
anti-invasive concentration of the compounds for cytotoxicity measurements. It was 
found that all compounds but carbazole blue and Honokiol FB56 were benign towards 





non-cytotoxic and thus still represent good candidate molecules for use against 
glioblastoma.  
 
Figure 2.6: Cytotoxic effect against primary rat astrocytes. (A) Honokiol derivatives 
and (B) Triphenylmethane dyes. Astrocytes were exposed to the compounds for 72 h with 
measurements taken every 24 h. Viability was compared to initial readings of wells and 
normalized to the untreated control wells. This assay showed cytotoxic activity with two 
compounds, one of which, Carbazole blue, was a lead anti-invasive compound. *p<0.05. 
 
2.5 Discussion 
The ability of glioblastoma to invade is the primary cause of recurrence and 
therapeutic failure. Many chemotherapeutics that are used are cytotoxic and as such, they 
have been correlated with increasing cell invasion and selection of the most malignant 
cancer cells through chemoresistance [112]. Thus, a new method of treatment with novel 
compounds is necessary in the treatment of glioma for a real change in survival time. 
Here we propose the use of two new classes of compounds in glioblastoma including 
triphenylmethanes and honokiol derivatives. Through inhibition of not previously 
inhbited pathways including NFkB and Nox, we show that there is anti-tumor effect in 




This anti-tumor effect is interesting because as compared to other 
chemotherapeutics, these compounds are nearly as effective at killing cancer cells [51, 
113, 218]. The added benefit of these compounds is that they have the potential to stop 
invasion via different pathways than previously examined. The RT2 glioma line is a 
highly invasive and aggressive model of glioma that generally will cause death in 
inoculated animals within two weeks [84, 219]. Therefore, showing enhancement of 
death in this line is an indication for further investigation of these cytotoxic compounds. 
Further, since it seems that the majority of these compounds are benign towards 
astrocytes at these concentrations these compounds could further be helpful due to the 
specificity towards astrocytoma. Also, coupled with previously published results showing 
in vivo anti-tumor effect of honokiol and in vitro results with DPI showing reduction of 
invasion of multiple tumor types, we believe that these compounds could have further 
effect on other cancers [210]. 
Though the cytotoxic selectivity is exciting, the purpose of the compound screen 
was to determine a candidate molecule for anti-invasive therapy. The rationale for the 
selection of the classes of compounds was to find novel possible mechanisms of action. 
Most anti-invasive compounds focus on inhibition of growth receptors which can have 
alternate anti-tumor effects, and MMP inhibitors, which have very specific action on the 
microenvironmental manipulation by the cells, but not the cells themselves [55, 187]. 
Therefore, these new compounds have the possibility of completely novel activity on 
cancer cells that could have far reaching effects on the disease. 
The final desired outcome is to determine a compound that will show an 
inhibition of invasion that is not attributable to cell death and that this compound will not 
kill astrocytes, the healthy counterpart to the astrocytoma. The anti-invasive potential of 
drugs has been tested with other compounds, however, there is often the confounding 
effect of cytotoxicity that is rarely controlled [55, 220-222]. In this study we determined 
first the concentration at which these compounds were cytotoxic and then followed up 
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with the invasion assay at the lower dose. Last we narrowed down to our final compound 
for future study by checking the specificity of the compound for cancer cells. The next 
steps in the investigation are to determine if this compound, Imipramine Blue, in fact 
inhibits invasion in vivo and to futher understand its mechanism. The final goal is to 
integrate this drug with cytotoxic compounds to affect change in the treatment paradigm 
of glioblastoma and hopefully alter the survival rates.  
From another perspective, we introduce a range of compounds that will be 
effective against glioblastoma in differing ways. Further, preliminary data incorporating 
combinations of the two classes of compounds shows enhanced cytotoxicity against the 
glioma that’s greater than the additive effect of just the single compounds (data not 
shown). This data indicates that the two compounds likely activate different pathways, as 
implied by the compounds from which they are designed, and that this effect is 
multiplicative. This is a powerful set of compounds to work with if, though NFkB is 
downstream of both signaling pathways, they in fact activate pathways that are 
synergistic in the effect. Further work must be done to explore this attribute and to 
determine the mechanisms by which these compounds inhibit invasion and increase 
apoptosis so that better combinations can be designed.  
In all, we show methodical identification of a novel anti-invasive compound 
Imipramine Blue, against an aggressive glioma model. Additionally, through examination 
of these compounds, which have overlapping yet different courses of action, we have 
revealed several with anti-tumor activity and anti-invasive activity. These compounds are 




CHAPTER 3  
ENCAPSULATION AND TESTING IMIPRAMINE BLUE  
3.1 Summary 
The invasive nature of glioblastoma (GBM) represents a significant challenge to 
the standard of care and contributes to poor clinical outcomes.  This is exacerbated by last 
line therapies such as Avastin which result in increased invasion of glioblastoma. Here 
we tested the hypothesis that an effective anti-invasive agent that ‘contains’ glioblastoma 
will enhance the efficacy of chemotherapy. We report a new anti-invasive agent, 
Imipramine Blue (IB), which effectively inhibits invasion of highly migratory tumor cells 
in vitro and in vivo.  Liposomally encapsulated IB (nano-IB) significantly inhibits 
invasion of GBM in an aggressively invasive RT2 rodent tumor model. We demonstrate 
that IB inhibits invasion through upstream dysregulation of actin polymerization.  Nano-
IB therapy followed by liposomally encapsulated Doxorubicin (nano-DXR), resulted in 
complete survival and remission in a syngeneic, invasive rat glioblastoma model RT2.    
3.2 Introduction 
Though only accounting for 2% of new cancer cases, brain tumors are a large 
clinical problem with poor prognosis after treatment and relatively minor change in 
survival times over the past 50 years [1]. This is mainly due to the minimal treatment 
response of the most common of primary brain tumors, glioblastoma which has a five-
year survival rate of 33% [223]. Current treatments aim to debulk the tumor using 
surgical resection, radiotherapy, and chemotherapy with temozolomide upon onset of 
symptoms and detection of tumor via MRI [224]. While non central nervous system 
cancers can result in metastasis to other regions of the body, brain tumors often do not 
metastasize outside of the brain, instead they invade and spread within the host 
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microenvironment [225].  Thus the invasive nature of glioma is a significant contributor 
to poor clinical outcomes.  
The ability to invade host brain tissue is a defining characteristic of glioblastoma 
compared to other more benign brain tumors.  Surgical resection often results in 
recurrence within 2 cm of the surgical removal [98].  Radiation of the microenvironment 
alone before implantation of cancer cells has seen enhanced invasion and malignancy of 
cancers [44].  Therefore, stopping invasion can potentially have significant implications 
for the efficacy of chemotherapy and radiation therapy. Current experimental anti-
invasive drugs such as EGCG, geldanamycin, and UPAR inhibitors are plagued by poor 
pharmacokinetics and tumor accumulation in vivo, high IC50s, unpredictable 
pharmacobiology leading to adverse side effects, cytotoxic activity at “anti-invasive” 
doses, and indeed are used as anti-tumor agents and not as anti-invasive agents [51, 191, 
220, 222, 226, 227].  Marimastat, an MMP inhibitor currently in Phase II trials, shows 
promise yet does not offer a cure of the disease in early animal models nor in human 
studies [55, 181, 228]. Current anti-invasive agents focus on inhibition of matrix 
metalloproteinases or are cytotoxic compounds (paclitaxel, temozolomide) given at lower 
doses [51, 229]. 
Here we describe a novel therapeutic, Imipramine Blue that is truly anti-invasive 
against glioma in nanomolar concentrations.  We have also developed a long-circulating 
nanoscale liposomal delivery vehicle (nano-IB).   PEGylated liposomal nanocarriers 
(Stealth) offer advantages for drug delivery that include FDA-approved status for several 
anti-cancer compounds such as cytarabine and Doxorubicin and well-studied 
pharmacokinetics and biodistribution for prevention and prediction of adverse side effects 
[230]. Further, due to the enhanced permeability and retention of solid tumors afforded 
by the neovascularization process, liposomal nanocarriers under 200nm in size will 
accumulate at the tumor [231, 232]. Therefore, use of such particles in conjunction with 
the development of a new compound allows prediction and understanding of circulation 
53 
 
times, organ accumulation, tumor dosing, and cell delivery without involved 
pharmacological studies [230, 233-235].  
In this study we report that a combination therapy strategy of first inhibiting 
invasion in an aggressive syngeneic rodent model of glioma using nano-IB, followed by 
cytotoxic nano-DXR chemotherapy significantly enhances the efficacy of chemotherapy 
compared to chemotherapy alone resulting in complete remission of tumor.   This 




Figure 3.1: Strategy of treatment with IB Traditional chemotherapy with nano-DXR 
(top row) treats an invasive tumor with chemotherapy and leaves behind residual cells 
which can create new tumors. By adding nano-IB (bottom row), we can contain the tumor 
and prime it for treatment with chemotherapy thus removing the tumor completely. 
 
3.3 Methods 
3.3.1 Synthesis of Imipramine Blue Dye  
Imipramine Blue Dye was synthesized according to [236].  Briefly, 1.0 g 
Imipramine was added to 1.02 g of 4-4’diethylaminobenzophenone in a clean, dry flask 
under an argon atmosphere under constant stirring at room temperature.  Phosphorus 
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oxychloride (0.50 mL) was then added to the flask dropwise, upon completion of addition 
the solution was heated at 107C for four hours.  The solution changed colors from a 
brown-black to a metallic blue.  After 4 hours, the reaction was quenched with water and 
the solvent was removed via rotary evaporation at 35° C. The resulting black plaque-like 
solid was extracted in chloroform.  The chloroform fractions were pooled and evaporated 
on a rotary evaporator resulting in a metallic blue oil. Chromatographic separation 
over on Alumina with 100:1 Ethyl-Acetate:Hexane to remove excess 4-
4’diethylaminobenzophenone and afterwards 50:50 chloroform:methanol gave 
Imipramine blue dye in 95% yield as a metallic blue solid. MS: (M+) 588.34. 
3.3.2 Cell culture and in vitro assays  
RT2 and RT2 glioma cell lines were a generous gift from Helen Fillmore 
(Virginia Commonwealth University), U87MG and C6 were purchased from ATCC, and 
9L was a generous donation from the Neurosurgery Tissue Bank at UCSF. All cell lines 
were maintained in DMEM (Mediatech, VWR) supplemented with 10% Fetal Bovine 
Serum, 1% Penicillin/Streptomycin, 1% Non-Essential Amino Acids, and 1% L-
glutamine (Gibco) and RT2 were maintained in the same medium with 1 mg/ml G418 
(Gemini Biosciences) added for selection. For invasion assays, chambers were coated 
with basement membrane extract (BME, 0.5 mg/ml; Trevigen) and cells were starved 
with serum free medium 24 hours prior to assay. Cells were plated at 1E6 cells/ml in top 
of an 8-µm pore size tissue culture insert insert (Millipore). After 2 hours, serum 
containing medium was placed in bottom well, drug was added to the top well, and cells 
were allowed to invade for 48 hours. Wells were washed with PBS, fixe with 4% 
Paraformaldehyde, stained with DAPI, imaged and quantified. For cytotoxicity assays, 
RT2 glioma or astrocytes were plated at 200,000 cells/ml in a 24 well plate and for 
proliferation assays, RT2 glioma were plated at 25,000 cells/ml in a 24 well plate. CCK8 
(Dojindo) was used to count cells at 24 and 48h (RT2) and 72 and 96h (astrocytes). For 
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combination cytotoxicity studies, cells were plated at 200,000 cells/ml in a 24 well plate 
and allowed to attach overnight. IB was added at a dose of 5µM for 3 hours, removed, 
and DXR was added at varying doses. Counts were taken using CCK8 over 72 hours and 
normalized to control conditions. For liposomal studies, the same procedures were 
followed but liposomal formulations were used in the same concentrations and timelines 
as above and compared to control liposomes (saline-containing).  
3.3.3 Encapsulation of Imipramine Blue 
Nano-IB were made according to with modifications. Briefly, 10mol% cholesterol 
(Sigma), 85mol% Distearoyl-phophatidyl-choline (DSPC, Avanti), 5mol% poly(ethylene 
glycol 2000)-distearoyl-phophatidyl-ethanolamine  and 0.01mol% distearoyl-
phophatidyl-ethanolamine-rhodamine and 2mg/ml Imipramine Blue (IB) were dissolved 
in 100% ethanol at 70°C. The solution was hydrated with 1x Phosphate Buffered Saline 
to a final concentration of 40mM lipids. The solution was extruded through a 0.8µm filter 
3 times, a 0.4µm filter 5 times, and a 0.2µm filter 10 times to a final size of 160nm as 
assessed by Dynamic Light Scattering. The solution was run through a Sepharose column 
(Sigma) to remove unbound compound. This solution was diafiltrated to a final drug 
concentration of 7 mg/ml in 140mM lipids as assessed by absorbance at 610nm(drug 
content) and fluorescence at 485/610(lipid content). 
3.3.4 Doxorubicin nanocarrier fabrication 
Doxorubicin was loaded into the liposomal nanocarriers using an ammonium 
sulfate gradient as previously described[237]. Briefly, liposomal nanocarriers (60mol% 
DSPC, 35mol% cholesterol, 5mol% DSPE-mPEG) were made by hydration with 
ammonium sulfate followed by dialysis against PBS.  These were mixed with 
Doxorubicin in saline (2 mg ml-1) at a ratio of 0.04 mg Doxorubicin to 1 mg of lipid and 
heated to 60°C for 1h. The liposomal nanocarriers were then immediately cooled on ice 
and subsequently diafiltrated to remove any remaining Doxorubicin and concentrate the 
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nanocarriers down to the same lipid molarity as the nano-IB. The formulations were 
sterilized by passing through a 0.2 µm filter. Final Doxorubicin content was assessed by 
lysing the liposomal nanocarriers with 5% Triton X-100 at 60°C and measuring the UV 
absorbance at 480nm.  
3.3.5 Pharmacokinetic Studies 
Animals were anesthetized via isoflurane inhalation. The tail was cleaned with 
isopropanol and a 24 gauge catheter was inserted into the tail vein. Free IB was prepared 
according to[238]. Briefly, drug was solubilized in a 50/50 Cremophor EL 
(Sigma)/Ethanol solution and then diluted with 0.9% saline to a final concentration of 5 
mg/ml. Either free IB or Lip-IB was delivered via the catheter after which the catheter 
was removed and bleeding inhibited. At given time points after injection, an orbital blood 
draw was performed and blood collected in heparinized gel tubes. The tubes were spun at 
15,000xg for 10 minutes at 4°C. Plasma was collected and directly read at 610nm(free-
IB) or lysed with 1%Triton solution and read.  
3.3.6 Tumor inoculation  
Animals were anesthetized via isoflurane inhalation and mounted on a stereotaxic 
frame. The head was shaved and cleaned and a 3cm incision was made through the skin 
to expose the skull. A 2mm burr hole was created in the skull using a Dremel hand tool 
mounted on the frame 2mm lateral and 2mm anterior to lambda. A Hamilton syringe was 
used to inject 10µl of cell solution over five minutes after which the syringe was slowly 
removed and the burr hole closed with bone wax. The wound site was closed using 
sutures (Ethicon), the wound cleaned, and buprenorphine administered intramuscularly. 
Animals were monitored daily after inoculation.  
3.3.7 Comparison and toxicity studies 
Animals were inoculated with tumor as described. On Day 4 following 
inoculation, nano-IB, liposomal Doxorubicin, or saline was administered via tail vein 
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injection. When animals displayed signs of morbidity they were sacrificed via intracardial 
perfusion with saline followed by 4% paraformaldehyde in PBS. Brains were postfixed 
for 1 hour in 4% paraformaldehyde and then transferred to a 30% sucrose in PBS solution 
for 72 hours. Brains were removed from sucrose, rinsed with PBS, embedded in OCT and 
frozen at -80°C. Brains were sectioned using a Leica Cryostat at 16µm. Other organs 
were dissected and paraffin embedded for H&E processing.  
3.3.8 Immunohistochemistry and Image Analysis 
Sections were stained with anti-neurofilament 160 antibody(Sigma) followed by 
secondary Alexa 594 (Invitrogen), anti-GFP antibody (Invitrogen) to enhance the GFP 
signal, and DAPI (Invitrogen).  Whole brain slices were imaged using widefield 
microscopy with Neurolucida tiling functionality. Images for margin quantification were 
imaged using a Zeiss LSM 510 confocal microscope.  Image J was used for tumor density 
calculations. Invasion beyond borders was assessed on on 3 sections through each tumor 
at 4 locations beyond the border. Border definition was determined by 2 parties on 
separate occasions (based on red-green spatial definition) and cells beyond border 
counted (confirmed with both green fluorescence and nuclear staining with DAPI). 
3.3.9 Microarray analysis 
Rats were perfused 11 days after inoculation (n=3 per group, treated and untreated 
as above) using DEPC-treated PBS and brains were removed and frozen at -80°C. 
Tumors were dissected out and RNA harvested using the Qiagen RNEasy kit (Milipore).  
Total RNA was quantified using an Agilent Bioanalyzer and converted to cDNA using 
Superscript Choice System (Invitrogen). The microarray and data analysis was performed 
as described (Ford paper) using the Affymetrix Rat 230 2.0 gene array. Each sample in 
the treated tumors was compared to untreated tumor controls using the Affymetrix 
GeneChip software. A gene was considered differentially expressed when the standard 
deiviation of the signal increase or decrease was significantly smaller than the absolute 
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change in average difference with a calculated confidence level of a gene greater than 
95%. Data were then imported into Genespring software to generate heatmaps and into 
Ingenuity Pathway Analysis to determine interactions of groups of genes with greater 
than 2-fold changes. 
3.3.10 Quantitative rt-PCR 
RNA from tumors in vivo was harvested as above and samples were pooled 
together to yield greater concentrations. RNA was quantified using a Nanodrop 
spectrophotometer and cDNA was made using Superscript Choice System (Invitrogen). 
Quantitative rt-PCR was run using SYBR green reagents and the StepOne Plus Analyzer 
(Applied Biosystems). The following primer pairs were used for each gene (IDT): α-actin 
(acta1; forward: 5’-GGC AAG CCA GCT TTC ACC-3’, reverse: 5’-CCT CAG GAC 
GAC AAT CGA CC-3’); profilin-1 (pfn1; forward: 5’-GGA AGA CCT TCG TTA GCA 
TTA CG 3’, antisense: 5’ CGT CTT GCA GCA GTG AGT CC 3’); calgranulin 
(S100A8; sense: 5’ GCA ATT AAC TTC GAA GAG TTC C 3’, antisense: 5’ CGA CTT 
TAT TCT GTA GAC ATA TCC 3’); RhoGDIα (arhgdia, sense: 5’ CTA CAT GGT CGG 
GAG CTA TGG 3’, antisense: 5’ GTT GTA ACT GCC CCG AGC AA 3’); scinderin 
(scin, sense: 5’ TTC TCC TAC CGC CTG CAC TT 3’, antisense: 5’-CGC CCA AAT 
AGT CGT CCA TCT-3’), .  
3.3.11 Western Blotting 
Protein lysates were harvested from treated and untreated tumors (n=3 per group) 
and pooled. Total protein was measured using BCA assay (BioRad). Equivalent total 
protein amounts (20µg protein) were run on a NuSep gel followed by incubation with 
primary antibodies: rabbit anti-profilin 1 (Abcam), goat anti-S100A8 (Santa Cruz 
Biotechnology), rabbit anti-arhgdia (Santa Cruz Biotechnology), rabbit anti-acta1 
(Abcam), and rabbit anti-scinderin (Abcam). Secondary incubation was performed with 
HRP-tagged anti-goat (Santa Cruz Biotechnology) or HRP-tagged anti rabbit 
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(Invitrogen). Gels were stripped and incubated with rabbit anti-GAPDH (AbCam) for 
normalization of signal. Integrated density measurements were performed with ImageJ. 
3.3.11 Survival studies 
Tumors were implanted as described for comparison studies into 10-12 week old 
Fisher 344 male rats. At 4 days after implantation, rats received either IB liposomes (IB) 
or saline liposomes (Control) via tail vein injection under isoflurane anesthesia. On day 7, 
MRI was performed as described followed by tail vein injection of either Doxorubicin 
liposomes (DXR), or IB liposomes (IB). Animals were monitored daily and MRI was 
performed at intervals to monitor tumor progression. Animals displaying signs of 
morbidity including hunched posture, abnormal vocalization, weight loss, poor hygiene, 
or decreased movement in accordance with Georgia Tech IACUC guidelines. Animals 
were sacrificed by CO2 inhalation upon display of any of these symptoms and the brain 
removed to confirm tumor presence and perform histology.  
3.3.12 Magnetic Resonance Imaging 
Animals were anesthetized by 1-2% Isoflurane and placed in a 7T MRI (Bruker 
Instruments, Billerica, MA) equipped with a 30mm head coil. A T2-weighted image was 
taken through the head using the following parameters: 2.0 s repetition time(TR), 48 ms 
echo time(TE), FOV=40mm x 40mm with a 256 x 256 matrix, slice thickness=1 mm, 
number of slices= 20, 2 averages per phase encode step requiring a total acquisition time 
of about 6 minutes per rat. MRI was performed before treatment began to confirm tumor 
presence and at intervals throughout the survival study to monitor the progression of the 
tumor and response to treatment. Rats not showing evidence of tumor were removed from 
the study. For T1-weighted MRI, animals were treated with either Gd-loaded nano-IB (for 
accumulation, 3 mg/kg IB) or free Gd-DTPA (Omniscan) for end of survival study tumor 
leak (final concentration of Gd was 0.15 mmol/kg).  T1 images were taken according to 
the following parameters: 2.0 s repetition time(TR), 48 ms echo time (TE), FOV=40mm 
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x 40mm with a 256 x 256 matrix, slice thickness=1 mm, number of slices= 20, 2 averages 
per phase encode step requiring a total acquisition time of about 6 minutes per rat.  
3.3.12 Statistical Analysis 
For in vitro assays, a one-way ANOVA was performed followed by Tukey post-
test for individual pairs comparisons.  For in vivo pharmacokinetic studies, points were 
fitted with a single phase exponential decay curve and compared using nonlinear 3-point 
regression. For the survival study, we used Mantel-Cox analysis to compare survival 
curves. In all studies, *p<0.05, **p<0.01, and ***p<0.001. Test statistics are reported as: 
test statistic (degrees of freedom) = value, p< # to give effect sizes. 
3.4 Results 
3.4.1 Structure of Imipramine Blue (IB) 
Imipramine Blue (IB, Figure 3.2A) was synthesized via a single-step process to 
yield a final diphenyl compound with MW=588 g/mol (Figure 3.2B). This compound is 
crystallized to a dark blue/brown powder that yields a deep blue colored solution when 
dissolved at neutral pH. The structure of IB was confirmed by NMR Spectroscopy 
(Figure 3.2C). IB absorbs light at 610 nm as determined through absorbance 
spectrophotometry (Figure 3.2D). This property was used throughout experimentation to 




Figure 3.2: Synthesis of Imipramine Blue. A) Structure of Imipramine Blue, a small 
hydrophobic diphenyl compound weighing 588 g/mol. B) NMR of synthesized 
Imipramine Blue. C) Single step synthesis method of Imipramine Blue and D) 
Absorbance spectrum of Imipramine Blue used for assessment of concentration showing 
a peak at 610nm.  
 
3.4.2 Imipramine Blue (IB) inhibits invasion of multiple glioma lines in vitro 
Cells were seeded on basement membrane extract in porous tissue culture inserts 
were exposed to IB in increasing doses from 0.01-10µM and normalized to controls to 
determine extent of invasion through the matrix. Doses remained below cytotoxic levels 




































Figure 3.3: Dose dependent cytotoxicity of glioblastoma RT2 and Astrocytes. IB is 
cytotoxic to RT2 GBM around 20µM though begins to be toxic to astrocytes at 50µM. 
Regardless, these cytotoxic doses are well above the EC50 of IB for halting invasion. 
 
IB was effective in inhibiting invasion of multiple glioblastoma cell lines at low 
concentrations (shown here at 5µM, Figure 3.4A). Further the ability of IB to inhibit 
invasion is dose dependent revealing an IC50 in the RT2 glioblastoma model of 10 nM 
(Figure 3.4B). Cells were seen to reduce spreading in 2D using live imaging. This 
inhibition of invasion was specific to tumor lines, with astrocyte migration remaining 







Figure 3.4: Imipramine Blue inhibits invasion in glioma cell lines A) IB inhibits 
invasion in multiple models of glioblastoma through basement membrane extract at doses 
below cytotoxic levels (5µM) B) In RT2 rat astrocytoma, IB inhibits invasion in a dose-
dependent manner below cytotoxic levels showing an IC50 of 10nM C) Astrocyte 
migration is not affected by IB in Boyden chamber assay. 
 
In this study, the RT2 glioblastoma model was employed for several reasons: 1) 
the RT2 model shows many attributes inherent to human glioblastoma that are not 
consistently observed in xenograft models such as white matter tract and perivascular 
invasion, pseudopalisading necrosis, extensive vascularization, and subpial spread 
(Figure 3.5) it has consistent time to death after implantation and 3) use of a syngeneic 
model allows observation of normal host responses to tumor development [239, 240]. 
Therefore, though IB was effective in inhibiting invasion of several glioma model lines in 
vitro, in vivo studies with an eGFP-RT2 (RT2) glioma intracranial xenograft model were 
used to fully investigate IB’s effects on invasion in situ [84].  
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Figure 3.5: Structural components of RT2 glioma RT2 exhibits perivascular invasion 
(1), white matter tract involvement (4), subpial spread (3), and perineuronal satellitosis 
(2). Further, this model shows evidence of pseudopalisading necrosis a hallmark of 
glioblastoma in humans (arrows). 
 
 
3.4.3 Design and Fabrication of liposomal Imipramine Blue (nano-IB) 
To determine the pharmacokinetics of IB alone, it was injected intravenously in 
Fisher rats using a formulation of cremophor and ethanol that allowed solubilization in 
saline[238]. This injection (3 mg/kg IB) yielded a poor circulation half-life of 11 minutes 
in adult male rats without tumor (Figure 3.7A, inset). Poor pharmacokinetics were likely 
due to the highly hydrophobic nature of IB at physiological pH resulting in quick 
absorption into the intravascular space after tail vein injection. To circumvent this 
shortcoming, we encapsulated IB in ~160nm PEGylated liposomes which showed 
comparable anti-invasive activity in vitro (Figure 3.6) [233].  




Figure 3.6: Encapsulation of IB in liposomes activity and characterization Using 
boyden chamber invasion assay at the EC50 as determined previously, IB liposomes were 
seen to inhibit invasion with mild decrease in potency (left). IB liposomes were imaged 
using Transmission Electron Microscopy and confirmed to be around 160 nm (right, 
scale bar is 200nm). 
 
IB could consistently be loaded into liposomes with a molar drug:lipid ratio of 
0.07. This low encapsulation relative to efficiency of loading compounds such as 
doxorubicin is due to the hydrophobic nature of IB yielding integration into the lipid 
bilayer as opposed to the hydrophilic core within the liposomes. Stability analysis 
revealed that structure of these liposomes was not compromised through IB loading as 
assessed by both release kinetics of IB incubated with serum at physiological 
temperatures and through loading and release of doxorubicin.  This was further 






























Figure 3.7: Encapsulation of IB in liposomes testing in vivo A) In vivo IB shows poor 
circulation time (inset: t1/2=11 minutes) and encapsulation prolongs circulation time 
(t1/2=18 hours).  B) T2-weighted images at largest tumor slice in live rats showing brain 
morphology. C) Omniscan-loaded IB liposomes in tumor site imaged with T1-weighting 
on day 4 (precontrast image shown) and  after 2, 4,and 10  days . Nano-IB accumulated in 
tumors after 2 days and showed distribution through brain after 4 days hours. Signal was 
gone 10 days after injection indicating degradation of nano-IB and dissipation of the 
gadolinium. 
 
Injection of nano-IB into adult male rats yielded a significant increase in the 
circulation time of the drug increasing half-life to 18 hours (3 mg/kg IB) (Figure 3.7A). 
It is well-established that many solid tumors exhibit a enhanced permeability and 
retention (EPR) effect which allows nanoscale particles such as liposomes and micelles to 
passively accumulate at the tumor in proportion to circulation time due to compromised 
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tumor vasculature [231, 241]. For the RT2 tumor model, this effect was confirmed both 
by injection of rhodamine-labeled liposomes with postmortem microscopy and through 
injection of Gadolinium-DTPA (Omniscan) loaded nano-IB followed by subsequent MRI 
for T1 enhancement (Figure 3.7C with companion T2-weighted images in 3.7B). This 
revealed that the nano-IB accumulates in RT2 tumors and that the nanocarriers remained 
at the tumor site for up to 4 days after injection. The signal dissipates and fades over time 
indicating nano-IB degradation and gadolinium clearance from the site. Using 
histological techniques, organs in animals receiving the nano-IB were collected and 
assessed through H&E staining for any signs of toxicity (Figure 3.8), particularly in the 
liver and spleen where it is known that liposomes will accumulate. There was no 
difference between the untreated and treated animals’ organs.  
 
Figure 3.8: IB yields no observable toxicity towards non-target organs as compared 
to untreated animals. Rats bearing tumors were delivered either nano-IB or saline 
liposomes and organs harvested after two treatments. There were no observable 
differences in vital organs. 
 
3.4.4 Nano-IB inhibits invasion in the RT2 model 
Nano-IB, (IB concentration of 3 mg/kg) was intravenously injected on day 4 and 
day 7, post inoculation of animals with RT2 cells. One sub-set of animals were sacrificed 
11 days after inoculation for tumor analysis. The nano-IB treated tumors were compacted  
with fewer regions of necrosis as compared to control tumors (Figure 3.9A).  
Treated
Untreated
Spleen Heart KidneyLiver Lung
100 um











Quantification of tumor density (DAPI stained nuclei/area of coronal section) increased 
significantly upon treatment (Figure 3.9D, right, t(8)=5.59, p< 0.001). Tumor margins 
were selected for analysis to account for differences in tumor shape due to invasion of the 
cells away from the injection site. The margin was defined to be the point at which there 
was >50% staining for either neurofilament (healthy brain-red) or GFP expressing RT2 
(green) as shown in Figure 3.9C. Cells crossing this boundary were counted at different 
locations throughout each tumor (n=4 animals per group). There was a significant 
decrease in the number of cells crossing the margin regardless of how far they migrated 
(Figure 8D, left, t(6)= 5.36, p<0.01). Consequently, the data demonstrated that increasing 
density of tumor inversely correlates with decreased invasion beyond the margin. 
Similarly, examining the margins using H&E (Figure 3.9B), there was a stark difference 
between the treated and the untreated tumors confirming the fluorescent images and 
analysis. In a sub-set of animals that were not euthanized on day 11 and allowed to live 
until they met the criteria for euthanization, nano-IB therapy led to a small (12.5%), yet 
significant increase in survival (t(7)=2.35, p<0.05). No significant increase in survival 





Figure 3.9: In vivo delivery of nano-IB yields a decreased in invasion A) Untreated 
(left) and treated (right) RT2 tumors in coronal slice with tumor stained with DAPI 
(white) showing a more condensed tumor (representative images from n=5 per group, 
scale bar=1mm).  B) Examination of tumor borders indicates a decrease in invasion 
shown by H&E staining, left:untreated, and right:treated, scale bar=50µm.  C) Staining 
tumor cells for GFP expression (green) and surrounding healthy brain stained with 
neurofilament (red), quantification of invasion beyond the border (blue dotted line) by 
counting cells per area of tissue (scale bar =100µm).  D) left: Quantification of tumor 
cells beyond borders shows a significant decrease in migrated cells (t(6)= 5.36, p<0.01). 
Right: this inversely correlates with quantification of tumor density (t(8)=5.59, p< 0.001) 





























































3.4.5 IB inhibits invasion through regulation of actin polymerization 
After nano-IB was delivered to tumors on day 4 and 7, in situ tumor samples were 
harvested for microarray analysis and western blotting (independent samples). A Rat 230 
2.0 affymetrix microarray revealed that the nano-IB treated tumors (n=3) had 
approximately 70 genes changing as compared to control untreated tumors (n=3) 
(Appendix 1). Further, this data was compared to healthy, non-tumor regions of brain 
(Appendix 1) from control animals (n=3) in the same area of the cortex to understand 
how these changes relate to underlying mutations in the tumor.  
Using Ingenuity Pathway Analysis, we determined the relationship between the 
changes in expression represented in the mRNA microarray and which upstream proteins 
may be involved in the changes in invasion in vitro and in vivo (Figure 3.10A). 
Interestingly, one subset of genes involved in actin polymerization and depolymerization: 
profilin-1 (-2.342), scinderin (+2.891), α-actin (-2.379), calgranulin (-2.101), and 
rhoGDP dissociation inhibitor alpha (+3.205) were greatly modulated in nano-IB treated 
tumors. Using rtPCR on pooled mRNA samples from 3 animals, these changes were 
confirmed quantitatively (Figure 3.10B). Further, using Western blotting on pooled 
protein samples from 3 animals, again most of these changes were confirmed to carry 
through to protein expression with the exception of the minimal decrease in profilin-1 
(Figure 3.10C and D).   This suggests that alters the invasion of tumors by affecting 




Figure 3.10: A candidate mechanism of action was determined in vivo using 
microarray analysis A)  Inegenuity Pathway Analysis on microarray results shows  actin 
regulatory elements and possible upstream protein regulators were shown to be altered in 
a manner that would decrease invasion of tumor cells.  B) Results from microarray were 
confirmed using rtPCR.  C) Analysis of pooled protein samples run on Western blot. D) 
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Figure 3.11: Effects on cell spreading seen in vitro. RT2 cells were incubated with 
ethanol, cytochalasin D, or Imipramine Blue for 24 hours then fixed and stained. Red=F-
actin (phalloidin), blue=nucleus (DAPI). Scale bar = 10µm. 
 
3.4.6 Combination therapy with Doxorubicin causes remission of aggressive glioma 
To determine the effect of nano-IB in enhancing survival, we investigated a 
combination therapy regimen with the chemotherapeutic, Doxorubicin. Doxorubicin was 
chosen because it has been implicated in enhancing invasion of tumors through its anti-
angiogenic effects [110]. Further, it is has been delivered in liposomal formulations 
minimizing toxicity and yielding similar delivery characteristics to our nano-IB with 
beneficial effects in brain tumors [32].  Last, to test the hypothesis of anti-invasive 
treatment aiding in chemotherapy and not some synergy of the two molecules, we 
performed IPA based on microarray data and known Doxorubicin interactions to show no 
possible synergy.  RT2 cells were treated in vitro with DXR and IB (both free and 
liposomal forms) to determine if there was a synergistic effect (Figure 3.12A). Treatment 
was performed at a range of concentrations (50nM-200µM DXR) and shown here for the 
IC50 of DXR in RT2 glioma [300nM+/-23.71 (–IB) R2=0.97, 220nM+/- 71.03 (+IB) 
R2=0.71, n.s.]. These data indicate no synergy in mechanism in vitro for enhancing cell 
death.  
Four groups were used in this study: control (saline liposomes), IB (nano-IB), 
DXR (nano-DXR), and IB + DXR (nano-IB, 3 mg/kg on day 4 followed by nano-DXR, 7 
Untreated Cytochalasin D (2uM) Imipramine Blue (2uM)
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mg/kg, on day 7). All groups received two injections of liposomes on days 4 and 7 to 
account for any potential lipid load effects [242]. Though previous data indicated a slight 
increase in survival of RT2 inoculated animals with two injections of IB, there was no 
increase seen with a single injection. For the conditions of this study, the survival time 
for this aggressive RT2 line ranged from 13 and 24 days on average over many trials 
(data not shown). MRI was taken at day 7 (Figure 3.12C) to confirm tumor presence 
before treatment. Animals were excluded if a tumor was not identified via MRI.  Lipid 
load was the same for all groups (55 µmol/kg) to account for differences in circulation 





Figure 3.12: Figure 6: Delivery of IB before Doxorubicin (DXR) yields increased 
survival after a single treatment A) Treatment of RT2 glioma with IB (5µM) and 
Doxorubicin (0.5µM) in vitro shows no enhancement of cytotoxicity using both free 
formulations and liposomal formulations. B) Survival study in vivo shows increased 
survival when animals were treated with nano-IB before DXR (p<0.05). C) MRI of 
animals from the combination group confirms disappearance of tumor over time in co-
treated tumor (right) as compared to recurrence in DXR alone treated tumor (left). D) 
End of study H&E histology shows hemosiderin in tumor site (top) and DXR treated 
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Remarkably, there was 100 percent survival in the sequentially treated group that 
received nano-IB followed by nano-DXR for a period of 200 days or greater (Figure 
3.12B). The nano-DXR treated group without nano-IB combination therapy had a small 
subset showing survival (as of end of study) and with the majority of the groups resulted 
in death (as assessed by display of signs of morbidity and confirmed by tumor presence) 
early in the study. There is a significant increase in the median survival time between the 
DXR group alone and the IB-DXR group from 44.5 days for DXR to >200 days for IB-
DXR therapy (Figure 3.12B). The survival data indicate that there is dramatic 
disappearance effect when nano-IB was prior to treatment with nano-DXR.  This was 
confirmed further by premortem MRI (Figure 3.12C) and postmortem histology (Figure 
3.12D) of surviving animals in both groups. The DXR group at six months showed 
evidence of tumor presence on MRI (left) with large-scale inflammation indicated in T2-
weighted images by excess fluid in the brain, and a necrotic core surrounded by 
differentially dense tissue (as compared to normal brain tissue). These attributes were 
similarly seen in earlier timepoint DXR group animals preceding display of signs of 
morbidity. In contrast, in IB-DXR animals, there was a black mass seen on the T2-
weighted MRI (right) which appeared at day 60 and maintained size and shape until the 
end of the study. Further, when animals were injected with free Omniscan (Gadolinium-
DTPA) and imaged, there was no contrast enhancement seen in the IB-DXR group 
though there was cortical enhancement in the remaining animals from the DXR group 
indicating revascularization and disruption of the blood brain barrier (Figure 3.13). 
Lastly, histological analysis of tissue postmortem indicated presence of hemosiderin 
positive staining indicative of reactive oxygen related stress at the original tumor site and 
evidence of abnormal tissue in DXR animals but not in IB-DXR animals (Figure 3.12D) 




Figure 3.13: T2- and T1-weighted MRI of DXR alone treated tumor. DXR treated 
tumor at end of study showing coronal sections through the brain away from the site of 
implantation (center square) in 1mm increments. MRI showed incidence of tumor-type 
structures through the brain. Further, injection of Omniscan showed contrast 




The ability to inhibit glioblastoma (GBM) invasion represents a significant 
clinical breakthrough. Many drugs have been heralded as being anti-invasive such as 
chemotherapeutics in low doses and other specially designed molecules [51, 243-245]. 
However, these drugs fail clinically or to date, there is no way to determine if, in fact, 
these drugs work as anti-invasive agents.  Thus a compound that specifically inhibits 
glioma invasion, should lead to better outcomes when administered in combination with 
currently available cytotoxic compounds (such as Doxorubicin) and can have serious, 










Imipramine Blue (IB) inhibits invasion of many glioma cell lines in vitro, and of 
the RT2 glioma in vivo.  Through quantitative analysis we show that invasion beyond the 
tumor border was significantly inhibited upon treatment with nano-IB. Correlatively, IB 
treatment increased tumor density which is advantageous to all current treatments of 
GBM. Resection of a more contained tumor (similar to lower grade tumors) has a higher 
success rate and limiting the area of irradiation prevents adverse side effects and 
activation of the surrounding brain [98, 106, 229] Further, Imipramine Blue, acts via a 
novel mechanism of action as compared to previously tested anti-invasive compounds 
[222, 243, 246, 247]. 
Regulation of depolymerization of F-actin is one of the mechanisms by which the 
RT2 tumors are spatially ‘contained’ in vivo, however, our analysis indicates that 
Imipramine Blue causes transcription level alterations as opposed to commonly seen 
direct interactions with F-actin.  Many of the genes that are implicated in the IB mode of 
action are commonly mutated in cancers leading to decreased cell stability and 
heightened motility [144]. Altered expression of actin-related genes in general has been 
seen in many cancers including glioma [248]. Acta1 (↓), scinderin (↑), calgranulin (↓), 
and profilin-1(↓) are implicated downstream of the RhoGTPases possibly indicating 
inhibition by RhoGDP Dissociation Inhibitor α (↑) in signaling [158, 249, 250]. 
Decreased rhoGDIα expression has been correlated with increased malignancy in brain 
tumors [251]. Overexpression of calgranulin (S100A8), calcium-binding transcription 
factor, correlates with malignancy of lung adenocarcinoma, colorectal cancer and cervical 
cancer [252-254].  Scinderin, a gelsolin homologue known to sever and cap actin 
filaments, is used in general cell motility [164].  Gelsolin has been shown to be 
downregulated in 60-90% of cancers, though scinderin is largely understudied in cancers 
[255].  In our analysis, scinderin was the most highly upregulated both at the 
transcriptional and the protein level indicating a probable role in decreasing the 
invasiveness of RT2 in vivo. Further, since these proteins tend to be preferentially 
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mutated in cancers, there is a selective effect for tumor tissues that is not translated to 
other cell types such as astrocytes.  However, since analysis was performed many days 
after exposure of cells to nano-IB (7 days of treatment), it is possible that these 
transcriptional level alterations may be a result of earlier cellular events. In the same vein, 
the lasting effect of treatment in the survival study may indicate that these expression 
level changes are more important than initial alterations in cell functionality. 
Ingenuity Pathway Analysis revealed that many proteins upstream may be 
regulating this cycle of large structure actin changes including the major players in cancer 
progression and metastasis (NFkB, PI3K, PKC)[216, 256]. Many of the other molecules 
implicated through microarray could have further anti-tumor activity in vivo that may not 
be seen in vitro such a extracellular matrix (ECM) secretion (versican), integrin-binding 
(ITGA6), and chemokine secretion for immune recruitment or training (CCL2, CCL9, 
CXCL13)[256, 257]. The ECM and the cell’s interaction with it is a major player in 
tumor progression showing increased motility with lower integrin binding and ECM 
secretion being vital for invasion [15, 145]. Further, chemokines are highly involved in 
both immune system interaction and migration of tumor cells away from the primary 
site[258]. These added changes in phenotype may contribute to the decreased malignancy 
of these tumors and response to chemotherapy in vivo, however, the decreased motility is 
the primary effect of the compound. 
Though nano-IB alone increased survival modestly in rats bearing the RT2 
glioma, its ability to enhance the efficacy of clinically approved chemotherapeutics such 
as DXR potentially represents a significant advance.   DXR is an excellent cytotoxic 
agent for the treatment of RT2 glioma with an IC50 well below that of comparable 
cytotoxic agents such as paclitaxel and temozolomide. Further, in its liposomal 
formulation it has been clearly demonstrated to be efficacious in minimization of tumor 
burden and recurrence after treatment [32].  Lastly, recent reports indicate that liposomal 
DXR’s mechanism of action is potentially like anti-angiogenic drugs in killing the 
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endothelium and thereby cutting off tumor blood supply[110]. In the RT2 model, we 
have observed that animals given nano-DXR will often survive longer but the tumors at 
the time of death are much more diffuse with metastasis throughout the brain. Hence, the 
use of a drug that could in fact inhibit the cells from invading even with treated with 
therapies that might enhance invasion presents a stringent test for the evaluation of nano-
IB’s anti-invasion efficacy.   
 One hundred percent of animals given sequential treatment of nano-IB with 
nano-DXR (n=5) survived with no observable tumor mass seen by contrast-enhanced 
MRI and histology as compared to nano-DXR animals. The ability of this combination of 
drugs to yield complete survival and tumor disappearance after only a single treatment is 
striking. Other studies have shown comparable survival with metronomic or multiple 
treatments but not in a single round of treatment [180]. The use of Doxorubicin has been 
avoided largely due to toxicity however and cost-benefit to the patient, liposomal 
encapsulation avoids such an effect and coupling with nano-IB enhances the efficacy and 
survival such that the cost-benefit ratio shifts[259].  
The tissue remaining after treatment with both drugs resembles hemosiderin-laden 
macrophages which are likely the result of the tissue dying with resulting blood-brain 
barrier sealing at the original tumor site. This morphology has been seen post resection in 
tumors both on MRI and histologically [260]. Further, the histology reveals diffuse 
spread of DXR-treated tumor which was also visible on T2-weighted MRI through the 
cortex. The combination of these two treatments is highly beneficial to the treatment of 
glioblastoma in only a single treatment. It is possible of course that there are, other 
possible secondary effects of the drug that can lead to enhancement in vivo though none 
was seen in vitro.  It has been observeed that MMP inhibitors have anti-angiogenic 
effects along with anti-invasive effects which could be occurring with IB as well [221]. 
This alteration could lead to enhanced delivery to tumor after pre-treatment and enhance 
the effect. Further, immune system involvement in cancer can dictate the response of 
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tumor cells to chemotherapy and could be at play here[261]. Regardless, 100% 









Glioblastoma (GBM) is a difficult disease to treat because of its invasive nature. 
Further, many chemotherapeutics that work against other cancers fail against 
glioblastoma because of the specific response of cells to invade the brain. There has been 
success with liposomal formulations of many chemotherpeutics with GBM, the most 
striking of which is doxorubicin. Further, due to the ability of DXR to efficiently and 
remotely load into liposomes, this formulation is advantageous for co-delivery with a 
high hydrophobic drug which will partition to the lipid bilayer of the nanocarrier. Using 
this approach, we have developed a co-loaded Imipramine Blue- Doxorubicin liposomal 
nanocarrier for intravenous delivery to highly invasive glioma. Imiparmine Blue (IB) is a 
potent anti-invasive compound that has shown promise in halting invasion and improving 
chemotherapy against glioblastoma in vivo. Here we show that the co-encapsulated IB-
DXR liposome enhances survival from a median time of 44.5 days in DXR alone animals 
to >180 days for IB-DXR in an aggressive rodent model of glioblastoma yielding 
survival in many animals through a single treatment. Hence, we propose that this 
formulation would be an efficient means of treating glioblastoma to enhance 
chemotherapeutic efficacy and attenuate the invasive response after treatment which 
minimizing patient discomfort. 
4.2 Introduction 
The ability of glioblastoma to invade in the brain is a primary cause of recurrence 
and failure of common anti-tumor therapies such as chemotherapy, radiation, and 
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resection [22, 98, 256]. Recently, a novel compound, Imipramine Blue was shown to 
inhibit invasion in the malignant glioblastoma model RT2 in rats with complete survival. 
In this paper, separate nanocarriers were used to deliver IB and doxorubicin. However, 
clinically, patients would prefer to have a single injection which could yield remission of 
their tumor. Using nanocarriers for combinatorial therapies is becoming a common 
application of the nanotechnology and is thought to be a possible way to ease both 
systemic burden of circulating nanocarriers and minimize patient visits [262].  
Imipramine Blue is a compound that halts invasion via a novel mechanism. 
Further, IB yields increased survival when combined with DXR. DXR kills cancer cells 
via DNA damage and subsequent apoptosis induction. Many cancers that have active 
MDR pumps can resist the ability of DXR to kill them [263]. However, it is unclear if IB 
is affecting this mechanism but instead is only yielding a synergistic effect in vivo. The 
mechanism by which survival is enhanced is purported to be due to the ability of IB to 
halt invasion. DXR has been shown to actually induce invasion of glioblastoma in vivo in 
rodent models [110, 264]. It is thought that this increase in invasion is due to the anti-
angiogenic effect that Doxorubicin has upon delivery. Doxoroubicin has been discounted 
in glioblastoma treatment in patients due to the toxicity that ensues from delivery and 
poor accumulation at the tumor site though liposomal doxorubicin has shown promise 
[32, 265]. 
Nanocarriers can be used to deliver chemotherapeutics in a passively targeted 
manner to solid tumors such as glioblastoma [235]. Liposomal nanocarriers consist of a 
phospholipid bilayer with an aqueous core. They can selectively accumulate in the tumor 
through the enhanced permeability and retention effect which takes advantage of the 
leaky vasculature of the brain tumor which will allow selective accumulation of the 
150nm particles [204]. Use of this formulation for doxorubicin has been successful 
against colorectal cancer yielding accumulation at the tumor site, tumor death, and 
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reduced toxicity to the patient [32, 266]. Therefore, liposomal nanocarriers have gained 
popularity in the clinic for several different drugs after gaining FDA approval [267].  
Co-delivery is a popular option for treatment of cancers because of the enhanced 
delivery and minimized stress to patients. The benefit of co-delivery of compounds is 
several fold. First, the tumor will receive both drugs without altering the 
pharmacokinetics of either compound. Second, possible drug interactions that can lead to 
toxicity if delivered separately are minimized. Third, the discomfort to the patient due to 
repeated injections is reduced. Many drugs have been co-delivered including doxorubicin 
and versepamil, and doxorubicin and vincristine leading to promising effects in animal 
models of cancer [268, 269].  
In this study, we develop a stable dual encapsulated IB-DXR liposomal 
nanocarrier that synthesized through passive encapsulation of IB followed by remote 
loading of DXR. Further, we conduct survival studies showing that the IB-DXR 
nanocarrier enhances survival in the glioblastoma model RT2 in rats yielding remission 
of tumors. Lastly, using MRI analysis we show the progression of the tumor in response 
to treatment and track its size, following with histology to examine further the effect of 
combination of these two compounds in vivo. 
4.3 Methods 
4.3.1 Synthesis of Liposomes 
Coencapsulated IB-DXR liposomes were synthesized by remote loading of DXR 
into 40 mM Stealth liposomes with passively loaded IB. IB liposomes were made as 
previously described  with the following modifications: the solution was hydrated with 
400 mM ammonium sulfate in place of the phosphate-buffered saline. The solution was 
dialyzed overnight in 1x PBS to yield the pH gradient for remote loading. DXR ( in 
saline (2 mg ml-1) was added to the solution at a ratio of 0.05 mg DXR per 1 mg lipid and 
heated to 60°C for 1h. Liposomes were passed through a Sepharose (GE Healthcare) 
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column and co-loaded liposomes were collected and concentrated via diafiltration to a 
final IB.  IB liposomes, DXR liposomes, and control (lipid only) liposomes were 
formulated using the same methods with final drug:lipid concentrations within 10% of 
co-loaded.  
4.3.2 Nanocarrier characterization 
Nanocarrier size was assessed using Dynamic Light Scattering. Final IB content 
was assessed by absorbance at 610nm, and final lipid content was assessed by 
fluorescence detection (485 ex/610 em). For DXR content, liposomal nanocarriers were 
lysed with 5% Triton X-100 at 60°C before measuring absorbance (480nm) and 
fluorescence.  Leak studies were conducted as previously described[270]. The thermal 
stability of the coencapsulated Doxorubicin was monitored in vitro. Coencapsulated 
liposomes were added to 25% v/v PBS and 50% v/v FBS and placed in 37°C water bath. 
At 24-hour increments, a sample of this mixture was taken and the amount of entrapped 
Doxorubicin was measured using fluorescence spectroscopy. The amount of encapsulated 
DXR was reported as a percentage of the initial amount encapsulated. 
4.3.3 Cytotoxicity assays 
RT2 glioma cell lines were maintained as described. For cytotoxicity assays, cells 
were plated at 100,000 cells/ml in 24-well plate and allowed to attach overnight. Wells 
were then treated with media solutions containing either coencapsulated liposomes, DXR 
liposomes, IB liposomes, or blank liposomes for 2 hours. The concentration of DXR was 
controlled at 5uM in each well. The concentration of IB in the wells with IB liposomes 
was equal to the concentration of IB in the wells with coencapsulated liposomes. Drug 
media was removed and fresh media was added after the two hours. Cells were then 
incubated with CCK8 (Dojindo) for 1 hour, media was removed and read at 490 
absorbance. CCK8 assay was performed again at 72 hr after drug treatment and all 
readings were normalized to control conditions.  
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4.3.4 Survival studies 
Animals were anesthetized via isoflurane inhalation and mounted on a stereotaxic 
frame. The head was shaved and cleaned and a 3cm incision was made through the skin 
to expose the skull. A 2mm burr hole was created in the skull using a Dremel hand tool 
mounted on the frame 2mm lateral and 2mm anterior to lambda. A Hamilton syringe was 
used to inject 10µl of cell solution over five minutes after which the syringe was slowly 
removed and the burr hole closed with bone wax. The wound site was closed using 
sutures (Ethicon), the wound cleaned, and flunixin meglumine administered 
intramuscularly. Animals were monitored daily after inoculation.  
Seven days after implantation, MRI was performed as described followed by tail 
vein injection of either Doxorubicin liposomes (DXR), IB liposomes (IB), IB-DXR 
liposomes (IB-DXR), or saline liposomes (Control), at doses of 3 mg/kg IB and 7 mg/kg 
DXR. Animals were monitored daily and MRI was performed at intervals to monitor 
tumor progression. Animals displaying signs of morbidity including hunched posture, 
abnormal vocalization, weight loss, poor hygiene, or decreased movement in accordance 
with Georgia Tech IACUC guidelines. Animals were sacrificed by CO2 inhalation upon 
display of any of these symptoms and the brain removed to confirm tumor presence.  
4.3.5 Magnetic Resonance Imaging 
Animals were anesthetized by 1-2% Isoflurane and placed in a 7T MRI (Bruker 
Instruments, Billerica, MA) equipped with a 30mm head coil. A T2-weighted image was 
taken through the head using the following parameters: 2.0 s repetition time(TR), 48 ms 
echo time(TE), FOV=40mm x 40mm with a 256 x 256 matrix, slice thickness=1 mm, 
number of slices= 20, 2 averages per phase encode step requiring a total acquisition time 
of about 6 minutes per rat. MRI was performed before treatment began to confirm tumor 
presence and at intervals throughout the survival study to monitor the progression of the 
tumor and response to treatment. Rats not showing evidence of tumor were removed from 
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the study. For T1-weighted MRI, animals were treated with either Gd-loaded nano-IB (for 
accumulation, 3 mg/kg IB) or free Gd-DTPA (Omniscan) for end of survival study tumor 
leak (final concentration of Gd was 0.15 mmol/kg).  T1 images were taken according to 
the following parameters: 2.0 s repetition time(TR), 48 ms echo time (TE), FOV=40mm 
x 40mm with a 256 x 256 matrix, slice thickness=1 mm, number of slices= 20, 2 averages 
per phase encode step requiring a total acquisition time of about 6 minutes per rat.  
4.3.6 Histology 
Sections were paraffin embedded and hemotoxylin and eosin stained for 
postmortem analysis. 
4.3.7 Image analysis 
MRI files were converted to image stacks and the tumor outlined by sight by a 
blinded student. The area was calculated using ImagePro analysis software and converted 
to volume based on the interslice thickness (1mm) and summed. When possible, volume 
was calculated in sagittal slices and compared to ensure there were no artifactual 
quantification difficulties in the coronal sections. In order to calculate the volumetric 
growth of tumors, images obtained from MRI were analyzed using the Image-Pro Plus 
software (Media Cybernetics, Inc., Bethesda, MD). The area where tumor was present 
was calculated in pixels for each slice of the sequenced images (20 slices). This area was 
then converted to mm^2 using a conversion factor of 72.8 pixels/mm^2. The tumor area 
from each slice was multiplied by the slice thickness (1mm) to obtain the volume. The 
tumor volume of the individual slices was then summed up get the total volume of tumor. 






4.3.8 Statistical Analysis 
For multi-comparison studies, one-way ANOVA was performed with Bonferroni 
post t-test for pair-wise comparisons. For survival studies, Mantel-Cox analysis was 
performed between groups to compare curves. *p<0.05, **p<0.01, ***p<0.001.  
 
4.4 Results 
4.4.1 IB and DXR can be co-loaded into stable liposomes 
Through the use of both passive and remote loading, we have been able to 
encapsulate both compounds into single liposomes (Figure 4.1). Use of the Imipramine 
Blue liposome formulation (requiring lower concentrations of cholesterol to enable lipid 
bilayer loading), DXR is remotely loaded with similar efficiency to literature reported 
values [233, 265, 271].  
 
 
Figure 4.1: Co-loading of IB and DXR in liposomes IB is passively loaded into 
liposomes and a pH gradient is formed after dialysis. Doxorubicin is then actively loaded 






However, it is necessary to load less DXR per lipid so that once liposomes are 
concentrated to the final IB dose, the same DXR dose is maintained. Further, through 
plasma stability studies, it was shown that there was only 20% leak of DXR from IB-
DXR liposomes which was not significantly different from that seen with the DXR 
formulation (stealth) (Table 4.1). Hence, we are confident in the ability of our 
nanocarrier to enable delivery to glioma safely through passive targeting. 
 
Table 4.1 Characterization of liposomes Data indicates the size, drug:lipid ratios, and 




4.4.2 IB-DXR nanocarriers show no synergistic cytotoxic effect in vitro 
In vitro experiments using both RT2 and U87MG glioma cell lines, the 
synergistic effects of IB and DXR were examined as a co-encapsulated formulation 
(Figure 4.2). Previous publication has shown that there should be no synergy with the 
dual encapsulated formulation and that is what our results confirm. Further comparison to 
separately delivered IB and DXR liposomes versus the co-loaded liposomes at the same 
total drug concentrations of each yields no increased or decreased cytotoxic effect beyond 
that of DXR liposomes alone. Therefore, we conclude that there is no advantage of the 
Formulation Average Size (nm) Leak after 48h DXR:Lipid Molar 
Ratio
IB 160 nm n/a n/a
DXR 150 nm 16.461% 0.09
IB-DXR 161 nm 16.934% 0.09
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IB-DXR co-loaded formulation to the individual cells above that seen with DXR 
liposomes alone. 
 
Figure 4.2: There is no enhancement of cytotoxicity with dual liposomes A) 
Cytotoxicity of RT2 glioma exposed to IB-DXR liposomes versus IB + DXR liposomes 
showed no change in viability B) Similarly, U87MG did not show enhanced cytotoxicity. 
***p<0.001 as compared to control by t-test. 
 
 
4.4.3 IB-DXR co-loaded liposomes enhance survival over DXR alone in vivo 
Through a single injection of the co-loaded liposomes 7 days after tumor 
inoculation, we saw an enhancement in survival times with a median survival time 
increase from 44.5 days in DXR alone animals to >200 days in the co-loaded IB-DXR 
administered animals (Figure 4.3). The change in survival curves was not significant, 
however, when analyzed via Mantel-Cox statistical test (Χ2(1)=1.580, p>0.05). However, 
the complete survivors at the end of the study as compared to the DXR alone treated 
group was greater and we are confident in saying there is a benefit to the delivery of IB-
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DXR coloaded as compared to the DXR alone and this is furthered by the postmortem 
analysis of the animals treated with the co-loaded formulation. 
 
Figure 4.3: IB-DXR increases survival over DXR alone treatment Survival data from 
6 month survival study  in rats inoculated with RT2 glioma indicating increased survival 
percentage with the dual-loaded liposome. Animals were treated one time at seven days 
post tumor inoculation and monitored with MRI. Animals were sacrificed upon display of 
criteria for euthanasia.  
 
4.4.4 IB-DXR animals have no evidence of tumor  
Through MR imaging we were able to track the progression of the tumor growth 
and response to treatment live (Figure 4.4). The control groups with no tumor remission 
(control and IB treated animals) showed tumor growth without any real remission leading 
to subsequent death of most animals before day 24 when the third MRI was taken. These 
animals had strong evidence of fluid influx into tumor represented by white areas (F) and 
large ventricles in the brain. Further, there was a morphological change in the 
surrounding brain indicating pressure from the tumor mass. DXR and IB-DXR animals 
had continued tumor growth after treatment on day 7 and then subsequent necrotic areas 
(N) as the cancer died due to lack of nutrients or due to treatment.  


























Figure 4.4: Pre and post treatment MRI for all groups. IB and control animals were 
euthanized before day 24. DXR and IB-DXR animals showed necrosis (N) by day 24 
which was 17 days after treatment. Further, through T2 images, excess fluid in the brain 




The last interesting result was the recurrence of indicators of inflammation in the 
DXR animal that was not present in the IB-DXR animals as the area of necrosis seemed 
to maintain after treatment in complete survivor animals. This result was similarly seen in 
the previous publication with the co-treated animals in this tumor model. Growth curves 
indicating the MR image “footprint” of the tumor throughout the study show this growth-
reduction-leveling of the growth characteristics in the IB-DXR animals and the 
subsequent uptick in tumor enhancement in the DXR alone animals (Figure 4.5). 




















Figure 4.5: Tumor growth curves for all groups shows regrowth of DXR tumors (n=2 
at end of study) vs maintenance of tumor size in IB-DXR treated tumors (n=4 at end of 
study). Other tumors showed exponential growth as is expected in control tumors. 




4.4.5 No tumor is present through histological analysis 
The ability of IB and DXR together to enhance tumor reduction is further 
validated in the post mortem histological analysis of the brains of the treated animals 
(Figure 4.6). MRI reveals a black mass that occurs starting at day 42 and persists until 
the end of the study at 180 days. Upon examination this tissue was brownish in color and 
when stained using H&E continues to appear brown with no apparent cells present. 
Further, there was no evidence of tumor tissue throughout the brain indicating eradication 
of the tumor from the primary site of inoculation. Similarly, there did not appear to be 
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any accumulation of blood from hemorrhage in the IB-DXR tumor indicating blood brain 
barrier closing as compared to other groups where there was a large amount of 
hemorrhage evidence at the time of death. This correlates with the presence or absence of 
higher levels of fluid on T2 weighted MRI. Hence, the MRI and survival data suggest that 
there is an absence of tumor regrowth throughout the brain. 
 
 
Figure 4.6: IB-DXR treated tumor in MRI (left, scale bar =1mm) and in post study 
H&E (right, scale bar = 50µm) on day 180 reveals lack of tumor recurrence but presence 






The ability to halt glioma invasion has many implications in the treatment of the 
disease. Development of such drugs is highly desirable because of the secondary effects 
of many of the common treatments of the disease including chemotherapy and radiation 
therapy which may induce invasion. Further to minimize patient visits and possibly create 
a consistent or metronomic therapy, a singly encapsulated nanocarrier is desirable in 
reducing toxicity, maximizing delivery, and minimizing patient visits for infusions. Here 
we have shown the development and application of a co-loaded IB-DXR liposomal 
nanocarrier for the treatment of glioblastoma. Further we have demonstrated that use of 
this treatment on a highly aggressive model of GBM enhances efficacy above those 
levels seen with DXR liposomes alone thereby validating the possibility of this 
combination to enhance survival.  
The development of the co-loaded nanocarrier is not a novel technology, 
however, this represents the first attempt at treating with an anti-invasive and a 
chemotherapeutic in the same liposome. Previous studies with liposomes include delivery 
of verapamil, a P-glycoprotein inhibitor, with Doxorubicin to overcome the multi-drug 
resistance often seen with the chemotherapeutic [268]. This treatment has shown success 
in overcoming MDR in vitro but in vivo results are yet to be seen. In another study, DXR 
and vincristine, an inhibitor of mitosis, were loaded into liposomes together and has 
shown success in reducing growth of mammary carcinoma and Kaposi’s sarcoma [269]. 
In these formulations, the drugs were remote loaded either by the same mechanism (pH 
gradients) or through a combination of mechanisms (pH for DXR and transition metal 
gradient for vincristine). In our study, the use of passive encapsulation of IB followed by 
remote loading of Doxorubicin was the simplest method by which to enhance 
encapsulation. However, remote loading of IB, once optimized, could offer equally 
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efficient loading of both and possibly enhanced release profiles in vivo leading to better 
survival rates. 
It should be noted though, that the release kinetics at the liposomal level are not 
the only reason for differences in efficacy over sequential or subsequent treatments. In 
the mouse mammary model with vincristine and Doxorubicin, it was seen that the tumors 
were more responsive to sequential and alternating treatments of the two drugs as 
opposed to the co-loaded formulation though they were equally toxic in vitro [269]. The 
authors attribute this to changes in pharmacokinetics leading to greater tumor 
accumulation of injected liposomes. This could be due to the liposomal sequential 
injections. It has been seen with stealth Doxil liposomes that repeated injections can lead 
to changes in side effects and biodistribution profiles of the drug even as close as one 
month apart [265]. Therefore, it could be that alterations in liposomal sequential dosing 
showing enhanced efficacy over simultaneous dosing should be interpreted loosely due to 
the potential of the liposomal deliveries to alter subsequent injections. Further, use of 
combinatorial dosing can be advantageous in this regard because there is avoidance of 
any unforeseen toxic side effects. In the study examining multiple injections of Doxil, it 
was seen that unwanted side effects in the form of skin lesions were minimized by 
spacing out injections to one per month [265]. This could mean that the development of 
co-loaded nanocarriers offers the best way to deliver more compounds with fewer side 
effects from delivery alterations. Further, with the promising enhancement of survival 
times seen in this study, we are confident in promoting use of such a compound in other 
models of glioma as well as non central nervous system cancers. 
Enhancement of survival times can also be attributed to the nature of the 
interactions of the two drugs in vivo. Though no synergy was seen in in vitro experiments 
with IB and DXR liposomes, a host of in vivo factors could affect the interactions of 
these drugs. In previous work with this novel compound it has been shown to be involved 
in pathways which can lead to a host of microenvironmental changes including immune 
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response and matrix alterations. Therefore, there could be a secondary effect stemming 
from IB beyond the anti-invasive attribute that is contributing to enhancement of 
doxorubicin. In fact, DXR has been shown to induce immune response and stifle inherent 
immune responses to cancer in breast carcinoma [261]. It also is known to cause 
upregulation and enhanced secretion of several matrix metalloproteinases (MMPs) in 
breast cancer and tumor endothelial cells. IB is implicated in pathways reversing these 
aspects of malignancy [112]. Therefore, the increased response in the presence of both 
compounds in vivo could be explained by these phenomena which cannot be observed 
readily in vitro.  
In all, we have shown the development of a novel co-encapsulated therapeutic 
combination incorporating a novel anti-invasive with a chemotherapeutic. This 
combination was previously seen to yield long-term survival in the RT2 glioblastoma in 
rats. Here we see promising survival times with similar tumor remission phenotypes at 
the end of study, however, there was not long-term survival in all subjects. The ease of 
using such a nanocarrier along with the development of a simple protocol for co-
encapsulation of a novel hydrophobic compound with a potent chemotherapeutic offer an 
advantage to the cancer field. We can examine the interaction of two drugs in vivo and 
observe there is synergy unobserved by the in vitro testing without concern for alterations 
in delivery profiles of subsequent injections. Further, with the development of a host of 
novel anti-invasive and chemopreventive agents that are hydrophobic, we can use this 
protocol to examine interactions of these compounds with chemotherapeutics that are 




CHAPTER 5  
CANDIDATE MECHANISM OF ACTION OF IMIPRAMINE BLUE 
 
5.1 Summary 
Imipramine Blue has been shown to inhibit invasion of glioma in vitro and in 
vivo. It is known that it works through inhibition of actin polymerization through 
regulatory proteins, however, the exact mechanism is not understood. Further, it was 
shown that use of this compound in conjunction with chemotherapy (doxorubicin) 
enhances tumor remission in rat glioblastoma. It would be useful to understand the 
mechanism of action of IB and thereby better predict and understand its use in cancer. 
The compound is a triphenylmethane which should have activity similar to that seen with 
diphenyliodide, a pan-Nox inhibitor. Through a series of studies, we explore the various 
inhibitory activities of IB in vitro beginning with actin polymerization inhibition through 
timecourse examination and binding assays. Then we show that IB inhibits Src-kinase 
related activation of invadopodia formation. Then, we show that IB inhibits both 
activation of NFκB and Nox4 through functional studies. Last, using a magnetic bead 
precipitation assay, we show that IB directly binds Nox4 in glioma cells. Therefore, we 
can say that IB has Nox4 antagonistic activity and complete the model for how IB halts 
glioma invasion in vitro and in vivo. Though more studies should follow, this is a base 
from which to further examine the effects of this interesting compound in cancer. 
5.2 Introduction 
Cancer invasion and metastasis is a difficult problem to solve for today’s 
therapies. Primary means of treatment of cancer focus on removing the tumor and not the 
metastasis. However, this method does not work for many types of cancer where 
metastasis is either an ongoing process when treatment occurs, or therapy that works to 
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remove the tumor actually enhances invasion. Long thought that cancer cells acquire the 
ability to invade over time, there is increasing evidence that many tumors are inherently 
invasive from onset [272]. Therapies such as anti-angiogenics and radiation have both 
shown increased migration of cancer cells in vitro and in vivo leading to recurrence and 
further malignancy of disease [43, 77]. Therefore, compounds that stop invasion are 
highly desirable as novel therapeutics against cancer. 
Imipramine Blue is a novel compound recently shown to inhibit invasion of 
glioblastoma. This compound was found through a screen of novel triphenylmethane 
derivatives against malignant glioma. Further, when coupled with more traditional 
chemotherapy, IB enhanced the ability of Doxorubicin to the point of complete 
remission. There is a benefit to pre-treating the tumor with IB yielding a sort of priming 
effect on the tumor. However, the mechanism by which this drug works is still not fully 
understood.  
Through microarray analysis, Imipramine Blue was shown to inhibit actin 
polymerization through upstream regulators. The effect on the cells was briefly explored 
through cell morphological observation which showed an inhibition of actin stress fiber 
formation. The data from microarray coupled with the cell morphology implicates actin 
polymerization as the key as opposed to loss of focal adhesions for inihibition of cell 
spreading. There are multiple upstream pathways that can lead to loss of actin stress 
fibers and cell spreading, however, and thus they should be explored to determine the 
mechanism by which IB is acting on cancer cells [160]. 
There are several candidate mechanisms by which actin polymerization can be 
regulated and several effectors were seen via IPA. These mechanisms include PI3K, 
PKC, NFkB, MAPK, and the RhoGTPases. PI3K is known to be mutated in a significant 
number of cancers with overactivity resulting in downstream migration, proliferation, 
survival, and growth signaling changes [273, 274]. MAPK is dysregulated in many 
cancers with downstream effects on proliferation via and migration via alterations in 
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cytoskeletal and adhesion regulation [275]. NFkB is implicated in every form of 
malignancy in cancer and can enhance cell motility through adhesion disassembly and 
assembly, cytoskeletal rearrangement, matrix metalloproteinase secretion and 
transcriptional level changes of multiple effectors of cell movement [212, 213]. The 
RhoGTPases are regulated in concert with all of these pathways and lead to the 
development of actin rich invadopodia [250]. The initial alterations in all of these 
upstream proteins can be linked to a variety of membrane linked receptors and 
transmembrane proteins.  
NADPH Oxidases are a class of molecules responsible for creating reactive 
oxygen species (ROS) which include H2O2 and O·. These molecules are responsible for 
inducing a variety of signaling effects including activation of inflammatory, migratory, 
and angiogenic pathways [176].  There are several different Nox molecules that localize 
in the membranes of the cell. Nox1-3 and 5 are activated by Rac and Nox4 can be 
activated independent of Rac [169]. These proteins make different ROS under cell stress 
conditions which will activate NFκB through cleavage of the IKK linker of the dimeric 
protein [276]. This will lead to transcriptional events and protein activation throughout 
the cell resulting in enhanced migration of the cell. Nox4 is different from the other Nox 
proteins in that it will activate independently of Rac binding. Further, Nox4 has several 
different splice variants that are thought to have slightly different functionality in the cell 
and are known to localize to either the endoplasmic reticulum or the nucleus. Lastly, 
Nox4 has recently been shown to be mutated in cancers which leads to development of 
many of the malignant phenotypes seen [178, 277]. This has been one link used in the 
inflammation to cancer hypothesis. 
In this manuscript, we show in multiple invasive cancer models that Imipramine 
Blue inhibits invasion. Further, that this invasion is indeed due to regulation of actin 
polymerization and not to direct binding to actin and that this alteration affects 
invadopodia associated actin structures. Through exploratory signaling studies, we then 
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show that IB has the ability to inhibit Nox4. Finally, we show, through a modified 
immunoprecipitation study, that IB actually binds to Nox4 where we believe it exerts its 
inhibitory effect. This series of studies indicates a first line effort to examine a 
mechanism of action in a more global way. 
5.3 Methods 
5.3.1 Invasion assays 
Invasion assays were performed according to ref in basement membrane extract 
(Trevigen) coated tissue culture insert inserts (Millipore). Briefly, 200,000 cells were 
seeded on top of BME in serum free medium and allowed to migrate towards serum 
containing media for 16 hours. Tissue culture inserts were fixed, stained with DAPI, and 
5 fields counted per tissue culture insert (3 tissue culture inserts per condition). Percent 
invasion of starting cell numbers was normalized to untreated controls for each cell type. 
5.3.2 Actin polymerization and depolymerization assays 
The effect of Imipramine Blue on actin polymerization and depolymerization was 
tested using the Actin Polymerization Biochem Kit (Cytoskeleton, Inc.) using the 
protocol provided with the kit. Cytochalasin-D (Invitrogen), a known inhibitor of actin 
polymerization was used as a negative control in the actin polymerization assay; 
phalloidin (Invitrogen), which inhibits actin depolymerization, was used as a negative 
control during the actin depolymerization assay.  
5.3.3 In vitro immunocytochemistry 
Cells were seeded in three 96 well glass-bottom plates (200 µl/well) at 50,000 
cells/ml and incubated at 37°C in a 5% CO2 atmosphere. The cells were then treated with 
Imipramine Blue (5 mg/ml) for 0 hours, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 
6 hours, and 24 hours. After treatment, Imipramine Blue was removed and cells were 
washed with 1X PBS. Cells were then fixed using 4% paraformaldehyde and stained 
using the following primary antibodies: α-actin (1:100), scinderin (1:5 ug/ml), NFκB 
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(1:100) , nox4 (1:100) (AbCam), profilin (1:100), rho-gdi (1:50) (Santa Cruz 
Biotechnology, Inc.), and acetylated microtubulin (1:200) (Invitrogen). After 24 hours, 
cells were stained with the following secondary antibodies: AlexaFluor 488 goat anti-
rabbit, and AlexaFluor 488 goat anti-mouse (Invitrogen). The cells were then stained with 
1X DAPI and phalloidin (1:200) obtained from Invitrogen. Cells were imaged using a 
Zeiss LSM 510 NLO with META MPE. 
5.3.4 Nuclear Localization 
Desipramine Blue (DB) was conjugated to amine reactive FITC (Invitrogen) 
using the protocol provided. Conjugated DB was then encapsulated in liposomes in 
preparation for delivery. RT2 cells were seeded at 100,000 cells/ml in four 8 chamber 
slides. Each slide underwent a different drug treatment (liposomal conjugated DB, free 
conjugated DB, free IB, untreated). Cells were then fixed with 4% paraformaldehyde at 
the following timepoints: 5 minutes, 15 minutes, 1 hour, 2 hours, 4 hours, 24 hours, and 
48 hours. Cells were stained with rhodamine phalloidin (Invitrogen) and  DAPI before 
imaging. 
5.3.5 Nox4 Inhibition Studies 
HVA assays were performed using Nox4 over-expressing Cos cells as described (1) after 
treatment with 0, 5, or 10μM IB for 1 h.  
5.3.6 Magnetic Bead Binding Assay 
Dynabeads (Dynal Biotech, Inc.) were conjugated to DB using the protocol 
provided. Control beads were also made by activating according to the protocol and 
withholding DB. Protein extracted from RT2 cells was treated with both the conjugated 
and unconjugated beads. The sorted protein from the conjugated beads, the supernatant 
from the conjugated beads, the protein from the unconjugated beads, the supernatant from 
the unconjugated beads, and the unsorted protein were all tested using a Western Blot. 
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The blot was stained with Nox4 primary antibody (AbCam) and stained with 
AlexaFluor488 goat-anti rabbit secondary antibody (Invitrogen). 
 
5.4 Results 
5.4.1 IB halts invasion in multiple cancer models 
Through tissue culture insert invasion assays, it was seen that IB could halt 
invasion of multiple models of malignant cancer at 5µM concentration (Figure 5.1). Cell 
lines had a varying degree of invasive potential ranging from 5% -20% untreated cell 
invasion. All cell lines responded similarly to the use of IB against them. This indicates 
IB’s ability to halt invasion of multiple cancer types beyond just the previously seen 
application to glioblastoma.  
 
 
Figure 5.1: Inihbition of invasion in other models of invasive cancer DU145, prostate 
cancer, ZR-75 breast cancer, and MDAMB435 breast cancer all show below 50% 





5.4.2 IB alters actin structural formation without direct binding to actin  
Through cell spreading observation it was apparent that cancer cells would 
become more rounded when exposed to IB (Figure 5.2A). This was further quantified 
using ImageJ showing a consistent increase in rounded cells over time and indicating 
increased rounding at 3 hours after treatment and maintaining to 24 hours (Figure 5.2B). 
This effect was only seen in RT2 and U87 glioma cell lines and not with the primary 




Figure 5.2: Cell spreading in presence of IB. (A) Glioblastoma cells (RT2 and U87) 
show rounding of cells after 3 hours of incubation with 5µM IB. Astrocytes maintained 
spread morphology even after 24 hours incubation. Green: F-actin (rhodamine 
phalloidin), Blue: Nuclei (DAPI). Scale bar = 20µm. (B) Assessment of circularity of 
cells through ImageJ indicating enhanced rounding of glioblastoma cells after 3 hours 
continuing to 24 hours with no change in astrocytes. Significance is based on comparison 















































We were interested to see if IB would bind actin directly and thus exert its effects 
through this mechanism. Though it was hypothesized that IB would not bind actin 
directly based on comparison to Cytochalasin D and Phalloidin compounds which do, 
assurance of this mechanism was important in future studies. Through use of in vitro 
actin polymerization and depolymerization studies we determined that IB does not inhibit 
the ability of actin to polymerize or depolymerize as compared to the aforementioned 
inhibitors at the same doses (Figure 5.3). This data confirms further the previous 
timecourse of IB action as direct actin interacting molecules tend to inhibit cell motility 
within minutes after application as opposed to hours.  
 
Figure 5.3: IB does not inhibit actin directly Results of in vitro polymerization (left) or 
depolymerization (right) assays indicate no interaction of IB with these processes. Pyrene 
actin monomers (polymerization) or filaments (depolymerization) were incubated with 
ATP and drug. Pyrene-actin releases a fluorescent signal as it polymerizes yielding the 
increase or decrease in signal upon filament formation or removal.  Cytochalasin D is an 
inhibitor of actin polymerization and shows this activity (left) at 1µM (p<0.05) as 
compared to IB at 1 µM which had no change from control. Phalloidin binds F-actin and 
prevents depolymerization (right) at 1 µM yielding a slower decrease in signal as 
compared to control (p<0.05). IB does not have this effect on F-actin. Curves were 


































5.4.3 IB inhibits and binds Nox4 
In conjunction with collaborators, we saw that IB inhibits production of ROS in 
Nox4 over-expressing cells (Figure 5.4). Therefore, we decided to determine if IB binds 
Nox4 directly. We used protein from the rat cell line RT2 along with a derivative of 
Imipramine Blue, Desipramine Blue (DB). This compound shows the same inhibition of 
invasion as IB with similar effects on actin structure formation, though it is less potent 
with a higher IC50.  The advantage to this compound is the ability to conjugate via amide 
bond formation due to lack of an ethyl group on the nitrogen of the Imipramine side 
group. Magnetic beads conjugated to this compound were incubated with protein at 37°C 
and then pulled down after which they were washed with detergent for removal of 
protein. This pull down was repeated several times for concentration of the protein for 
blotting with Nox4 antibody. Further, samples were incubated with IB first, followed by 
the beads to inhibit conjugation, as well as initial protein sample was taken for 
comparison. Further, cells were incubated with the conjugated beads to show 
functionality of the molecule through morphological analysis and revealed the ability of 
the conjugate to inhibit stress fiber formation and cell spreading after 3 hours (Figure 
5.5). 
 
Figure 5.4: IB inhibits H2O2 generation by Nox4 Nox4 over-expressing Cos cells were 
delivered IB for one hour in increasing doses and ROS generation was determined by HVA assay. 




























Figure 5.5: IB binds to Nox4. A) Functional capabilities of the DB-particle showing 
rounding of the cells that are exposed to DB-beads (lower image) showing similar 
characteristics to DB alone treated cells (middle image). Untreated cells (top image) 
show minimal rounding. B) Schematic of the DB-magnetic bead conjugate showing 
binding site of beads. C) Western blot indicating Nox4 presence of pulled down protein 
with wells as follows: 1-ladder, 2-empty, 3-beads alone after wash, 4-protein from 
unconjugated beads, 5-protein before incubation with beads, 6-supernatant from pulled 
down protein, and 7-protein pulled down by beads. Only lane 7 stained positively for 
Nox4 at a 30kDa band indicative of Nox4 splice variant 4D.  
 
Results indicate a single band (lane 7) from the bead pulldown group around 
30kDa with no hybridization elsewhere. The most common band for Nox4 occurs around 
65kDa but there are several splice variants of this protein including one at 30kDa with 
full Nox4 functionality. This variant lacks the transmembrane domain of Nox4, but still is 
able to produce H2O2 effectively. We did not see hybridization in the beads alone after 
wash (3), incubated protein with non-conjugated beads(4), non-incubated protein (5), or 
the supernatant from the pulled down protein (6). We expected to see a band in lanes 4 
and 5 due to protein in the sample, however, we believe that the concentration of the 









protein by using the beads allowed more total Nox4 to be concentrated and thus a 
stronger band to appear.  
5.4.4 IB localizes to the nucleus of RT2 glioma 
We were further interested in determining where the drug localizes in the cell. 
Nox4 is primarily a cell membrane protein but can localize to many other locations 
within the cell including the endoplasmic reticulum, the cytoplasm, and the nucleus 
[170]. Using the same conjugation strategy as with the beads, we conjugated DB to a 
FITC tag and incubated cells with this construct. Cells were also incubated with IB alone, 
carrier alone, or FITC alone (not shown). After 24 h, cells were stained for actin and the 
nucleus. In all cells that showed a rounded phenotype, we observed bright FITC 
localization in the nucleus overlapping with DAPI (Figure 5.6). This indicates that the 
drug localizes to the nucleus after 24 hours.  
 
Figure 5.6: IB localizes to the nucleus of RT2 cells. Using FITC-conjugated DB (green, 
top), we tracked the drug to the nuclei (blue, DAPI) of tumor cells after 24 hours. Cells 
were counterstained for F-actin (red, rhodamine phalloidin) to determine if cell 
morphology changed as expected and compared to non-conjugated DB (middle) and 


















The use of a novel compound to halt invasion of cancer is a highly desirable 
pharmaceutical. Imipramine Blue is a potent inhibitor of cancer cell invasion, however, 
until now, it was unknown through which mechanism this drug was working. It was 
previously shown that IB potently inhibits actin polymerization through regulation of 
actin binding proteins such as scinderin and profilin-1, as well as regulatory proteins such 
as calgranulin and RhoGDIα. However, these changes needed to be effected by upstream 
signaling proteins.  
Through literature searches and the predicted mechanism of IB based on the 
design of this compound, we set out to determine its specific interactions and how it is 
changing migration. To begin, the universality of IB’s effects were determined in 
multiple cell types in other cancers. This proved that the inhibition of invasion is nearly 
universal amongst cancers. This indicates that there is an underlying mechanism for 
invasion that is inactivated in many cancer types and shows the benefit to using IB in a 
clinical setting. Further, this proves that the effect of IB is not just glioma specific which 
is important as there are many differences in glioma development as compared to other 
non-central nervous system cancers [283]. Further results indicated that IB inhibits cell 
spreading specifically in cancer cells and not their healthy counterparts yielding rounding 
of RT2 and U87MG glioma but not astrocytes. It was observed that this change takes 
about 3 hours confirming previous live imaging analyses of glioma cells treated at the 
same doses. This result indicates that there is an upstream mechanism involved in the 
inhibition of invasion which was further confirmed through the actin depolymerization 
and polymerization studies showing no direct effect on the monomer or polymer actin.  
Src-kinase, a key player in invadopodia formation in cancer, has been seen to be 
inhibited with IB (Diaz, B. & S. Courtnedige, unpublished data). Src-kinase in this regard 
is known to activate Tks5 leading to activation of Nox4 and ROS generation causing a 
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host of intracellular changes including invadapodia formation [148]. Src kinase is also 
known to be involved in just about every other aspect of cancer progression and 
malignancy so inhibition of this protein in one regard may lead to further reaching effects 
on cancer [56]. Recently, it has been seen that during inflammation, Src is regulated by 
the polymerization of actin [284]. It was shown that inhibition of actin polymerization by 
cytochalasin D inhibited Src activation. Therefore, we thought that the inhibition of Src 
may be a secondary effect of the inhibition of actin polymerization though further study 
is necessary to determine the exact events occurring upon treatment.  
Using activation assays via TNF-α induction of NFkB, it has been shown that IB 
inactivates NFkB localization to the nucleus and its ability to act as a transcriptional 
factor (Aggarwal, B., unpublished). NFκB can also be involved in cytoplasmic protein 
regulation leading to an ever increasing cascade of signaling mechanisms [216]. 
Inactivation of this protein is known to inhibit RhoGTPase mediated actin 
polymerization, nucleation of new actin filaments, and pooling of G-actin [160]. Further, 
NFκB is activated by presence of reactive oxygen species. Again though, NFκB has been 
shown to inactivate based on the actin dynamic state of the cell, though in cancer, its 
normal function is highly disrupted due to mutation. This can lead to constitutive 
activation of the protein but is often mediated by upstream cleavage proteins and 
transcription factors. Therefore, we proposed that Nox4 is the mediator of this activation 
of NFkB as well as the Src kinase mediated mechanism. 
 It remains to be seen if IB generally decreases the ROS in cancer cells and if this 
is particularly pronounced in those cancer cells with overactive Nox4 versus other Nox 
proteins. The ability of IB to bind Nox4 was determined through the magnetic bead 
assays where IB bound Nox4 enough to yield a significant band of concentrated protein 
on the Western blot. Further, the ability of IB in culture with the beads to block this 
binding showed the affinity of the IB alone and the validity of the assay. Future studies 
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will examine more closely the binding kinetics of this pair, though as an initial effort 
these results are significant.  
The particular splice variant shown to bind from the RT2 cells was interesting. 
However, this splice variant (4D) may be solely due to the cell line and not the particular 
specificity of the drug. We believe this to be the case because of the universality of the 
drug in many cancer types shown here and in previous work and the known non-
universality of the particular splice variants[175]. The 4D splice variant lacks the 
transmembrane domain but is capable of producing ROS. This specificity can begin to 
give us clues as to the particular inhibitory site of IB and aid in development and 
description of nanocarrier delivered IB that has been previously used. The 4D splice 
variant is also known to localize to the nucleus of cells and so using FITC-conjugated IB 
we see the trafficking of the compound to the nucleus and the resulting effect on actin 
stress fibers and cell spreading after 3 hours of incubation. These signs, along with the 
previous results of the effect on invadopodia and polymerization lead to a conclusive 





Figure 5.7: Proposed mechanism of action of IB with known downstream effects. IB 
binds Nox4 and exerts inhibitory activity which leads to decreased ROS (in the form of 
H2O2 or radicals). This leads to downstream inhibition of NFκB and possible changes in 
actin polymerization and transcription of indicated proteins from previous microarray 
data which lead to invasion inhibition. Further, actin depolymerization can inhibit Src 
kinase activation and subsequent activation of Tks5 which leads to podosome formation 
and Nox4 activity. Therefore, the invasion inhibition is a circular process that leads to 
enhancement of invasion inhibition. Further, the pathways have other overlapping 
pathways involving other proteins, but these are the most straightforward interactions 






6.1 Discussion of Overall Thesis 
The work of this dissertation represents several first steps in the fight against 
brain tumor invasion in many regards: 1. A multi-compound screen for a drug that will 
stop invasion while controlling for other attributes of drug action against cancer, 2. An in 
depth look at one particular compound, Imipramine Blue, in vitro and in vivo to 
determine its effects on cancer, 3. Methodology for incorporating an anti-invasive drug 
with a chemotherapeutic for remission of glioblastoma, and 4. Discovery that this 
compound works by a mechanism not extensively pursued in cancer cell invasion. 
High-throughput drug screening is a common method for identifying new 
compounds against a variety of diseases [287]. Use of array technology is an ever-
growing area of biomaterials and processing research. Similarly, the generation of these 
compounds is more and more being moved to in silico to assist in the design and 
development of target specific compounds [288]. Along with this is the modeling of 
signaling pathways and downstream effects of blocking or activating of the various 
protein targets. However, these methods all rely on experimental methods to determine 
the protein definition and role in the large number of pathways in cancer. Also, cancer is 
a disease in which many of these targets may be mutated for constitutive or variant 
activity as compared to normal variants and thus represent a difficult modeling challenge 
[289].  Further, since pathways in cells are not fully elucidated, predicted effects on cells 
are unclear and movement of such compounds to an in vivo setting can represent an even 
larger challenge where cancer cells are no longer isolated but interacting with a host of 
different cell types. Efforts to model these changes in silico and in vitro are becoming 
more available but the only real way to determine the activity of a drug still is to test in 
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vivo and eventually through clinical studies. That being said, use of drug screening is an 
effective way to identify an agent for specific purposes. 
In the first part of this dissertation, a small drug screen of two select classes of 
molecules was conducted. These molecules were chosen for a parent molecule’s success 
against tumor invasion coupled with a proposed novel mechanism in hopes of creating a 
new push forward in the anti-invasive molecule search. Most anti-invasive compounds 
previously developed focused on inhibition of the matrix metalloproteinases (MMPs). 
These molecules are upregulated in cancer and are often necessary for invasion, however, 
they are not the primary role player in the ability of cancer cells to move [290]. In clinical 
trials, it has been seen that these have moderate effects when coupled with other 
treatments though still not much more than a few months increase in survival in 
glioblastoma patients [182]. Cancer cells often need to degrade the ECM to move, 
however, it’s not always necessary. Because of the undifferentiated state of most cancer 
cells and their amoeboid-like migration, they can instead move through pores in the ECM 
as opposed to making their own [291]. They also do not need to maintain adhesive 
contacts with the surrounding ECM and thus can continuously move nonlinearly through 
the matrix and into the healthy brain [292]. Self-sufficiency in growth signals and 
chemokines can also assist in this enhanced migration [293]. Therefore, the new push in 
anti-invasive agents is the growth factor inhibitors such as EGFR, PDGFR, and FGFR 
antagonists as well as the tyrosine kinase class of inhibitors. These molecules, however, 
have multiple effects on cancer cells including reduced growth, proliferation, invasion, 
and angiogenesis [293]. These compounds are also highly specific, which is beneficial to 
tumor screening methods for overexpression of the particular receptor of interest, 
however, means they are not universally able to work for every type of cancer in every 
patient. Further, most of these compounds are monoclonal antibodies which are still very 
expensive and difficult to manufacture [294]. 
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Therefore, we focused on small molecule compounds with novel mechanisms of 
action (aside from growth factor receptor and MMP inhibition). Through the screening of 
compounds using a multi-tiered approach incorporating cytotoxicity and invasion assays 
in multiple cell types, we identified one compound, Imipramine Blue (IB) that inhibits 
invasion at low doses and showing cancer-specific cytotoxicity only at higher doses. 
Most studies of anti-invasive compounds only focus on the decrease in percent invasion 
without studying the confounding effect of cytotoxicity and thereby can draw 
inappropriate conclusions. By understanding the concentration at which IB begins to kill 
cancer cells (IC50=20µM) and the one at which it will inhibit invasion (IC50=20nM) we 
can understand better the effects of using a specific anti-invasive compound in vivo. This 
is important, because we know that when delivered in vivo the compound will have a 
widely varied effect as opposed to in vitro due to the distribution of the drug within the 
tumor and the possible per cell dose of drug. For instance, compounds such as 
Doxorubicin and temozolomide are subject to multi-drug resistance (MDR) and this can 
be selected for over time in populations of cells within the tumor [112]. Due to the 
heterogeneous nature of their delivery, the low concentration effects of these compounds 
can lead to induction of MDR or selection of subpopulations of cells which will make it 
more difficult for repeat treatments to help [101]. Studies incorporate multiple forms of 
chemotherapies to try to overcome this, but the delivery will always be limited and thus 
cell populations will be propagated in a heterogeneous way. This is similarly true in 
radiotherapy where it is known that low-level doses of radiation enhance tumor invasion 
while high doses will kill tumor cells [43]. Through use of a drug with low-level anti-
invasive characteristics can, hopefully, halt invasion of the cells when it’s not killing 
them and thus create an anti-tumor effect without this selection mechanism. 
In the third chapter of this dissertation, the drug, Imipramine Blue was closely 
examined for this anti-invasive effect. Through multiple testing mechanisms including in 
vitro and in vivo invasion quantification, it was shown that IB will halt invasion of 
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glioblastoma. This translation is missing from a lot of studies of novel anti-invasive 
compounds [136, 222, 226, 295, 296]. Due to problems with delivery issues of potent in 
vitro anti-invasives, translation into in vivo studies is difficult. Further, once these studies 
are conducted, the invasive potential of the drugs takes a sideline to the simpler measures 
of growth and survival of tumors [191, 244, 245, 247, 297, 298]. Thus, if no change is 
seen in these attributes, the drug is often sidelined, but if growth is inhibited, this 
becomes the primary focus of treatment.  
With this compound, IB, only a moderate increase in survival was seen (~12% 
increase) with small effects on tumor size. However, since the initial goal was anti-
invasive we were able to detect a much more impressive attribute of activity in vivo 
through quantification of tumor density and border invasion. Thus, though the drug alone 
was not a potent anti-tumor agent, through careful selection we were able to find a 
potent-anti-invasive agent at a deliverable dose in vivo. In this way we could test the 
overall hypothesis that using an anti-invasive, but not cytotoxic agent with a potent form 
of clinically available anti-tumor therapy will result in enhanced efficacy of that therapy 
leading to increased survival 
In chapter three and four, the incorporation of IB with Doxorubicin (DXR) was 
closely examined using two approaches: sequential nanocarrier delivery and 
simultaneous co-encapsulated nanocarrier delivery. Both of these strategies resulted in 
enhanced survival as compared to the chemotherapeutic alone. Though these experiments 
are presented separately for publication purposes, they were done simultaneously, so the 
only difference between the studies is the order of delivery. It is interesting that there 
appears to be a benefit to priming the tumor before treatment with the chemotherapeutic. 
Further, the lack of synergy in vitro with both sequential and simultaneous delivery of 
compounds indicates that this is an in vivo specific enhancement of tumor death. This 
result indicates that there is a mechanism in vivo that is not observable in vitro whereby 
IB is enhancing efficacy of the Doxorubicin. There are many reasons that this could be 
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occurring including drug delivery, interactions with the tumor microenvironment or 
alterations of interactions with the host on a systemic level. 
It has b een seen that multiple injections of liposomal nanocarriers can alter the 
course of circulation time and clearance from the bloodstream [299]. This has primarily 
been observed with toxic drugs such as Doxorubicin which, upon uptake by the 
reticuloendothelial system (RES) damage the primary mediators of clearance, 
macrophages. This effect is used to determine the saturation levels of lipid in the 
bloodstream indicating the point at which the RES system can no longer clear liposomes 
from circulation [300]. This can lead to enhanced circulation times with multiple 
injections of liposomes and altered toxicity levels. Thus, it is known that multiple 
injections of Doxorubicin nanocarriers lead to enhanced delivery after first injection. 
However, for blank liposomes or non-toxic compounds, the saturation level cannot be 
determined as there is not an observable effect on RES [301]. It remains to be known it 
IB is actually affecting macrophage function, though it is not expected due to the already 
seen cancer specificity. Use of saline liposomal nanocarriers for control groups not 
receiving sequential delivery controlled for any lipid-only based effect. 
Another possible reason for enhanced efficacy with sequential treatments by 
delivery mechanisms is that IB is altering the angiogenic state of the tumor and thereby 
enhancing the EPR effect for the subsequent nanocarriers [241]. It is common for anti-
invasive therapeutics to have effects on angiogenesis and blood vessel structure and 
function [221, 227, 302]. This could be due to a variety of factors including endothelial 
cell recruitment through tumor cell signaling, migration of tumor associated endothelial 
cells, tube formation of endothelial cells, altered cell-cell junctions in blood vessels 
leading to altered leakiness, or changes in the pressure differential across the blood vessel 
wall allowing more leak into tumor [272]. In supplementary studies (Appendix B), the 
alteration in delivery of nanocarriers to tumors was preliminarily examined using 
advanced MRI imaging techniques with gadolinium-loaded nanocarriers. These studies 
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were complemented with in vitro observation of vascular endothelial cell invasion and 
matrix degradation. These early results indicate a possible enhancement in liposomal 
delivery in vivo though results are not significant. This validates in vitro studies 
indicating no significant change in endothelial cell invasion with treatment or alterations 
in the ability of cancer cells to degrade a Collagen IV matrix indicative of changes in 
vascular cell lining in brain tumors. However, further studies are necessary to statistically 
prove the lack of effect due to need for increased power. Therefore, it is still possible that 
there is an alteration in the delivery to the tumor, though the exact reason and extent of 
this is still unknown.  
Therefore, in Chapter 5, we completed work begun in Chapter 3 regarding the 
determination of the mechanism of action of IB. In this way, we could determine other 
reasons for synergy between the two compounds as well as predict side effects and 
combinatorial effects for future integration and clinical studies. In Chapter 3, using 
microarray analysis to initially determine all molecular changes involved in vivo, a host 
of responses were observed including changes in cytoskeletal regulation, chemokine 
secretion, matrix degradation and secretion, and adhesion changes. Microarray can be a 
very useful tool but can also create complicated data sets and difficult interpretations that 
must be validated. Therefore, we chose to focus on the cytoskeletal components of the 
microarray since these are most readily linked to invasion of cancer cells without further 
complications of alternate proteins and pathways as can be seen with adhesions and 
matrix degradation components [216]. Therefore these cellular changes were quantified 
on the transcriptional level and confirmed on the protein level to validate these alterations 
and indicating that the effect on scinderin and rhoGDIα were most pronounced. 
Moving in vitro in Chapter 5, these elements were more closely examined and 
various hypotheses were tested to determine the target of IB. We showed that IB halts 
spreading of glioma cells without affecting astrocytes after 3 hours of drug exposure. 
Through subsequent indirect studies it was shown that IB inhibits binds to and inhibits 
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reactive oxygen species production by NADPH Oxidase 4 (Nox4). This leads to 
inhibition of NFκB activation and transcriptional control of cytoskeletal dynamics. This 
in turn can lead to inhibition of Src by decreased actin polymerization and downstream 
inhibition of Tks5-dependent Nox4 activation and invadopodia formation. Thus, by 
inhibiting one part of this cycle, there can be a multiplicative change in the ability of the 
cell to invade through multiple modalities. This is an interesting overall hypothesis but 
intricate cell signaling and receptor binding studies must be conducted to confirm these 
changes and their effects in multiple cancer cell types.  
However, knowledge of this mechanism opens doors of possibility for the 
understanding of drug interactions and in vivo translation. It is known that ROS induce 
changes in blood pressure and inflammatory response [174, 303]. These are attributes that 
are not readily studied in vitro and could be effectuating the change seen upon co-
treatment in vivo. Further immune cell recruitment and matrix reorganization in vivo have 
been shown to have far reaching effects on many cancer therapeutics. Chemotherapy can 
induce changes in immune cell recruitment by cancer cells to the benefit of the tumor and 
can also directly affect cells to reduce immune response [304]. Changes in the chemokine 
environment as indicated by the in vivo microarray analysis could play a distinct role in 
the higher benefit of chemotherapy with IB in both sequential and co-delivery. Further, 
alterations of the ECM can affect the ability of chemotherapy to work. It is known that 
through matrix binding in several cancer types including lung and breast, cancer cells can 
be more resistant to chemotherapy induced apoptosis [305]. Thereby, through alterations 
in matrix degradation and secretion in vivo, IB may be reinstating the ability of 
Doxorubicin to kill certain subpopulations of cancer cells that were previously resistant. 
These are just two of the more well-studied ways that IB may be enhancing efficacy in 
vivo over in vitro experiments. However, the tumor microenvironment is volatile and 




That being said, we believe that the primary mechanism by which IB decreases 
incidence of tumor recurrence is through the inhibition of invasion of cancer cells. 
Though the extraordinary effect seen with DXR could be due to a number of downstream 
and upstream mechanistic effects, the inability of the cancer cells to move away from the 
tumor bulk is undeniable and useful for application in all treatments currently used on 
glioblastoma. The state of the field at the moment is relatively static. There are many 
clinical trials ongoing for new therapeutics but each outcome shows only a minor uptick 
in the survival time of these patients [306]. Further, the ability to integrate therapies is the 
primary focus of these studies, building on top of current treatment used in glioma by 
adding treatments used in other cancers instead of overhauling it. But why not change the 
course of therapy? In this dissertation, it is shown that IB halts invasion by a novel 
mechanism, and by doing so, enhances the efficacy of a traditionally potent 
chemotherapeutic. Though more validation and study is necessitated, this first step 
represents a paradigm shift in the current treatment regimen which involves obliterating 
the bulk of the tumor and following up with more fine-tuned treatment. Through this 
dissertation, I hope to display that use of a pre-treatment molecule before destruction of 
the primary tumor could yield a substantial benefit to the outcomes of treatment in 
glioblastoma. Though this is just one molecule and one step, it is important to highlight 




6.2 Future Directions 
This dissertation represents early progress in the identification and development 
of a novel compound Imipramine Blue. Further, it proves the overarching hypothesis that 
if this compound as an anti-invasive molecule is incorporated with chemotherapy, 
Doxorubicin, enhanced survival is achieved in glioblastoma. However, there is much 
more to do to fully prove this hypothesis and advance the state of this drug. For instance, 
is there an in vivo effect other than invasion that assists in the ability of Doxorubicin to 
cause remission? Will there be further effects with different anti-tumor treatments such as 
temozolomide and radiation, common anti-glioma treatments? Further, the class of 
compounds first screened in this study is interesting for the possibility of future anti-
cancer research and deserve investigation as alternate molecules for halting invasion 
while inhibiting tumor growth. Last, to move forward with this compound there are many 
mechanistic, universality of cancer treatment, and drug delivery steps that would be 
useful for future cancer research and possibly other areas of research including 
inflammation biology. 
The ability of IB to cause remission of tumors with Doxorubicin is extraordinary. 
The universality of this is still to be determined and it should be examined in other 
models. This includes tumors which are more readily treated with Doxil® including 
sarcoma and ovarian cancer to determine if there is benefit in models where it is already 
used. Further the universality of the treatment of brain cancer may also be explored in 
using other models such as continuation of the studies with the human glioblastoma cell 
line U87MGEGFRVIII which represents an inherent mutation found in almost 60% of 
brain cancers. Preliminary survival studies using convection-enhanced delivery are 
shown in Appendix 4 show a slight benefit to co-delivery of compounds, however, 
further study is necessary for conclusive evidence of IB enhancement of doxorubicin 
therapy in this less invasive model. 
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However, on the brain tumor side, it would be most interesting to continue studies 
incorporating IB with currently used treatments of glioblastoma. This includes 
temozolomide, radiotherapy, and anti-angiogenic therapy. The latter two are particularly 
interesting because of the application to multiple types of cancer and the strong 
correlation between these treatments and invasion induction [189]. Promising studies 
showing benefit with temozolomide and other anti-invasives indicate that there may be a 
strong effect. Further, initial data in vitro indicates that this combination yields a 
synergistic effect in U87MG (Appendix C). Further study into the reason for this synergy 
and if this is beneficial in vivo should be a high priority in development of this drug. 
Additionally, with the possible alteration in drug delivery characteristics after treatment 
with IB this synergy may be further amplified in vivo as was seen with Doxorubicin. 
Radiation therapy is used in over 50% of cancers in humans and thus if any benefit is 
seen to incorporation of IB with this therapy, there could be a huge impact on the cancer 
field at large. Radiation induced invasion and side effects are a major clinical problem 
along with the induction of cancer after treatment due to non-specific targeting of 
radiation. With more common use of highly specific techniques like stereotactic 
radiosurgery complementation of an anti-invasive drug could be highly helpful in tumor 
containment and subsequent removal. Further, the ability of IB to subdue many 
inflammatory pathways would likely reduce the induction of the invasion of the tumor 
cells resulting from microenvironmental effects. These have been shown to be highly 
important in the change in tumor phenotype though the mechanisms by which they act 
are not fully known. Lastly, anti-angiogenic therapy suffers the large problem of invasion 
induction. This is the best correlated of the treatments and the invasive response in 
multiple types of tumors. Use of IB before this last line treatment could lead to much 
better prognosis and is well worth investigating in preclinical models. 
For all of these combinatorial approaches to be examined, it would be helpful to 
better understand the effects of IB on many aspects of cancer outside of the invasive 
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response and based on the proposed mechanism of action. Initial studies in angiogenic 
response are a start, however, this field is a well-developed area of cancer research with a 
variety of interesting techniques and measures. Therefore, use of a novel drug with 
possible anti-angiogenic action would both benefit the knowledge of the drug-tumor 
interactions as well as contribute to a better validation of these measures and 
understanding of the phenomenon in tumors in general. Further permeability studies in 
vivo and cell effects in vitro would be useful and more detailed studies involving tumor-
associated blood vessels from human models in particular would assist a better 
understanding of the drug effects. Permeability studies could also lead into studies as to 
the effect of IB on things like interstitial tumor pressure. In Appendix 5, a manuscript is 
presented showing the effects of interstitial fluid flow on tumor cells and invasion. This 
flow is due to pressure differentials from tumors into the healthy brain. If this pressure 
build up can be altered by IB, this effect could be minimized. Further, decrease of 
pressure in the brain is the primary reason for observable symptoms and thus the reason 
for immediate surgical removal of tumors. Steroids are also used to decrease pressure and 
alleviate symptoms, particularly for inoperable tumors. If IB affects the interstitial tumor 
pressure, the degree of malignancy could be decreased and the ability to treat both 
operable and inoperable tumors could be enhanced. Examination of this pressure change 
would yield interesting information about both IB effects and the tumor environment in 
general. 
On a more systemic basis, the ability of IB to halt ROS is substantial because of 
the role of ROS in many aspects of physiology including blood pressure and immune 
response. The correlation between inflammation and cancer progression is a growing 
field and thus the ability of IB to halt this response through inhibition of ROS and 
through alterations in chemokine secretion as shown in the microarray analysis deserve 
further exploration. A drug that can reduce the ability of a cancer to evade the immune 
system or induce the inflammatory response would be interesting with more novel 
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vaccine based or immune-cell based therapies which are showing promise in preclinical 
studies. Further, these responses could lead to secondary indications for the compound in 
immune disorders or inflammation. Use of novel ROS detection agents in vivo coupled 
with in vitro studies would yield positive changes in ROS secretion in the tumors and 
then the subsequent immune alterations could be more closely examined through 
immunohistochemistry and flow cytometric analysis. Since the literature well 
substantiates the involvement of the immune system in cancer progression, the results of 
such analysis would be highly impactful on a better understanding of both the drug and 
disease progression related to its mechanism. 
To further substantiate the ability of IB to inhibit invasion in multiple types of 
cancer and to validate complimentary studies on the effects of IB in vivo on angiogenesis 
and inflammation, more in depth analysis of the mechanism is advisable. The 
understanding of the underlying mechanisms for the involved proteins is strong, though 
Nox4 is only recently becoming a well-studied molecule in cancer progression. 
Therefore, there is a strong base of techniques and background for the specific signaling 
analysis of the various components involved in halting cancer invasion of which we have 
only begun to examine. Preliminarily, further specificity studies of IB and Nox4 are 
desirable to determine if there is any interaction with other Nox family proteins and if so, 
what the comparable Kds are for the various forms and isotypes. Comparison to 
diphenyliodide is advisable for examination of potency and specificity as this molecule is 
a pan-Nox inhibitor shown to elicit many of the same effects as IB. Further, the 
understanding of inherent mutations of Nox4 and if these affect the ability of IB to work 
in cancers would assist in incorporation of this treatment on a patient-by-patient basis. 
Lastly, using methods involving modeling and literature searches, drug interactions, 
signaling mechanisms, and specific binding structures could be determined to better assist 
in development of new compounds and integration of therapy. Along with this, revisit of 
other molecules in the drug screen and newer compounds developed since the drug 
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screen may provide more potent compounds for testing in vivo using the methodology put 
forth in this dissertation. Along with this, the switch from a purely anti-invasive 
compound at delivered doses to one that showed more cytotoxic activity likely through 
the same mechanism could yield a stronger anti-tumor effect alone without incorporation 
of other therapies. Last, combination of the classes of molecules may be examined for 
further benefit as these two classes are thought to inhibit NFκB pathway through 
differing initial inhibition, there is evidence for a potent combinatorial effect beyond that 
seen with combinations with more traditional chemotherapeutics.  
As with all drugs, testing in multiple models is beneficial both to prediction of 
clinical translation, and to understanding the limitations of the treatment. Though IB is 
shown to exert inhibitory activity on multiple models in vitro, further exploration of this 
drug in vivo is more useful for clinical translation. Syngeneic implantable rodent models, 
while offering many advantages used in this dissertation, lack many benefits necessary 
for validation of a drug. Using an inducible model of a brain cancer, possibly of 
medulloblastoma, a slower growing cancer that is highly invasive, may yield a better idea 
of the way IB could be used in a clinical setting. Further, use of human models such as 
primary glioblastomas either with IB alone or in combination of traditional therapies 
would indicate the ease of translatability to the clinical setting. Though there is initial 
work being done in these models at the moment, more thorough investigation and results 
are yet to be seen. 
Further, use of IB outside of the nervous system is an interesting prospect. Using 
models that are highly metastatic would indicate if the halt of invasion can translate to 
inhibition of metastasis. There are few models that show this effect but examination in 
any of them with positive results would be highly significant to the cancer field at large. 
Development of such a therapy also offers possibilities for development in the drug 
delivery field. Intravenous delivery to solid tumors is always a possible mechanism due 
to the EPR effect, however, lymphatic delivery of an anti-invasive may yield a more 
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potent response due to lymphatic involvement in metastasis. It is well-known that 
nanocarriers delivered subcutaneously will traffic to the lymph, however, to what extent 
is this necessary for an anti-invasive and what are the optimal parameters and timepoints 
for halting metastasis has yet to be seen [307, 308]. Other models of cancer that are not 
solid tumors such as leukemia or lymphoma could represent an interesting area for 
delivery development and effects on invasive potential on these types of circulating 
tumors. This could be applied both to non-solid tumors as well as circulating tumor cells 
in the blood stream from solid tumors. This area is a rapidly growing sector of research 
where anti-invasive therapies could play a yet unforeseen role. 
Lastly, taking advantage of the use of nanocarrier delivery systems, multi-
modality treatment is an area for further expansion of the technology. In this dissertation, 
we have already seen that IB can be co-loaded with Doxorubicin and gadolinium to yield 
desired in vivo effects. However, can this multi-modality be furthered with other imaging 
agents and therapies for use in different models of cancer. The tuning of the 
combinatorial delivery of drugs and imaging agents for tracking metastasis, angiogenesis, 
and even inflammation while possibly modulating the ability of tumors to do these things 
is an area of research that could expand. There is already high interest in this type of 
therapeutic, termed theranostics and yielding NIH funding specifically for this type of 
research[308]. Incorporation of an anti-invasive with the other modalities of therapy and 
diagnostic is one step further in nanotechnology and another step closer to understanding 
and eradicating cancer.  
Along with this, the drug delivery aspects of IB are yet to be fully explored. Using 
liposomes due to the FDA-approval, loading capabilities, and well-understood in vivo 
effects is just the first step. Local delivery of IB may yield impressive results post 
resection and allow better efficacy of subsequent therapies and even to subsequent 
surgeries if the tumors are seen to grown back as non-invasive entities. Further, in 
continuing use of liposomes, development of remote loading capabilities would optimize 
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manufacture thereby reducing cost of component lipids and waste of excess IB. Further 
these particles may then yield more potent delivery of the drug to the site while 
minimizing lipid side effects in patients. 
This type of exploration would also lead into the development of the drug at a 
clinical level. With such promising results seen in animal models with little evidence of 
toxicity, movement into humans seems to be a high possibility. To begin, it would be 
beneficial to test toxicity on human cells derived from liver and spleen as the most 
common targets of liposome delivery, we would be able to identify potential toxicity. 
Outside of the laboratory, movement into clinical trials would be exciting. Most 
compounds being tested currently, as listed in the introduction, are targeting growth and 
apoptosis and are mostly being translated from other cancer models into glioblastoma. As 
aforementioned, glioblastoma is a somewhat unique disease and therefore, movement of 
a compound that has been developed for GBM and shown high efficacy in animal models 
represents a unique pathway to the clinic. Therefore, I believe that along with the other 
proposed routes of research, a parallel push to the clinic would represent the most 
impactful outcome of the work in this dissertation. Further, through a clinical result, the 
paradigm shift of pre-treatment of invasive glioblastoma to halt invasion before it 
worsens would yield, I believe, a significant standard of care change in treatment and 
thereby allow for a jump forward in the clinical outcome of this disease that has not been 
seen in decades. 
In this vein, the investigations in this thesis represent the possibility to change the 
way we treat brain tumors and invasive tumors in general. The idea of pre-treatment of 
tumors before more aggressive therapies is hinted at with chemoprevention, however, 
few studies have thoroughly investigated this possibility. Further, development of agents 
with this specific purpose is not commonly pursued due to the lower impact of the studies 
that can be produced alone and the intensity involved in multi-compound delivery 
schedules. The current treatment paradigm is not working for glioblastoma as well as 
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other invasive models of cancer so there may need to be a total shift in the way we deal 
with cancer from the beginning to really eradicate the disease. Personalized therapies are 
interesting but expensive and chemotherapy is still widely used despite the multitude of 
side effects. Therefore, through development and use of agents that do not kill cancer 
cells but rather change them is an area for rapid expansion. 
On the  drug delivery side, this dissertation displays a trend that is beginning to 
occur. Generally, there are labs that develop compounds and labs that develop drug 
delivery methods. These tend to be exclusive and only after long clinical trials and 
exploration are compounds optimized in delivery vehicles. At this point, it’s difficult to 
promote change in the methods due to FDA hurdles and necessary clinical trials. In this 
study, we show the introduction of a compound and development of the delivery system 
simultaneously. In this way, the compound can really be tested in vivo with more 
significant results and exploration. Further, studies for pharmacokinetics and 
biodistribution are well-understood due to the long-standing history of liposomal 
nanocarriers. This represents a shift in how we interface biomaterials with the cargo. By 
developing the two simultaneously, we avoid the circulation problems inherent to the 
compound and understand the tumor distribution of the complex. Further, we have the 
ability to better assess localization and circulation of these compounds through imaging 
agents. I think that this is a significant in the movement of the field to a more 
collaborative interface at the translational level. 
Lastly, this thesis represents a highly collaborative work among chemists, 
engineers, biologists, and physicians to tackle one problem: glioma invasion. I think that 
the ability for us to move amongst groups of researchers as bioengineers is essential to 
the vitality and ingenuity of this field. The willingness to develop a variety of skill sets 
and interact can create a substantial alteration in the research ongoing in the field and 
better advance the clinical side as well as the experimental side to better tackle the 

















Aamp 2.08 -2.14 angio-associated, migratory cell 
protein 
Acta1 16.29 -2.34 actin, alpha 1, skeletal muscle 
Anp32a -1.01 -2.23 acidic (leucine-rich) nuclear 
phosphoprotein 32 family, member A 
Arhgdia -10.59 3.19 Rho GDP dissociation inhibitor 
(GDI) alpha 
Cct6a -6.19 2.75 Chaperonin containing Tcp1, subunit 
6A (zeta 1) 
Cebpd -2.23 -2.63 CCAAT/enhancer binding protein 
(C/EBP), delta 
Cxcl1 -39.89 -2.17 chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating 
activity, alpha) 
Cxcl13 -67.58 3.89 chemokine (C-X-C motif) ligand 13 
Cxcl2 -36.24 -2.71 chemokine (C-X-C motif) ligand 2 
Cxcl9 -9.60 2.14 chemokine (C-X-C motif) ligand 9 
Cxcl9 -16.08 2.11 chemokine (C-X-C motif) ligand 9 
Cybb -46.87 2.51 Cytochrome b-245, beta polypeptide 
Cybb -21.68 2.09 cytochrome b-245, beta polypeptide 
Fabp4 -3.42 -2.77 fatty acid binding protein 4, 
adipocyte 
Gdf15 -2.47 -2.35 growth differentiation factor 15 
Grxcr1 1.77 2.06 glutareDXRin, cysteine rich 1 
Hapln2 9.09 -2.20 hyaluronan and proteoglycan link 
protein 2 
Hbb -9.62 -2.25 hemoglobin, beta 
Il10 -7.47 -2.00 interleukin 10 
Il1r2 -9.41 -2.14 interleukin 1 receptor, type II 
Irf2 -2.93 1.99 interferon regulatory factor 2 
Itga6 -3.12 2.16 Integrin, alpha 6 
Jmjd3 -1.54 -2.27 jumonji domain containing 3 
Ly86 -15.57 2.02 lymphocyte antigen 86 
Map1b 7.48 2.02 microtubule-associated protein 1B 
Mbp 38.89 -3.06 myelin basic protein 
Mfhas1 -1.23 2.10 malignant fibrous histiocytoma 






















Mfrp 10.15 -1.99 membrane frizzled-related protein 
Mobp 47.81 -2.25 myelin-associated oligodendrocyte 
basic protein 
Mx1 -13.17 2.31 myxovirus (influenza virus) 
resistance 1 
Nfrkb -1.60 2.01 nuclear factor related to kappa B 
binding protein 
Otx2 6.67 -2.04 orthodenticle homolog 2 (Drosophila) 
P2ry14 -3.67 2.12 purinergic receptor P2Y, G-protein 
coupled, 14 
Pf4 -8.96 -2.29 platelet factor 4 
Pfn1 -2.42 -2.34 profilin 1 
Ppp1r14a 17.65 -2.10 protein phosphatase 1, regulatory 
(inhibitor) subunit 14A 
Ptgds 29.03 -2.09 prostaglandin D2 synthase (brain) 
RT1-Db1 -12.17 2.06 RT1 class II, locus Db1 
RT1-Db1 -12.17 2.06 RT1 class II, locus Db1 
S100a8 -18.66 -2.10 S100 calcium binding protein A8 
Scin -16.73 2.80 Scinderin 
Sepw1 3.62 -2.21 selenoprotein W, 1 
Sf3b5 1.17 -2.59 splicing factor 3b, subunit 5 
Slc6a6 -4.76 -2.07 solute carrier family 6 
(neurotransmitter transporter, 
taurine), member 6 
Sostdc1 26.63 -3.86 sclerostin domain containing 1 
Tardbp -2.26 -2.13 TAR DNA binding protein 
Tgoln1 -1.31 2.14 trans-golgi network protein 
Tram1 -3.55 2.32 Translocation associated membrane 
protein 1 
Ttr 32.59 -7.53 transthyretin 
Uba6 -3.84 2.22 Ubiquitin-like modifier activating 
enzyme 6 
Vcan -6.22 -2.17 versican 
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APPENDIX B  
EFFECT OF IB ON ANGIOGENESIS 
(Abridged work completed by undergraduate Eleanor De Hitta and used in her senior 
thesis) 
B.1 Introduction 
Gliomas develop their vascularized networks through the process of angiogenesis, the 
development of blood vessels.  In tumor development, angiogenesis is marked by a few 
hallmark characteristics.  Growth factors released from tumor cells activate receptors on 
nearby pre-existing blood vessels, causing the release of enzymes called matrix 
metalloproteinases (MMPs)[309].  Matrix metalloproteinases degrade the basement 
membrane or inner lining of the blood vessel to make room for the development of new 
blood vessels.  In glioma, MMP-2 and MMP-9 are significantly overexpressed [310].   
Simultaneously, the blood vessel’s pre-existing endothelial cells release chemical 
messengers to induce endothelial cell recruitment towards the site of angiogenesis 
(known as endothelial cell chemotaxis).  Blood vessels are mainly composed of 
endothelial cells.  They are the building blocks of the blood vessel foundation.  
Endothelial cells will then adhere to the site of degraded basement membrane.   Next, the 
newly recruited endothelial cells will form tube-like structures with neighboring 
endothelial cells.  These networks will facilitate the development of blood vessel 
formation [311].   
Throughout the process of angiogenesis, growth factors are overexpressed.  An 
imbalance of these growth factors causes the newly formed vessels to be disorganized 
and underdeveloped[312].  The endothelial cells which make up the lining of the vessel 
have large gap junctions as a result of the imbalance in growth factors[313].  The creation 
of large gap junctions increases the permeability of the blood vessel, which causes fluid 
accumulation in tumors. Tumor permeability has been observed to increase up to 20 fold 
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compared to healthy patients.[314]  The blood-brain barrier is the separation between 
blood and cerebrospinal fluid.  It is highly selective of deciding what can reach brain 
tissue.  Gliomas disrupt the structure of the blood-brain barrier, allowing for unwanted 
fluid to accumulate.  Fluid accumulation (edema) can increase interstitial fluid pressure 
and neurological deficits.  Furthermore, interstitial fluid pressure has been shown to 
decrease drug delivery.  Although edema can be treated with steroid therapy, it is not 
favored due to the adverse side effects associated with steroids.  Therefore, development 
of anti-angiogenic therapies is favored to reduce symptoms of edema and increase drug 
delivery.[314]     
T1-based magnetic resonance (MR) contrast agents have enabled more applications 
of magnetic resonance imaging (MRI) in tumor detection, tumor characterization, and 
vascular imaging.    Gadolinium (Gd) chelates are ideal for imaging because they 
decrease T1 relaxation times.[315]  However, bolus injection timing is important  due to 
gadolinium’s small window of efficacy and three hour half-life.[316]  For in vivo small 
animal studies, Gd-chelates cannot produce a clear image with an optimized 7T scanner.  
Ghaghada et al. synthesized gadolinium liposomes: core encapsulated, surface 
conjugated, and dual (core encapsulated and surface conjugated) formulations. Three 
days after tail vein injections of the different formulations, animals were imaged.  Rats 
which were administered the dual gadolinium formulation exhibited significantly higher 
nanocarrier-based T1 relaxivity, signal to noise ratio, and contrast to noise ratio, 
compared to rats with contrast-enhanced and surface conjugated gadolinium 
liposomes.[315]   
In this study, we examined the ability of a novel anti-invasive agent, Imipramine 
Blue, to alter the angiogenic state of the tumor. This is based on previous data showing 
enhanced efficacy of Doxorubicin nanocarriers to kill tumors when pretreated with 





B.2.1 Cell culture 
U87MG human glioma cell line was purchased from American Type Culture 
Collection, (Manassas, VA) and grown in T-75 flasks in growth medium.  U87MG 
growth medium consisted of Dulbecco’s Modified Eagle’s Medium (DMEM)  
supplemented with 10% Fetal Bovine Serum (FBS), 1% Penicillin/Streptomycin (P/S), 
1% Non-Essential Amino Acids , and 1% L-glutamine (L-glut) (Gibco, Carlsbad, CA).  
RT2A and 3RT1-RT2A (eGFP-expressing RT2A) rat glioma cell lines were obtained 
from Helen Fillmore in the Department of Neurosurgery from the Virginia 
Commonwealth University.  RT2A was grown in T-75 flasks in U87MG growth medium 
previously mentioned.  3RT1-RT2A growth medium included the same formulation for 
U87MG and RT2A growth medium with the addition of 1mg/ml G418 sulfate (Gemini 
Bio-Products, West Sacremento, CA).  Basal media for U87MG, RT2A, and 3RT1-RT2A 
consisted of DMEM supplemented with 1% Penicillin/Streptomycin, 1% Non-Essential 
Amino Acids , and 1% L-glutamine. 
Human Umbilical Vein Endothelial Cells (HUVEC) were a generous gift from 
Larry V. McIntyre and cultured in T-75 flasks treated with 0.2% gelatin (Sigma, St. 
Louis, MO) in Medium 199 (M199, Mediatech, Manassas, VA) supplemented with 
16.28% Fetal Bovine Serum, 0.98% Penicillin/Streptomycin,  0.98% L-glutamine, 0.2% 
heparin (1000 USP units ml−1, Baxter Healthcare, Deerfield, IL), and 0.16% endothelial 
mitogen (25 mg reconstituted in 2 ml M199, Biomedical Technologies, Stoughton, MA).  
Low serum media consisted of M199 supplemented with 0.05% Fetal Bovine Serum, 
0.98% Penicillin/Streptomycin, 0.98% L-glutamine, 0.2% heparin, and 0.16% endothelial 
mitogen. 
 
B.2.2 DQ Collagen Assay 
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A 96-well plate was coated with the dye-quenched collagen and BME solution (1 mg/ml 
each in DMEM).  U87MG or RT2 were seeded in wells (50,000 cells/well in 50µl) and 
treated with varying concentrations of Imipramine Blue (0 to 100 µM).  Plates were then 
incubated for 16-24 hours and FITC imaged under 10x magnification.  Average FITC 
intensity levels were determined using ImageJ Software, normalized to the control 
(0µM), and compared using a one-way AN ANOVA to detect significant differences.  If 
the one-way ANOVA detected a significant difference, a Tukey comparison was used to 
determine which pairs were significantly different 
B.2.3 Endothelial cell invasion assay 
50,000 Human Vascular Endothelial Cells (HUVECs) per well were seeded in 
tissue culture inserts coated with the matrigel. Imipramine Blue was added to each well in 
increasing doses on the apical side. Wells were filled with basal media to the level of 
media in the tissue culture insert, preventing a pressure gradient.  Plates were incubated 
for 24 hours then fixed with 4% paraformaldehyde, DAPI stained, and imaged to quantify 
invasion (as % of total).  Invasion percentages were normalized to the control (0µM) and 
compared using a student’s two sample t-test (2 tail, α=0.05) to observe significant 
differences. 
B.2.4 Liposome Synthesis 
Imipramine Blue liposomes and saline liposomes were synthesized as previously 
described (Chapter 4)Dual gadolinium liposomes were synthesized as described ref. 
Briefly, DPPC, Gd-DTPA bis(stearylamide) (Gd-DTPA-BSA), cholesterol, and DSPE-
PEG 2000 with a molar ratio of 30:25:40:5 were dissolved in a chloroform-methanol (1:1 
v/v) solution.  The lipid solution was then evaporated to dryness using a vacuum and 
hydrated with a solution of gadodiamide (OmniScan®) to a final lipid concentration of 
40mM.  The solution was stirred at 60°C for 90 minutes.  The liposomes were then 
extruded five times through a 400 nm Nuclepore membrane, seven times through a 200 
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nm Nuclepore membrane, and ten times through a 100 nm Nuclepore membrane.  The 
final liposome solution was then dialyzed against PBS to remove free gadolinium. 
Liposomes were measured by Dynamic Light Scattering to determine the diameter. 
B.2.5 In vivo Vascular permeability quantification  
The in vivo vascular permeability study followed the timeline outlined in Table 
B.1.  .  Typically, rats inoculated with the untreated RT2 tumor model show signs of 
morbidity by day 12.   
Table B.1: Timeline of treatment and imaging schedule 
Day Treatment 
0 Inoculate tumor  
4 Tail vein injections 
Group 1, nano-IB (n=3) 
Group 2, plain liposomes (n = 3) 
7 Pre contrast images for random members of groups 1 and 2 
Tail vein injections of dual gadolinium liposomes, both groups 
10 MRI both groups 
12 Perfusions 
 
B.2.6 Animal studies 
Tumors were inoculated as described with 200,000 RT2 cells in 10µl into the 
cortex of Fisher 344 male rats (six rats total). On day 4 after tumor inoculations, the rats 
were administered either saline liposomes or IB liposomes (5 mg/kg).  Day 4 was chosen 
as the first day of injection because it is when angiogenesis is first seen in histological 
analysis.  On day 7, both groups were administered 0.15 mmol Gd/ kg rat after pre-
contrast MRI. Timeline is in Table ##. 
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B.2.7 Magnetic resonance imaging 
On day 7 prior to tail vein injections, one animal from each group was MR 
imaged for precontrast reference.  Animals were anesthetized by 1-2% Isoflurane, then 
placed in a 7T MRI (Bruker).  A T1-weighted image was taken through the head using 
the following parameters: a range of 50ms - 2.0 s repetition time (TR), 48 ms echo time 
(TE), FOV = 40 mm x 40 mm with a 256 x 256 matrix, slice thickness = 5 mm, number 
of slices = 1, 4 averages per phase encode step requiring a total acquisition time of about 
45 minutes per rat.  Furthermore, a 3x3 cut out of a clear 96-well plate containing varying 
concentrations of dual-gadolinium liposomes were imaged for use as a standard for 
concentration determination. 
B.2.8 Kinetic analysis for determination of permeability 
Vascular Permeability was assessed by determining each tumor’s endothelial 
transfer coefficient (KPS [ml min-1100 cc-1 of tissue]) similarly to a method developed by 
Daldrup et al.[317]  Concentration of gadolinium in the tumor (CT) is a function of 
gadolinium accumulation in interstitial (CI) and plasma spaces (fpvCp, where fpv is the 
fractional plasma volume of the tumor tissue [mL cc-1 of tissue] and Cp is the 
concentration of gadolinium in the plasma [mmol ml-1]) as seen in Eq. 1.     
 =  +   (1) 
 
The rate of interstitial gadolinium accumulation (Eq. 2) is a function of the endothelial 
transfer coefficient (KPS), the concentration of gadolinium in the plasma and the reflux 
from interstitial water back to the plasma, where k is the reflux rate constant.   
dCI(t)
dt
= KPSCpt-kCI(t) (2) 
The solution to Eq. 2 is shown below in Eq. 3.   
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  yields Eq. 4.   
 =   


+   (4) 
B.2.9 MRI data extraction 
Pre-contrast images were not used for the kinetic analysis of MR images because 
it was determined that the difference in tumor sizes from day 7 and day 10 would affect 
the amount of gadolinium accumulated at the tumor.  MR images were converted into 
MATLAB color maps by a program provided by Dr. Johannes Leisen.  The color maps 
displayed T1 relaxivity and inverse T1 relaxivity (1/T1) values.  T1 and 1/T1 color map 
scales were adjusted (T1: (0, 4000); 1/T1: (4E-4, 8E-4)). Areas on the 96-well plate T1 
color map corresponding to varying concentrations of gadolinium were traced, and 
average RGB (red, green, blue) values were recorded.  The RGB values were then 
converted to T1 values on the color map scale, and an exponential regression was created 
relating the amount of gadolinium (mmol) to T1 values. 
ImageJ was used for tumor analysis.  Tumors on T1 color maps were outlined.  
Tumor area and mean tumor RGB values were extracted.  RGB values were converted to 
T1 values using the color map scale.  Finally, the T1 values were converted to amounts of 
gadolinium (mmol) using the exponential regression.  These values were divided by the 
product of the tumor area and MR image depth (volume of tumor section), converted to 
mmol/cc and recorded as CT(t=72 hours).  
No pharmacokinetics studies have been published for the dual gadolinium 
liposome formulation developed by Ghaghada et al., so gadolinium accumulation in the 
138 
 
plasma was modeled from a stealth liposome model.[315, 318]  This model is analogous 
because of the similar lipid content.  This model was applied to gadolinium 
accumulation.  The vehicle of delivery (liposome) is what limits the amount of core 
encapsulated gadolinium which will be released into the plasma, so this is an applicable 
model for Cp(t).  It was assumed that dual-gadolinium liposomes would have the same 
release profile in the plasma concentrations of mg/ml were converted to mmol/ml. 
Daldrup et al. used k =0 for albumin-conjugated gadolinium.[317]  Liposomes 
have a similar clearance rate as albumin, so k was also assumed to be 0 for the dual-
gadolinium liposomes.  Fractional plasma volume of 0.177 mL cc-1 was taken from 
control animals by a similar study by Gossman et al.[319] Rats were inoculated with U87 
gliomas and MR imaged on day 16 to evaluate an anti-angiogenic therapy using the 
method described by Daldrup et al.[317]  KPS was then solved using Eq 4.    
B.2.10 Perfusions and Brain Processing 
On day 12 the animals were perfused intracardially with PBS.  Prior to perfusion, 
the rats were anesthethized by an intraperitoneal injection of ketamine, xylazine, and 
acetylpromazine (respectively 50, 10, and 1.67 mg/kg).  Extracted brains were fixed in 
4% paraformaldehyde in PBS for 1 hour at 4°C then stored in 4% sucrose (wt-vol % in 
PBS) at 4°C until saturated, embedded in optimal cutting temperature compound (OCT), 
stored at -80°C and cryosectioned coronally into 16 µm slices.   
B.3 Results 
B.3.1 MMP Activity is not affected by IB until it reaches cytotoxic doses 
Some significant differences were observed in U87 and RT2 MMP activity 
(Figure B.1).  A significant difference was observed in U87 cells between 0.001 µM IB 
and 50 µM IB treatment groups(p=0.000).  Similarly, significant differences were 
observed in RT2 cells between 1 µM IB and 50 µM IB (p=0.016).  U87 MMP activity 
showed no definite increasing or decreasing trends as Imipramine Blue treatment 
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increased.  As IB treatment increased, RT2 MMP activity increased from 0 µM IB to  0.1 
µM IB and 1 µM IB, peaked, and then decreased from 1 µM IB to 100 µM IB. 
 
 
Figure B.1: MMP Activity in IB-Treated U87 (left) and RT2 (right) cells.  Cells were 
seeded on a basement membrane extract which included a dye-quenched collagen IV.  
When the collagen IV is cleaved by MMP-2 and MMP-9, a green fluoroscein is emitted. 
Data graphed is the change in this intensity over the baseline 0µM concentration. Only 
the high concentrations of IB showed significant decrease Collagen IV cleavage 
(*p<0.05). At this concentration, IB is known to be cytotoxic to both cell lines. 
 
 
B.3.2 Huvec invasion is not significantly affected by IB 
HUVECs that were plated in matrigel and allowed to invade did not show a 



















































Figure B.2: Treated HUVEC invasion decreased but was not significant (p=0.08, in 
one experiment).  HUVECs were seeded and treated  either 0 µM IB or 5 µM IB (n=3 
per treatment), incubated for 24 hours, 4% paraformaldehyde fixed, DAPI stained, and 
imaged.  Invasion through the tissue culture insert was quantified and normalized to the 
control.   
 
B.3.3 In vivo vascular permeability quantification 
Though the IB-treated group seemed to have an increase in vascular permeability, 
no significant differences were observed between treatment groups in terms of 
endothelial transfer coefficients and cross-sectional tumor area (p1=0.3488, p2=0.187).  
MR images are seen in Figure B.2, displaying the inverse T1 relaxivities which is 


























Table B.2: Endothelial Transfer Coefficients (K
PS
) and Cross-Sectional Tumor 
Areas  
Saline Liposomes  Imipramine Blue Liposomes 
ID # KPS 
Cross-
sectional 
tumor area ID # KPS 
Cross-sectional  
tumor area 
1 0.647 0.808 4 13.466 0.058 
2 6.927 0.126 5 3.398 0.209 
3 0.908 0.576 6 3.907 0.248 




Figure B.3: 1/T1 MR Brain Image Color maps. Color maps generated from MR data 
representing the inverse relaxivities.  The red denotes the areas where gadolinium 
accumulated.  Top row shows tumors treated with saline liposomes.  Bottom row shows 







B.3.4In vivo staining of blood vessels reveals no observable differences 
Performing staining of tumors after the study revealed no readily observable 
differences in blood vessel quantity or morphology. There appeared to be blood vessels 
heterogeneously distributed throughout the tumor and that this distribution was 
unaffected by the treatment. Figure B.3 shows representative images from different 




Figure B.4: Effects of Imipramine Blue on Blood Vessels of Rat Glioma (RT2).  Rats 
were inoculated with glioma and treated with either nano-IB or saline.  Brains were 
cryosectioned, stained for RECA-1, endothelial cell marker (red), and imaged throughout 
the tumor.  Rats treated with saline (A) appeared to possibly have more blood vessels 








MMP-2 and MMP-9 activity appears to not be affected by varying concentrations 
of Imipramine Blue.  Although U87 and RT2 cells treated with 50 µM IB were 
significantly different from other treatment groups, it is expected that the significant 
decreased observed is due to cell death.  From previous in vitro cytotoxicity assays, 40 
µM IB was determined to be the average lethal dose for U87 and RT2, in vitro.  This 
supports the prediction that Imipramine Blue does not affect basement membrane 
degradation, the first stage of angiogenesis.  For future studies, it is suggested that 
positive control group be added, such as emodin, an MMP-2 and MMP-9 inhibitor 
observed in glioma cells.[320]  The addition of a positive control group will confirm the 
appropriate sensitivity of the assay if no fluorescence is emitted.  Zymography could also 
be performed for more quantitative results.   
The HUVEC invasion assays suggest endothelial cell migration decreases when 
cells are treated with Imipramine Blue, but the results are not significant.  Increasing the 
sample size for each treatment will provide more results, so a definite conclusion 
concerning IB-treated endothelial cells can be made.  The assay performed only assesses 
the effect of IB on treated endothelial cells.  Future experiments can simulate the effect of 
IB-treated glioma cells and their ability to recruit endothelial cells.  This would involve 
glioma cells plated in a 24 well plate.  Once adhered, cells would be treated with either 0 
µM IB or 5 µM IB in basal media.  Cells would be treated for 3 hours.  In vitro, the 
effects of IB have been observed as early as 3 hours after treatment.  After 3 hours of 
treatment, media will be replaced with low serum HUVEC media.  Tissue culture inserts 
containing seeded with untreated HUVECs using the method mentioned previously, will 
then be   placed in the glioma-coated 24-well plate and incubated for 24 hours.  Invasion 
through the membrane will be quantified using the same method previously mentioned.  
The addition of the coated glioma cell lines will simulate the tumor environment with the 
secretion of its chemokines during incubation.  
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No conclusions were made on the effect of Imipramine Blue on tube formation.  
Future experiments should include tube formation assays involving HUVECs treated 
with: varying concentrations of IB and a positive control tube formation inhibitor such as 
Avastin.[321]  This will assess Imipramine Blue’s possible abilities to prevent endothelial 
cell tube formation. 
No significant differences were observed between treatment groups in terms of 
endothelial transfer coefficients and cross-sectional tumor areas.  A similar study was 
conducted comparing the effects of an anti-VEGF therapy on endothelial transfer 
coefficients in U87 inoculated tumors (400,000 cells in matrigel-media suspension per 
animal).  Tumors were MR imaged on day 16.  Given the cell amount inoculated and the 
additional amount of time to MR image, tumor sizes from the U87 study were larger.  
Furthermore, KPS values were ten times greater in U87 PBS-treated tumors (control 28.6 
±8.6 mL min-1cc-1 of tissue, mean ±SD) compared to the RT2 saline liposome-treated 
tumors (control 2.83 ± 3.55 mL min-1cc-1 of tissue, mean ±SD).    Tumor size varied 
greatly within treatment groups.  This could be due to improper tumor inoculation or 
natural tumor size variability depending on the individual animal.  Increasing the sample 
size and using a new syringe needle will likely lower the variability within tumor groups.   
Many assumptions were made for this study, limiting the results.  Fractional 
plasma volume constants were taken from the control animals in the study by Daldrup et 
al.  The study’s treatment groups had significantly different fractional plasma volume 
constants.  If the treated Imipramine Blue animals did have a difference in vascular 
permeability, then estimating the fractional plasma volume to be the same could have 
eliminated a possible significant difference in endothelial transfer coefficients between 
treatment groups. For future experiments, a better method for determining fractional 
plasma volume should be implemented.  Additionally, a dual-gadolinium liposome 





COMBINATORIAL TREATMENT WITH TEMOZOLOMIDE 
(Project completed/in progress by Undergraduate Sydney Rowson) 
C.1 Introduction 
Imipramine Blue has shown efficacy at halting invasion of glioblastoma and 
benefit in combination with Doxorubicin in vivo. However, the most commonly used 
chemotherapeutic treatment in glioblastoma is oral temozolomide (TMZ), a DNA 
alkylating agent[20]. Integration of this chemotherapy with the traditional course of 
therapy including radiation and resection resulted in significant increases in remission 
and survival times. However, the outlook is still not promising for these patients.  This is 
largely due to the invasion of tumors post-treatment which can be halted with Imipramine 
Blue (IB) a novel Nox4 inhibitor. However, there is another reason for failure of TMZ 
specifically which results from the resistance of tumors to the drug. 
TMZ resistance occurs in a large percentage of glioblastoma patients and results 
from overactivity of the gene O6-Methylguanine-DNA Methyltransferase (MGMT)[33]. 
This enzyme removes methyl groups from the O6 position of guanine in DNA. 
Methylation is one mechanism by which genes are silenced and thus regulated within the 
genome within cells. It is also the mechanism by which many chemotherapeutics, such as 
TMZ and carmustine, act to damage the genome and induce apoptosis in cancer cells. 
High activity of MGMT leads to increased reversal of therapy-induced alkylation and 
thus resistance to chemotherapy[322].  
Interestingly, MGMT itself is regulated through MGMT of the CpG island in the 
promoter region of many cancers[34]. When this area is hypermethylated, MGMT is less 
active, and cancer cells respond better to alkylating agent chemotherapy. Further, 
hypermethylation is correlated with increased survival time in patients[323]. Therefore, 
hypermethyation of the promoter region of MGMT is indicative of a more treatable 
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tumor that will respond to TMZ better. Further, induction of hypermethylation leads to 
beneficial treatment response to TMZ in previously resistance cell types. Since TMZ is 
the primary treatment in glioblastoma chemotherapy, it is valuable to have therapeutics 
which can cause this change and thereby increase response to TMZ in resistant tumors. 
Imipramine Blue has already shown benefit with Doxorubicin, a topoisomerase II 
inhibitor used in a number of malignant cancers. Though no synergy was seen in vitro, 
there was a significant benefit to delivering these agents in sequence in vivo. This was 
attributed to the ability of IB to halt invasion of tumors in vivo thus allowing better 
response to the treatment. However, IB generates a host of downstream effects on cancer 
cells that could also benefit chemotherapy, both in vivo with Doxorubicin and possibly 
with TMZ. 
In this study, we examined the ability of IB to increase the efficacy of TMZ in 
both glioblastoma cell lines and primary glioblastoma neurospheres. Further we 
examined the ability of IB to halt invasion of neurosphere primary glioblastoma cells. 
C.2 Methods 
C.2.1 Cell Culture 
U87MG (ATCC) and RT2 (courtesy Helen Fillmore, Virginia Commonwealth 
University) glioma cells were maintained in DMEM containing 10% FBS and 1% 
Pen/Strep. Three primary neurosphere cultures were graciously given to us by Daniel 
Brat, Emory Department of Pathology. They were maintained in Neurobasal A 
(Invitrogen) media supplemented with N2 (Invitrogen, 1%), B27 (Invitrogen, 2%), FGF 
(Stemcell Technologies, 10ng/ml), EGF (StemCell Technologies, 20ng/ml), L-glutamine 
(VWR, 0.5%), pen/strep (VWR, 1%), and Heparin (StemCell Technologies, 0.4%) in 
non-tissue culture treated flasks.  Neurospheres were grown in suspension and passaged 
upon reaching 200-500µm in size. Every 2-3 days, cultures were supplemented with 
media containing fresh FGF, EGF, and heparin (1 ml/day). 
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C.2.2 Cytotoxicity Assays 
U87MG and RT2 cells were seeded at 100,000 cells/ml in 24-well plates 
overnight. They were then treated with IB (+IB) or ethanol (-IB) for 3 hours, then 
washed. Temozolomide in DMSO was added in increasing concentrations and cells were 
incubated with it for 96 hours. Readings were taken once a day using CCK8 cell counting 
assay by incubation and removal of media for assay. Fresh temozolomide was added 
every day after this assay. Neurosphere cytotoxicity assays were performed similarly, 
with differences in the culture techniques. Cells were seeded at 50,000 cells/ml and 
spheres were allowed to establish (approximately 1 week) in round-bottom 96 well 
plates. Cells were fed as normal during this time. For addition of drugs and readings, the 
plates were centrifuged at 1000 rpm and the media removed and cells washed. This was 
repeated for each reading. 
C.3 Results 
IB enhances the efficacy of temozolomide the induce its cytotoxic effect in the 
U87MG glioma cell line. There was a significant decrease in cell viability at 72 hours at 
the highest concentration 200µM and at 96 hours both 100µM and 200µM showed a 
significant increase in cell death with IB (Figure C.1). This indicates that IB yields 
enhanced cell death with temozolomide. Further, there was no cell death seen at the 
higher concentrations without IB indicating resistance of this cell line to the drug. None 





Figure C.1: Viability with Temozolomide and IB treatment 
C.4 Discussion and Conclusion 
It is apparent that there is a synergistic effect between IB and TMZ in vitro in 
U87MG glioblastoma. However, this effect does not seem to be universal and may 
indicate particular sensitivity of different models to the pathway that IB is affecting. 
Further, based on previous data, this sensitivity does not necessarily translate to the 
ability of IB to affect invasion. Though RT2 is the most responsive to the anti-invasive 
effects of IB, it does not have enhanced benefit from the delivery of IB with 
temozolomide. This may indicate another attribute of the inhibition of Nox4 that is not 
previously documented in the literature.  
Future studies include further examination of the effect of IB on neurospheres 
including stem cell populations, establishment of neurospheres in the presence of 
treatment, and invasion assays in 3D. Preliminary work was done with these cultures, 







































































































however, further investigation of the universality of IB in these primary glioblastomas is 
highly useful information. Further, in cell lines and cultures where there is a benefit to 
giving IB with temozolomide, methylation site specific rtPCR is ongoing for 
determination of enhanced sensitivity due to the primary mechanism of resistance: 




APPENDIX D  
IB-DXR NANOCARRIERS AGAINST U87MGEGFRVIII 
(Abstract submitted to Society for Neuro-Oncology with Konstantinos Hadjipanayis, 
MD, PhD) 
Glioblastoma invasion is a major reason for recurrence after treatment.  Recently, 
we saw in a rat glioblastoma model (RT2) that combination of Doxorubicin and 
Imipramine Blue, a novel anti-invasive agent that acts via inhibition of Nox4, enhances 
survival as compared to Doxorubicin alone. This study used systemic delivery to examine 
the efficacy of this treatment. However, it is known that use of convection enhanced 
delivery (CED) can yield better distribution of therapeutics within tumors and thus show 
better efficacy. Further, use of a human glioblastoma line transformed to express the 
EGFR variant 3 receptor known to yield enhanced invasion and malignancy of tumor in 

























Figure D.1: Kaplan-Meier Survival Plots of mice implanted with U87MG EGFRVIII. 
Treatment occurred seven days after tumor inoculation via CED to the center of the tumor. 
Mice were monitored on a daily basis after treatment (n=6-8 per group). 
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In this study, we used liposomal nanocarriers containing Doxorubicin and 
Imipramine Blue for convection enhanced delivery to an aggressive human glioblastoma 
U87MG-EGFRV3. Mice were inoculated with tumors and treated seven days later via 
CED delivery with 5µl of nanocarriers containing: Saline (n=5), IB (16µg, n=5), DXR 
(20µg, n=8), or IB-DXR (16µg IB, 20µg DXR, n=8). Mice were monitored by MRI 
before and after treatment to determine tumor response and then allowed to live until they 
met the criteria for euthanasia. Postmortem, brains were sectioned and stained for 
hematoxylin and eosin. Further, the combinatorial treatment was tested in vitro on the 
cell line to determine any synergistic effects on cell viability. 
Both the DXR and IB-DXR groups showed enhanced efficacy (Figure D.1) by 
increasing survival times above control groups (p<0.001 for each as compared to control 
using Mantel-Wilcox test). There was no benefit for co-delivery of the IB with DXR. 
However, in the previous studies the drugs were delivered sequentially and thus there 
may be a benefit if this strategy is employed in the model. However, there was complete 
survival and remission in 3 animals per group that received the DXR-loaded nanocarriers 
indicated a benefit to this therapeutic in CED against EGFRV3 positive glioblastomas. 
Histology and in vitro studies are ongoing to determine differences between tumor and 
cell viability in response to combinatorial treatment. However, this data is striking in the 
ability of the nanocarriers delivered via CED to yield complete survival in this highly 





 EFFECTS OF INTERSTITIAL FLOW ON GLIOMA INVASION 
 
(Manuscript in preparation from year abroad on Fulbright Fellowship) 
From: Interstitial flow increases glioma invasion via CXCR4-dependent autologous 
chemotaxis  in a 3D microenvironment 
Jennifer M Munson2  Ulrike Haessler1 , Ravi V BellamkondB , Melody A Swartz1 
1Laboratory of Lymphatic and Cancer Bioengineering, Institute of Bioengineering and 
Swiss Institute for Experimental Cancer Research, École Polytechnique Fédérale de 
Lausanne (EPFL), Switzerland  
2   Department of Biomedical Engineering,  Georgia Institute of Technology, Atlanta, GA, 
USA 
E.1 Abstract 
Brain tumor invasion is a significant clinical problem leading to recurrence and 
resistance to treatment. Glioma cells invade in distinctive patterns that correlate with 
chemokine gradients, flow patterns, and structural heterogeneity in the brain. In other 
tumors, interstitial flow caused by lymphatic drainage actively enhances invasion and 
metastasis towards lymphatics. We hypothesized that fluid drainage from brain tumors 
into the cerebrospinal fluid could play an active role in glioma invasion. Using in vitro 
3D glioma model systems, we show that slow interstitial flow can enhance cell invasion 
in multiple glioblastoma models. These flow effects were CXCR4-dependent, as they 
could be abrogated upon blocking CXCR4 or adding exogenous CXCL12 to the matrix. 
Using immunocytochemistry and western blotting, we show that CXCR4 is actually 
activated under flow conditions for the most flow-responsive cell possibly contributing to 
the enhanced chemokinesis observed through live imaging. Lastly, we identify a group of 
cells that has enhanced chemotactic potential in the direction of flow by using live 
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imaging and analysis, that can be blocked by inhibiting CXCR4 or through saturation of 
CXCL12 in the matrix. We propose that this migration in the flow direction is caused by 
autologous chemotaxis and using modeling we show that a local pericellular gradient can 
be formed under slow flow conditions. This study has implications for the study of brain 
tumors in that interstitial flow is an active regulator of the invasive potential of cancer 
cells and not just a passive carrier.  
E.2 Introduction 
Glioblastoma (GBM) is a highly infiltrative and deadly form of brain cancer. It is 
characterized by diffuse growth and invasion of tumor cells into the surrounding brain 
tissue [11]. The migration of glioma cells into the brain has a very distinctive pattern 
including invasion along white matter tracts, blood vessel basement membranes, and 
movement around the outside of the brain parenchyma [12]. These patterns have been 
examined to determine the reason for this selective invasion though no definitive answer 
has been found [325-327]. It is unclear why GBM invasion follows such patterns, but 
hypotheses include following the path of least resistance, fluid flow, structural cues, and 
protein interactions to the white matter tracts [13, 14, 328].  
As for chemokines that guide invasion, CXCL12 and its receptor CXCR4 have 
been the most strongly correlated in brain cancer as well as in brain development [329, 
330]. CXCR4 upregulation is found in almost every cancer type and is implicated in cell 
homing to metastatic sites.  More invasive tumors express higher levels of both CXCR4 
and CXCL12 [331, 332]. Further, activation of CXCR4 by phosphorylation is found in 
abundance in higher grade brain tumors [333]. Thus, CXCL12 likely guides brain tumor 
invasion, yet its relationship to the invasive patterns seen along white matter tracts has 
not been clarified.  
Fluid flow in the brain, on the other hand, has been studied and correlated with 
white matter tracts [13]. Such interstitial fluid flow can theoretically redistribute 
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chemokine gradients  that can, in turn, guide cell migration[334]. For example, melanoma 
and breast carcinoma invasion is correlated with expression of the chemokine receptor 
CCR7, and we showed in vitro that slow interstitial flow could enhance the invasion of 
CCR7-expressing human cancer cells that also expressed CCR7 ligands [335]. Since 
CCR7-directed migration is required for immune cell migration to the lymphatics, and 
since fluid flow is always directed from the periphery towards locally draining lymphatic 
vessels, this “autologous chemotaxis” could be an important mechanism of leukocyte 
homing to the lymph nodes, a mechanism which tumor cells mimic[336]. Further, we 
showed that stromal fibroblasts can enhance cell invasion due to a TGF--dependent 
mechanism that is activated by flow. Both of these mechanisms may promote invasion 
towards draining lymphatic vessels in the periphery[337]. 
Though lymphatic vessels are not present in the brain, fluid flow in the brain is 
tightly regulated and drains to lymphatic pathways in the neck[338]. Ependymal cells in 
the choroid plexus secrete CSF, which flows in response to ciliary beating along the 
ventricle lining. Disregulation of these ciliary cells leads to improper neuronal patterning 
and developmental problems [339]. Flow normally is generated at the choiroid plexus in 
the fourth ventricle, moves  through the interstitium of the brain and drains around the 
outside of the brain to be reabsorbed in the ventricles[340]. However, when a brain tumor 
develops there is a change in the flow pattern resulting from pressure differentials caused 
by tumor fluid influx, cyst development, and edema resulting in drainage from the tumor 
into the CSF and yielding hydrocephalus [341]. Glioblastoma commonly develops in the 
frontal lobes of the cortex coming in close contact with white matter tracts, paths of least 
resistance along which fluid can drain through the brain. It has been found that tumors 
originating further from these tracts have a better prognosis after treatment and less 
recurrence implicating these pathways in tumor spread [342].  
These flow pathways not only correlate with the structural features of white 
matter tracts but also have been correlated with chemokine gradients (such as CXCL12) 
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and growth factor gradients (such as VEGF) leading to angiogenesis and migration at the 
leading edges of these tumors [10]. Further, other tracts such as blood vessels and 
meningeal linings are hotspots for tumor cell migration and correlate with least resistance 
flow pathways and chemokine secretion in the brain [258, 343]. Therefore, it stands to 
reason that these three features are interrelated. 
Here we propose a new mechanism for tumor cell invasion in the brain: namely, 
that fluid flow directs CXCL12 gradients and increases CXCR4 activity in glioma cells, 
leading to directed cell migration. In vivo, we observed a strong correlation between 
CXCL12, flow patterns, and glioma invasion patterns in the rat brain. Using three-
dimensional in vitro culture systems, we show that glioma cells, when exposed to 
interstitial flow, become more invasive, both randomly and in the flow direction. This 
increase in invasion was dependent on CXCR4 signaling, and involved at least two 
mechanisms: autologous chemotaxis (i.e., gradient amplification of cell-secreted 
CXCL12 in the flow direction, causing chemotaxis) and flow-increased CXCR4 
phosphorylation. Therefore, we introduce fluid flow as an important modulator of glioma 
invasion. 
E.3 Methods 
In vivo glioma analysis 
Fisher 344 male rats were inoculated with 3RT1-RT2 (eGFP expressing RT2) 
glioma via stereotactic injection. A 2mm incision was made and a burr hole drilled 3mm 
lateral and 1mm anterior to bregma. A Hamilton syringe was used to inject 250,000 cells 
in 10µl L15 media 3.3 mm below the dura. On day 10 after injection, Evans blue (50 
mg/kg in saline) was injected into the tail vein 12 hours prior to intracardial perfusion 
with 4% paraformaldehyde. Brains were collected, incubated in sucrose, cryoembedded, 
and sectioned at 16µm before staining for CXCL12 and GFP. Images were acquired 
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using confocal microscopy (Zeiss LSM510 Meta) and analyzed for co-localization of 
pixels with ImageJ software (NIH, Bethesda MD). 
Cell lines and culture  
RT2 cells were a kind gift from Helen Fillmore; U87MG and C6 cells were from 
ATCC (city, state) and 9L cells were kindly provided by the Neurosurgery Tissue Bank 
at University of California San Francisco. All cells were cultured in DMEM (Gibco) with 
10% Fetal Bovine Serum and 1% penicillin/streptomycin, passaged with 0.05% trypsin. 
3D cell assays 
Experiments were performed with 12mm diameter, 8µm pore cell culture inserts 
(Millipore, Billerica, MA) in a modified Boyden chamber assay. 105 tumor cells were 
seeded in 100 µl in 0.1% hyaluronan (Glycosan Biosystems) and 0.12% rat tail collagen I 
(BD Biosciences). For chemotactic studies, CXCL12 (100nM) was added to the bottom, 
top, or both (with addition to the gel).   After 16 hr in a 37°C/5% CO2 incubator, gel 
containing nonmigrated cells was removed and the inserts were fixed in chilled 4% 
paraformaldehyde. Cells were stained using DAPI and counted using an inverted 
microscope. For experiments with blocking by AMD3100 (10µM) or CXCL12 presence 
(100nM) the chemical was incorporated into the gel and present in all media.  
Migration under Flow 
The above setup was modified to examine the effects of physiological flow on 
tumor cell migration. After the gel was cast and allowed to set, a pressure head of 1cm 
media was established that led to an average velocity of 0.7 µm/s through the cell/gel 
compartment (flow rate determined in separate experiments using measured permeability; 
data not shown). For static conditions, media was placed on top to prevent drying out and 
brought to the media line on the outside to ensure no pressure differential. Migration in 
the presence of basal media, media with CXCL12 (100nM), or AMD3100 (10µM) was 
assessed.  
Western Blot Analysis  
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CXCR4 and p-CXCR4 expression was analyzed by Western blot using 0.5 mg/ml 
chicken anti-CXCR4 (Sigma), rabbit anti-p-CXCR4 (S339) (AbCam), HRP-conjugated 
goat anti-chicken IgG  and anti-rabbit IgG (BioRad), and a Western Pico ECL substrate 
kit (Pierce, Rockford, IL).  
Antibodies, Flow Cytometry, and Immunofluorescence 
The following antibodies were used for immunostaining mouse brain tissue: anti-
mouse CXCL12 (AbCam), FITC-labeled anti-rat GFP, anti-mouse fluoromyelin, and 
DAPI (all from Invitrogen). For cultured cells, anti-rat CXCR4 (Sigma), phospho-
CXCR4 (AbCam), and PhAkt (AbCam) were used. Alexafluor-labeled secondary 
antibodies were obtained from Invitrogen, and AF594 phalloidin (Invitrogen) was used 
for F-actin. For flow cytometric analysis, permeabilized and non-permeabilized cells 
were compared for CXCR4 expression. 
ELISA for CXCL12 
CXCL12 protein secretion was quantified using an ELISA kit (R&D) from cells 
seeded in 2D or 3D culture conditions in basal medium after 16h  static or flow 
conditions. To account for matrix-bound ligands, three compartments were analyzed: free 
protein in the medium, matrix-associated protein (by digestion with collagenase D (BD 
Biosciences), and cells (by lysis using standard RIPA buffer protocols Sigma). Protein 
amounts were normalized to cell number harvested in each experiment and data 
combined over experiments.  
Live imaging and analysis of cells under flow  
RT2 cells were seeded at 5x105 cells/ml in a 3D flow chamber (Shields et al, 
2007) in 3D gels as described for static-flow assays but with L-15 medium in place of 
DMEM and at a density of. Images were taken every 15 minutes for 16-24 hours at four 
locations for each chamber (4 chambers total: 2 static, 2 flow).  Cells in videos were 
tracked using ImageJ and analyzed using MATLAB for migration parameters. A 
reference point was selected in each frame to account for focus drift due to experimental 
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set-up and used in analysis. After live imaging, FITC-dextran was flowed through the 
system to determine flow rates by FRAP analysis and assess any fluid channeling.   
Polarization assays and CXCR4 image analysis 
RT2 glioma cells, at 5x105 cells/ml in the hyaluronan/collagen matrix, were 
seeded into radial flow chambers [140, 337] and exposed to pressure-driven flow for 16 
hours. Chambers were fixed in 4% paraformaldehyde, permeabilized with 0.05% triton, 
and immunostained using the appropriate antibodies. High resolution images were taken 
using confocal microscopy and wide-field microscopy was used for assessment of 
polarized cells in all regions of the chamber. For image analysis studies, imaging 
parameters were held constant for all pictures and intensities were measured in ImageJ 
and normalized to static conditions. 
Computation of Extracellular CXCL12 Distribution 
Extracellular CXCL12 gradients were computed using a 3D model according to: 

 + 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where Ci is concentration of species i, t is time, v is velocity, Di is the diffusion 
coefficient, and Ri is the rate of reaction (matrix binding and cleaving of chemokine). The 
cell was modeled as a 20 µm diameter sphere embedded 150 mm from the bottom surface 
of a 500 mm thick porous ECM (Hyaluronan) with 3 mm of medium atop the matrix. The 
Brinkman equation was used to determine the velocity profile through the ECM around 
the cell using a value for permeability of K = 10-12 cm2 (determined from the literature) 
and range of v = 0, 0.02, 0.2, and 2 µm/s [344]. Three species i were modeled: P, the cell-
released protease; CXCL12, the cell-released CXCL12; and HS-CXCL12, the matrix-
bound CXCL12. Constant flux boundary conditions were assumed for both P and 
CXCL12 at cell surfaces, with CXCL12 fluxes measured experimentally (Supplemental 
data), along with zero flux inlet boundary conditions. The diffusion coefficients were 
159 
 
assumed to be 140 µm2/s for CXCL12 and 80 µm2/s for P  [334]. The following 
binding/release kinetics were used to model the species: 
#$12 + '( )*+,-  #$12 − '( 
'( − #$12 + / )01234-  #$12 + '( + / 
where HS = heparin sulfate binding sites; HS-CXCL12 = matrix-bound CXCL12; and 
kon, koff, and krel are rate constants for the reactions shown. kon and koff were assumed to 
be 9.3 x 104 M-1 s-1 and 0.116 x 10-4 M-1 s-1, respectively, based on our own 
measurements (Kd=12.4 nM, Supplemental data), and krel was assumed to be 1 x 10
5 M-1 
s-1.  HS was calculated to be 2.6 mM with 1% HA content in the gel. 
The rate equations were as follows: 
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where R refers to the overall rate of production and C refers to the concentration of each 
of the components. CHS was assumed to be much greater than CCXCL12 based on the 
calculated number of binding sites to total CXCL12 ligand concentration ratio and so was 
treated as a constant. Mass balances for free ligand, bound ligand, and protease were 
solved simultaneously using transient analysis to estimate the combined CXCL12 
gradient established after 50,000 s (approximately equal to the experimental time frame). 
The calculations were performed using COMSOL Multiphysics modeling software (Bern, 
Switzerland) on a personal computer. 
Statistical Analysis 
Data was analyzed using one-way ANOVA with Tukey’s post-test for pairs of 
data and Bennett’s test for unequal variance was used to adjust significance. Results are 
reported as test statistic (degrees of freedom) = value, with p<# and *p<0.05, **p<0.01, 






In vivo, RT2 glioma invasion correlates with fluid flow and CXCL12 expression 
To determine whether invasion pathways correlate with fluid flow patterns and 
CXCL12 expression, we inoculated male Fisher 344 rats with eGFP-expressing RT2 
GBM [84], a highly invasive model of GBM that shows many attributes of human GBM 
invasion. Nine days later, flow pathways were visualized by Evans blue injected into the 
tail vein, which binds albumin and leaks out of tumor vasculature[345]. Serial sections 
were compared for localization of white matter tracts and nuclei (Figure E.1A), cancer 
cells (Figure E.1B, F), flow patterns (Figure E.1C,G) and CXCL12 (Figure E.1D,H). 
Coronal images were overlaid (Figure E.1I,J), the tumor bulk subtracted out, and 
overlap R calculated yielding an overlap in pixels for all three of the components . 
Results confirm previous implications that these features indeed overlap in the brain from 




Figure E.1: Flow pathways, CXCL12 gradients, and tumor invasion overlap in the 
brain. (A) Structural staining of coronal brain slice (scale bar=1mm) with tumor outlined 
(white dotted line), showing white matter tracts (yellow, Fluoromyelin stain) and cell 
nuclei (gray-blue, DAPI). (B) Two regions on the tumor were selected for examination: 
high flow and low flow as determined by Evans blue dye flow from tumor vessels into 
interstitial space.  In high flow regions, tumor cells (green, GFP) show invasion with flow 
patterns (red, Evans Blue) in the same direction as CXCL12 gradients (cyan, CXCL12) 
outside of the tumor bulk (white dotted line). In low flow regions, there is less staining 
outside of tumor bulk (white dotted line). (C) Colocalized CXCL12 and flow (lavender) 
relative to the tumor margin (white) (Scale bars=300µm). The overlap correlation 
between flow, CXCL12, and tumor cells outside the tumor margin was R2 = 0.957. 
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Glioma invasion is enhanced in response to interstitial flow or CXCL12 gradients 
We compared four glioblastoma cell lines in vitro for response to interstitial flow: 
RT2 (invasive, rat–derived GBM), U87MG (in vitro invasive, human-derived GBM), C6 
(invasive, rat-derived GBM), and 9L (non-invasive, rat-derived astrocytoma). Using 3D 
cultures in porous inserts (8 µm pore size) with interstitial flow rates of 0 or 0.72 ± 0.02 
µm/s, we found that the three invasive cell lines invaded more under flow conditions, 
with roughly twice the number of cells invading through the gel and across the membrane 
in the flow direction compared to that in static conditions. Interestingly, the noninvasive 
astrocytoma 9L did not increase invasion in response to flow (Figure E.2). This was 







Figure E.2 Glioma invasion is increased by interstitial flow in a 3D culture model. 
(A) Cross-section of 3D culture from insert after flow application stained for hyaluronan 
(red) and type I collagen (green); cell nuclei are blue (Scale bar = 50µm). (B) Baseline 
invasiveness of four glioma cell lines under static conditions after 16h. (C) Effects of 
slow (0.2 m/min) interstitial flow on invasion. (D) Chemoinvasion of cells up a 
gradient of CXCL12 under static conditions. Data shown are means and standard 
deviations from 4-10 independent experiments; *p<0.05, **p<0.01, ***p<0.001. 
 
 
We next compared the invasiveness and chemotactic response to CXCL12 
gradients of the four cell lines, since response to CXCL12 has previously been correlated 
with degree of malignancy [346, 347]. Cells were cultured in a 3D matrix in porous 
inserts and allowed to chemoinvade towards CXCL12 in the lower chamber under static 
conditions. Invasion increases towards CXCL12 gradients were similar to those seen in 
response to flow. Hence, our data suggest that the more malignant tumor cell lines 
respond more strongly to both flow and gradients of CXCL12 and that their response to 
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flow and CXCL12 gradients are similar, with the RT2 cell line showing the strongest 
flow response. In fact, this data shows strong correlation (Figure E.3) 
 
 
Figure E.3 Flow response correlates with chemotaxis and invasion in cell lines. (A) 
For all cell lines tested, correlation of normalized flow-enhanced invasion vs. % 
migration in 3D. (B) Correlation of normalized flow-enhanced invasion vs. chemotactic 
migration up an exogenous gradient of CXCL12.  
 
Flow-enhanced invasion is CXCR4-dependent 
To determine whether the increased invasion of glioma cells was correlated to 
CXCL12 signaling, we examined invasion under flow with either AMD 3100, a CXCR4 
antagonist, or 100 nM exogenous CXCL12 (uniformly distributed) to overpower any 
possible endogenous CXCL12 gradients that may exist [348]. Under these conditions, the 
flow response did not occur in RT2 (Figure E.4A) nor for C6 and U87MG (Figure E.5), 
though CXCL12 did enhance cell invasion in general as expected from previous 
chemotaxis assays (F(5,64)=12.67, p<0.001). Interestingly, the secretion and expression 
of CXCL12 did not increase in any cell line between static and flow conditions. Similarly 
the % of cells expressing CXCR4 and the overall mean value of CXCR4 did not 
165 
 
significantly increase (Figure E.6). This indicates that there is not simply a change in 
cellular expression in response to flow that accounting for the CXCR4 dependence.  
 
 
Figure E.4: Flow-enhanced invasion is CXCR4 dependent. (A) The enhanced 
invasiveness of RT2 glioma in flow vs. static conditions is lost when CXCR4 is blocked 
with AMD3100 or when 100 nM exogenous CXCL12 is added uniformly, without a 
gradient. (B) CXCL12 protein levels as measured by ELISA. (C) Representative images 
of RT2 cells (nuclei, blue), stained for CXCR4 (red) and phosphorylated CXCR4 (green) 
after 16h of flow or static conditions; scale bar=5 µm and arrow indicates direction of 
flow. (D) Quantification of signal intensity (normalized) from immunostained cells; n=62 
cells from 2 separate experiments. (E) Representative Western blots of total and 





Figure E.5 Blocking or activating CXCR4 inhibits flow-enhanced invasion increase in 
glioma models (A) Blocking and activation in U87MG showing decreased flow response. 
(B) Blocking and activation in C6 glioma showing decreased flow response. (C) 
Blocking and activation in 9L showing no change in flow response though activation 




Figure E.6 CXCL12 and CXCR4 expression levels do not change under flow 
conditions. (A) CXCL12 expression (secreted + cellular) levels for cell lines under static 
and flow conditions. (B) CXCR4 expression levels as determine by flow cytometry for 





CXCR4-dependence could be due to activation under flow conditions 
Using again the radial flow chamber, cells were exposed to flow and stained for 
CXCR4 and phosphorylated CXCR4 (p-CXCR4). Phosphorylation of CXCR4 is known 
to indicate activation of this receptor and increased activity at tumor borders is correlated 
with increasing progression of disease in humans [333, 349, 350]. It was noticed that 
there was an increase in staining for CXCR4 of cells though overall this was slight when 
averaged over the entire chamber and experiments. p-CXCR4 appeared to increase 
significantly between static and control conditions (Figure 4A). Upon analysis based on 
intensity of pixels, there was a greater increase in p-CXCR4 staining under flow 
conditions though neither change was significant (Figure E.4C, D) (CXCR4: 
t(18)=0.7624, n.s. p-CXCR4: t(18)=1.268, n.s.). To further confirm this increase, cells 
from tissue culture inserts were collected for Western blotting and there was an increase 
in p-CXCR4 between static and flow conditions for RT2 (Figure E.4E) though not for 
CXCR4 (Figure 4C). This change was not seen for the other cell lines though indicating 
that this is not necessarily the primary mechanism for enhanced cell invasion under flow 
conditions.  
Cells polarize in flow direction in a CXCR4-dependent manner  
Cells were seeded in radial flow chambers (described in [351]) for further 
observation since imaging in tissue culture inserts is limited to those crossing the 
membrane (Figure 4B). Flow was applied from the center point radially through the 
matrix. After overnight flow, cells were fixed and stained for PhAkt (green) which is 
known to localize to the leading edge of migrating cells (Figure 3E). There was an 
increase in polarized cells from static to flow conditions (t(26)=3.22, p<0.01) and this 
polarization was blocked with AMD3100 (t(34)=3.873, p<0.01) (Figure 3D). Further, 
cells exposed to CXCL12 were polarized to a similar extent as those exposed to flow but 
not significantly different from CXCL12-exposed static cells (data not shown). This data 
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confirms visually the CXCR4-dependent mechanism of flow-enhanced invasion in RT2 
glioma that was seen for all cell lines in tissue culture inserts. 
Live imaging reveals both increases in chemokinesis and chemotaxis of glioma under 
flow 
Cells were seeded in pillar chambers in the same 3D matrix  as described 
previously (Haessler, et al. 2011). Flow was applied passing first through an empty gel 
before flowing through cells in 3D and after experiments while imaging under 
brightfield.  Flow rates were determined and ranged over experiments between 2µm/s-
20µm/s. Cell tracking and analysis over multiple locations (Figure E.7A  and Figure 
E.8) and replicates revealed a significant increase in the number of RT2 cells migrating 
under flow from static conditions (Figure E.7B, t(12)=5.35, p<0.01). We also analyzed 
persistence to determine if cells were changing directness with which they migrate 
revealing no change under flow. Similarly, cell speed  and frequency of cell speeds 
(Figure E.7D) did not change significantly under flow conditions. We did, however, 
observe a shift in cell velocities (VF) towards the direction of flow (Figure E.7C), 
however, this change was non-significant due to the small number of cells with this 
velocity shift (Figure E.7E). Averaging VF over the per cell velocity reveals a shift again 
in the direction of flow accounting for variability within the sample (Figure E.7F and G). 
The results of this analysis reveal that there is a significant increase in chemokinesis 
under flow conditions which could account for the increased invasion seen in previous 
assays. However, there is a subpopulation of cells that actually begins to migrate in the 




Figure E.7: Cell migration favors the flow direction. (A) Representative images with 
tracks shown from  videos of RT2 cells migrating under static and flow conditions for 16 
h; scale bar=50µm. Tracks end at the dot with preceding path shown. (B) Quantification 
of the fraction of cells that migrate more than 2 cell diameters in 16 h; *p<0.05. (C) 
Average cell velocity in the flow direction. (D) Histogram of the distribution of average 
cell speed. (E) Histogram of velocity in the flow direction, normalized to the average 
speed for each cell (VF/V). Shaded areas are those outside of the standard deviation. (F) 
Area-under-the-curve analysis showing one standard deviation showing change in flow 




Figure E.8: Cells tend to migrate in the direction of flow when analyzed. A) Polar 
plot of video  of cells in static conditions in 3D matrix and B) polar plot of Video  of cells 
exposed to flow. Plots indicate a slight tendency of cells to migrate in the flow direction. 
These plots represent 2 examples for one set of experiments used in Figure 5. 
 
Cells polarize in the direction of flow  
Using the radial flow chamber setup again, we analyzed the degree to which cells 
were polarized in the direction of flow. For each image, the position in reference to the 
central flow inlet was noted and cells polarized cells were given a direction based on a -
30°/30° zone around the direction of flow and the directions 90° from this point. Under 
static conditions, cells were approximately equally polarized in all directions (307 cells 
total, 12.4% polarized) (Figure E.9A). When flow was applied, there was a significant 
increase in the percentage of cells polarized in the flow direction (435 cells total, 25.5% 
polarized; F(3, 100) = 19.88, p<0.001) indicating a preference for migration or priming in 
the direction of flow. Further, when the CXCR4 receptor was blocked with AMD3100 
and flow applied, this shift went away and the cells returned to near static polarization 
(158 cells total, 16.5% polarized). Therefore, flow acts to polarize cells in the direction of 




Figure E.9: Flow-directed cell migration is consistent with CXCR4-mediated 
autologous chemotaxis. (A) Polarization of cells in response to flow in presence/absence 
of AMD3100 or CXCL12 (***p<0.001). (B) Radial flow chamber analysis for cell 
polarization in each direction (0°, 90°, 180°, and 270° to flow direction) shows increase 
in polarization in flow direction (0°) and blocking with AMD3100 and CXCL12.  (C) 
Representative images for each condition with PhAKT staining (green) and nuclei (blue) 
under flow (right column) and static (left column)  (scale bar=5 µm). White arrows 
indicate flow direction. Scale bars=10 µm. *p<0.05. (D) Model of CXCL12 secretion by 
RT2, binding to HA-Collagen matrix, under increasing flow rates shows increasing 






CXCL12-dependent autologous chemotaxis explains directional cell polarization and 
migration 
Autologous chemotaxis has been proposed as a mechanism for enhancement of 
tumor cell invasion and dendritic cell migration under flow conditions [335, 336]. Cancer 
cells that express both the chemokine, CXCL12, and its receptor, CXCR4 are candidates 
for this type of chemotaxis. Under static conditions the cell secretes CXCL12 (for RT2 
0.16 pg CXCL12 secreted/h/1000 cells), this chemokine binds the matrix radially 
outward from the cell surface where it can be later cleaved through cell secretion of 
matrix degrading enzymes (MMPs). Therefore, the cell feels no gradient around itself and 
stays in place. However, when there is interstitial flow, now when the cell secretes 
CXCL12 the chemokine is carried downstream of the cell and binds the matrix. This 
results in an uneven distribution of CXCL12 around the cell body.  
Using experimentally-determined parameters for matrix Kd (12.6 nM, Figure 
E.10), and CXCL12 secretion rates, along with literature-reported values for matrix 
degradation, and diffusion, we modeled the gradient formation at increasing flow rates 
(Figure 6C). Gradients across the cell formed with as little as 0.02µm/s and increased 
significantly at 2µm/s a physiologically relevant flow rate in brain tumor or edema 
conditions [13, 340, 341]. Gradients observed under these flow rates (Figure E.9C) have 
been shown to be high enough to elicit migration in other cell types such as neutrophils 




Figure E.10 CXCL12 binds to the hyaluronan/collagen matrix. Binding used to 
determine the Kd for CXCL12 and the matrix. This value was used as a modeling 
parameter for development of the gradient in Figure 6D. 
 
 Lastly, to further explore the role of CXCL12 in glioma and how it might be 
involved in autologous chemotaxis, polarization in the direction of flow was determined 
in the presence of CXCL12 (Figure E.9B). Though there were more cells polarized than 
under static conditions and CXCR4-blocking (171 cells total, 30.9% polarized), the 
tendency towards polarization in the direction of flow was lost. This indicates that there 
is a chemotactic mechanism occurring under flow conditions separate from the 
chemokinetic mechanism which can be blocked through antagonism of CXCR4. 
Additionally, the change from general polarization to polarization in the direction of flow 
accounted for 12.8% of the cell population and through immunocytochemistry, the total 
amount of cells presenting both CXCL12 and CXCR4 was around 18.9% indicating that 
there may be a subpopulation of cells that are inclined to autologous chemotaxis, though 
far more cells express CXCR4 which can lead to chemokinesis to account for the 
remainder of the flow response seen in our assays.  
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Thus, using multiple in vitro modeling systems, our experimental results demonstrate that 
significantly, 1) interstitial flow increases invasion of multiple glioma cell lines in vitro, 
and 2) this increase is CXCR4-dependent resulting in both increased chemokinesis and 
chemotaxis in the direction of flow as shown through live cell imaging and 
immunocytochemistry. Lastly, we propose that the chemotaxis seen under flow is due to 
autologous chemotaxis resulting in CXCL12-mediated polarization. 
E.5 Discussion 
In this study, we propose a new mechanism to explain patterns of glioma invasion 
in the brain. It has previously been proposed that cancer cells respond to heterogeneity of 
extracellular matrix as evidenced by migration along leptomeningeal pathways, the 
basement membranes of vasculature, and the spread of cells along subpial lining [10, 15]. 
It has also been proposed that cancer cells respond to the structural cues and reduced 
resistance for invasion along white matter tracts and neuronal structures to account for 
farther distant metastases [14, 325, 328]. The idea of fluid flow enhancing metastases to 
far-distant locations in the central nervous system has been attributed to passive 
movement of cancer cells in cerebrospinal fluid as evidenced by presence of cancer cells 
in CSF samples and the coincidence of flow pathways with migration pathways [13, 37, 
327]. Lastly, the ever-growing literature for chemokine involvement in paracrine loops in 
the brain shows the ability of adult neurons and glia in the brain to secrete growth factors 
and chemokines leading to migration and chemoattraction, expanding upon the already 
strong base of systemic metastases for other cancer types [69, 258, 331, 354].   
These theories treat these phenomena as separate entities, determining that each 
must be responsible for the spread of cancer cells in its own way and that the 
colocalization of the structure, chemokines, flow pathways, and invasion is somewhat of 
a coincidence. Studies have aimed to integrate structural cues with chemokinetic cues, 
matrix alterations with chemokines, and cell-cell interactions with chemokines to explore 
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the interactions of these enhancers of invasion leading to varied results [71, 105]. 
However, this study presents the first exploration of the ability of interstitial flow to not 
just act as a passive carrier of glioma cells in the central nervous system, but as an active 
modulator of glioma malignancy and invasion. This is important in the way we approach 
the study of brain tumors and the design of therapeutics.  
To begin to observe this coincidence we provided an observational in vivo 
examination of CXCL12 gradients, tumor cell invasion in a model of astrocytoma that 
shows many of the hallmarks of glioblastoma invasion inherent to the human disease, and 
the fluid flow pathways as assessed as drainage from the tumor. This result shows that 
there is a co-localization of these elements in the brain and this also correlates with the 
direction in which the major white matter tracts (corpus collosum) spread through the 
brain. Building upon these observations, which have been previously implicated in the 
literature, though not explored simultaneously, we hypothesized that they are not only 
interrelated in location but in mechanism [10, 12, 13, 121, 325]. To do this, examination 
in vitro was necessary to dissect the reasons behind invasion and elucidate a mechanism 
in a controlled manner.  
Many cell culture model systems have been developed for the study of glioma 
migration including the brain slice model, Boyden chamber, and neurosphere culture 
[128, 355]. In an effort to determine the effects of interstitial flow, we optimized a 3D 
cell culture system using hyaluronan and collagen to mimic the brain microenvironment 
while allowing passage of flow. Using a simple tissue culture insert that allowed for 
higher throughput examination and more complex systems that could yield defined flow 
rates and allow for cell visualization we repeatedly observed the same phenomenon: 
increase of invasion of cells under flow conditions as compared to the normal static 
counterpart.  
Flow implication in function of cells is a common occurrence. In the immune system, 
interstitial flow increases in response to injury allowing chemokine gradients to form 
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towards the lymphatics and initiate dendritic cell homing and has also been 
advantageously used for development of vaccines [356]. Further, the transmural flow at 
the walls of lymphatics activates the endothelial cells altering transport functions of the 
lining and has been implicated in increasing chemokine signaling shown to increase 
tumor cell invasion further[134, 335]. Interstitial flow is also implicated in altering the 
tumor stroma, increasing fibroblasts invasion, changing the extracellular matrix 
alignment, and establishing signaling for blood vessels [133, 337, 357]. In the nervous 
system, the exploration of flow has largely been confined to neurodevelopment and 
disease states such as hydrocephalus. We argue that tumor drainage is an important 
phenomenon in the invasion and dispersal of tumors from the primary site.  
To elucidate the way in which tumor cells are impacted by interstitial flow we 
examined the involvement of the chemokine/receptor pair, CXCL12/CXCR4. Highly 
implicated in cancer progression and in particular in all aspects of brain tumor 
progression including proliferation, survival, angiogenesis and invasion, and showing 
correlation with patterns of invasion in the brain, we targeted this chemokine/receptor 
pair [331, 346, 354, 358]. The ability of AMD3100 to block the flow-induced increase of 
invasion was striking and indicated that there was an involvement of the CXCR4 receptor 
in the enhancement of migration. Further, when cells were faced with global CXCL12 
concentrations higher than those necessary to elicit chemotactic responses, they no longer 
enhanced invasion in response to flow though general cell movement was increased.  
Increases in the amount of CXCL12 secreted or CXCR4 expressed would be one 
explanation for the flow response, though for all cell lines, this was not the case. The 
activation of CXCR4 is another explanation for the loss of flow effect in the presence of 
CXCL12 since CXCL12 is known to activate the receptor and activation is correlated 
with a higher grade tumor with more invasive phenotype[333]. However, the strong 
increase in phosphorylation was only seen for the strongest flow-responsive cell line 
(RT2). Hence, the increase in receptor activation can only account for some of the 
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increased invasion seen under flow conditions. We show that the migration of cells in 
response to flow may have two components: first the increase in chemokinesis stemming 
from increased activation of the cell (both by CXCR4 or other mechanisms) and 




Figure E.11: Hypothesized mechanism of how fluid flow affects glioma invasion 
patterns. The biophysical tumor microenvironment, both in terms of the extracellular 
matrix cues and fluid flow cues, guide preferential invasion patterns. Fluid flow is faster 
along paths of least resistance, namely white matter tracts. A fraction of glioma cells both 
secrete CXCL12 and express CXCR4, enabling them to chemotact in the flow direction 
towards gradients of self-secreted CXCL12 that is skewed by flow. Additionally, flow 





Using modeling and implicit experiments, we show that the directional polarization of 
cells disappears when confronted with a uniform CXCL12 gradient in the RT2 model of 
invasive glioma and that gradients can form around cells with as little as 0.02µm/s, below 
the experimentally observed flow rates of 0.2-0.9µm/s in the rat brain. Gradients as low 
as 1% across a cell body have been shown to elicit directional migration [352, 353]. In 
the hydrocephalic brain that arises during tumor growth and progression, flow rates can 
increase by 1-fold as drainage occurs which would yield an even increased gradient 
around cells in the interstitium and implicitly increased cell invasion to across 
distances[341, 359]. 
The evidence presented here implicates interstitial flow as an active player in the invasion 
of brain tumors into healthy tissue. Through in vitro analysis based on in vivo and 
literature-based observations, slow flow rates in the interstitium are substantial enough to 
increase tumor invasion and hence decrease the survival time in patients. The coincidence 
of flow patterns with white matter tracts could indicate an alternate theory though it is 
more likely that these two phenomena work in concert to enhance cell invasion in the 
brain. Through fluid flow towards the white matter tracts and the structural cues of the 
tracts themselves, tumor invasion can be enhanced further. Similarly, many cell types in 
the brain secrete CXCL12 yielding reservoirs of the chemokine throughout the cortex. 
One particular region, the meningeal lining, secretes CXCL12 and could be an added 
factor in enhanced invasion in the brain [343]. Further, microglia and astrocytes have 
been implicated in enhancing progression of glioma, but in our studies, there was not an 
observable interaction with interstitial flow as has been seen with other cancers [69, 71, 
337]. However, such microenvironmental factors are important in the study of glioma 
invasion as they have been studied in other cancers. 
In this study we aimed to examine one aspect of the brain microenvironment in the 
context of glioma invasion: interstitial flow (Figure E.11). Previously ignored as a 
passive component of glioma spreading and brain function, we have shown data that flow 
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in the brain is an active modulator and the way in which it enhances glioma function 
involves interactions of chemokine/receptors common to glioma. Further, we have 
provided evidence to hypothesize the existence of autologous chemotaxis in another 
cancer model existing away from lymphatic function. This study has implications in 
current therapies involving enhancing convection through the tumor (convection-
enhanced delivery) in order to deliver drugs, microenvironmental 3D modeling, and how 






1. National Cancer Institute Brain Tumor Study in Adults: Fact Sheet, 
U.S.D.o.H.a.H. Services, Editor. 2000, National Cancer Institute: Bethesda, MD. 
2. Stats and facts. Breast cancer: progress and challenges. Manag Care Interface, 
1999. 12(7): p. 36-7. 
3. Abrams, P., Facts and future lines of research in prostate cancer: concluding 
remarks. BJU Int, 2000. 85 Suppl 2: p. 49-51. 
4. Dorsey, E.R., et al., Funding of US biomedical research, 2003-2008. JAMA, 
2010. 303(2): p. 137-43. 
5. Legler, J.M., et al., Cancer surveillance series [corrected]: brain and other 
central nervous system cancers: recent trends in incidence and mortality. J Natl 
Cancer Inst, 1999. 91(16): p. 1382-90. 
6. Mikkelsen, T., Brain tumor invasion : biological, clinical, and therapeutic 
considerations. 1998, New York: Wiley-Liss. xv, 464 p. 
7. Kleihues, P., P.C. Burger, and B.W. Scheithauer, The new WHO classification of 
brain tumours. Brain Pathol, 1993. 3(3): p. 255-68. 
8. Louis, D.N., et al., The 2007 WHO classification of tumours of the central 
nervous system. Acta Neuropathol, 2007. 114(2): p. 97-109. 
9. Scherer, H.J., Structural Development in Gliomas. American Journal of Cancer, 
1938. 34(3): p. 333-351. 
10. Zagzag, D., et al., Hypoxia- and vascular endothelial growth factor-induced 
stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one 
plausible explanation of Scherer's structures. Am J Pathol, 2008. 173(2): p. 545-
60. 
11. Claes, A., A.J. Idema, and P. Wesseling, Diffuse glioma growth: a guerilla war. 
Acta Neuropathol, 2007. 114(5): p. 443-58. 
12. Giese, A. and M. Westphal, Glioma invasion in the central nervous system. 
Neurosurgery, 1996. 39(2): p. 235-50; discussion 250-2. 
181 
 
13. Geer, C.P. and S.A. Grossman, Interstitial fluid flow along white matter tracts: a 
potentially important mechanism for the dissemination of primary brain tumors. J 
Neurooncol, 1997. 32(3): p. 193-201. 
14. Johnson, J., et al., Quantitative analysis of complex glioma cell migration on 
electrospun polycaprolactone using time-lapse microscopy. Tissue Eng Part C 
Methods, 2009. 15(4): p. 531-40. 
15. Bellail, A.C., et al., Microregional extracellular matrix heterogeneity in brain 
modulates glioma cell invasion. Int J Biochem Cell Biol, 2004. 36(6): p. 1046-69. 
16. Rong, Y., et al., 'Pseudopalisading' necrosis in glioblastoma: a familiar 
morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J 
Neuropathol Exp Neurol, 2006. 65(6): p. 529-39. 
17. Mendez, O., et al., Knock down of HIF-1alpha in glioma cells reduces migration 
in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol 
Cancer, 2010. 9: p. 133. 
18. Nishikawa, R., Standard therapy for glioblastoma--a review of where we are. 
Neurol Med Chir (Tokyo), 2010. 50(9): p. 713-9. 
19. Chaichana, K.L., et al., Recurrence and malignant degeneration after resection of 
adult hemispheric low-grade gliomas. J Neurosurg, 2010. 112(1): p. 10-7. 
20. Dinnes, J., et al., A rapid and systematic review of the effectiveness of 
temozolomide for the treatment of recurrent malignant glioma. Br J Cancer, 2002. 
86(4): p. 501-5. 
21. Nabors, L.B. and J. Fiveash, Treatment of adults with recurrent malignant 
glioma. Expert Rev Neurother, 2005. 5(4): p. 509-14. 
22. Park, J.K., et al., Scale to predict survival after surgery for recurrent glioblastoma 
multiforme. J Clin Oncol, 2010. 28(24): p. 3838-43. 
23. Sanai, N., M.Y. Polley, and M.S. Berger, Insular glioma resection: assessment of 
patient morbidity, survival, and tumor progression. J Neurosurg, 2010. 112(1): p. 
1-9. 
24. Stummer, W., et al., Extent of resection and survival in glioblastoma multiforme: 
identification of and adjustment for bias. Neurosurgery, 2008. 62(3): p. 564-76; 
discussion 564-76. 
25. Raore, B., et al., Metastasis Infiltration: An Investigation of the Postoperative 
Brain-Tumor Interface. Int J Radiat Oncol Biol Phys, 2010. 
182 
 
26. Attenello, F.J., et al., Use of Gliadel (BCNU) wafer in the surgical treatment of 
malignant glioma: a 10-year institutional experience. Ann Surg Oncol, 2008. 
15(10): p. 2887-93. 
27. Kleinberg, L.R., et al., Clinical course and pathologic findings after Gliadel and 
radiotherapy for newly diagnosed malignant glioma: implications for patient 
management. Cancer Invest, 2004. 22(1): p. 1-9. 
28. Westphal, M., et al., Gliadel wafer in initial surgery for malignant glioma: long-
term follow-up of a multicenter controlled trial. Acta Neurochir (Wien), 2006. 
148(3): p. 269-75; discussion 275. 
29. Westphal, M., K. Lamszus, and D. Hilt, Intracavitary chemotherapy for 
glioblastoma: present status and future directions. Acta Neurochir Suppl, 2003. 
88: p. 61-7. 
30. Nataf, F., et al., Radiosurgery with or without A 2-mm margin for 93 single brain 
metastases. Int J Radiat Oncol Biol Phys, 2008. 70(3): p. 766-72. 
31. Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide for 
glioblastoma. N Engl J Med, 2005. 352(10): p. 987-96. 
32. Fabel, K., et al., Long-term stabilization in patients with malignant glioma after 
treatment with liposomal doxorubicin. Cancer, 2001. 92(7): p. 1936-42. 
33. Hegi, M.E., et al., MGMT gene silencing and benefit from temozolomide in 
glioblastoma. N Engl J Med, 2005. 352(10): p. 997-1003. 
34. Metellus, P., et al., Prognostic impact of O6-methylguanine-DNA 
methyltransferase silencing in patients with recurrent glioblastoma multiforme 
who undergo surgery and carmustine wafer implantation: a prospective patient 
cohort. Cancer, 2009. 115(20): p. 4783-94. 
35. Lata, S. and A. Molczyk, [Side effects of temozolomide treatment in patient with 
glioblastoma multiforme--case study]. Przegl Lek, 2010. 67(5): p. 445-6. 
36. Brandes, A.A., et al., Recurrence pattern after temozolomide concomitant with 
and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: 
correlation With MGMT promoter methylation status. J Clin Oncol, 2009. 27(8): 
p. 1275-9. 
37. Seiz, M., et al., Far-distant metastases along the CSF pathway of glioblastoma 
multiforme during continuous low-dose chemotherapy with temozolomide and 
celecoxib. Neurosurg Rev, 2010. 33(3): p. 375-81; discussion 381. 
183 
 
38. Okawa, T., [History of radiotherapy for cancer]. Gan To Kagaku Ryoho, 1999. 
26 Suppl 1: p. 15-22. 
39. Bucci, B., et al., Fractionated ionizing radiation exposure induces apoptosis 
through caspase-3 activation and reactive oxygen species generation. Anticancer 
Res, 2006. 26(6B): p. 4549-57. 
40. Lehnert, B.E. and R. Iyer, Exposure to low-level chemicals and ionizing 
radiation: reactive oxygen species and cellular pathways. Hum Exp Toxicol, 
2002. 21(2): p. 65-9. 
41. Epstein, J.B., et al., Quality of life and oral function in patients treated with 
radiation therapy for head and neck cancer. Head Neck, 2001. 23(5): p. 389-98. 
42. Ohuchida, K., et al., Radiation to stromal fibroblasts increases invasiveness of 
pancreatic cancer cells through tumor-stromal interactions. Cancer Res, 2004. 
64(9): p. 3215-22. 
43. Wild-Bode, C., et al., Sublethal irradiation promotes migration and invasiveness 
of glioma cells: implications for radiotherapy of human glioblastoma. Cancer 
Res, 2001. 61(6): p. 2744-50. 
44. Bauman, G.S., et al., Effects of radiation on a three-dimensional model of 
malignant glioma invasion. Int J Dev Neurosci, 1999. 17(5-6): p. 643-51. 
45. Ogawa, Y., et al., Reactive oxygen species-producing site in radiation and 
hydrogen peroxide-induced apoptosis of human peripheral T cells: Involvement of 
lysosomal membrane destabilization. Int J Mol Med, 2004. 13(5): p. 655-60. 
46. Argyriou, A.A., E. Giannopoulou, and H.P. Kalofonos, Angiogenesis and anti-
angiogenic molecularly targeted therapies in malignant gliomas. Oncology, 2009. 
77(1): p. 1-11. 
47. Ferrara, N., et al., Discovery and development of bevacizumab, an anti-VEGF 
antibody for treating cancer. Nat Rev Drug Discov, 2004. 3(5): p. 391-400. 
48. Ferrara, N., K.J. Hillan, and W. Novotny, Bevacizumab (Avastin), a humanized 
anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res 
Commun, 2005. 333(2): p. 328-35. 
49. Kamba, T. and D.M. McDonald, Mechanisms of adverse effects of anti-VEGF 
therapy for cancer. Br J Cancer, 2007. 96(12): p. 1788-95. 
50. Jain, R.K., Normalization of tumor vasculature: an emerging concept in 
antiangiogenic therapy. Science, 2005. 307(5706): p. 58-62. 
184 
 
51. Terzis, A.J., et al., Proliferation, migration and invasion of human glioma cells 
exposed to paclitaxel (Taxol) in vitro. Br J Cancer, 1997. 75(12): p. 1744-52. 
52. Zhao, M., et al., Magnetic paclitaxel nanoparticles inhibit glioma growth and 
improve the survival of rats bearing glioma xenografts. Anticancer Res, 2010. 
30(6): p. 2217-23. 
53. Baker, M.J., et al., Complete response of a recurrent, multicentric malignant 
glioma in a patient treated with phenylbutyrate. J Neurooncol, 2002. 59(3): p. 
239-42. 
54. Huysentruyt, L.C., L.M. Shelton, and T.N. Seyfried, Influence of methotrexate 
and cisplatin on tumor progression and survival in the VM mouse model of 
systemic metastatic cancer. Int J Cancer, 2010. 126(1): p. 65-72. 
55. Tonn, J.C., et al., Effect of synthetic matrix-metalloproteinase inhibitors on 
invasive capacity and proliferation of human malignant gliomas in vitro. Int J 
Cancer, 1999. 80(5): p. 764-72. 
56. Ahluwalia, M.S., et al., Targeting SRC in glioblastoma tumors and brain 
metastases: rationale and preclinical studies. Cancer Lett, 2010. 298(2): p. 139-
49. 
57. De Witt Hamer, P.C., Small molecule kinase inhibitors in glioblastoma: a 
systematic review of clinical studies. Neuro Oncol, 2010. 12(3): p. 304-16. 
58. Levin, V.A., Are gliomas preventable? Recent Results Cancer Res, 2007. 174: p. 
205-15. 
59. Griffin, A.C., Cancer chemoprevention. J Cancer Res Clin Oncol, 1980. 98(1): p. 
1-7. 
60. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 
57-70. 
61. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 
2011. 144(5): p. 646-74. 
62. Pietras, K. and A. Ostman, Hallmarks of cancer: interactions with the tumor 
stroma. Exp Cell Res, 2010. 316(8): p. 1324-31. 
63. Igney, F.H. and P.H. Krammer, Death and anti-death: tumour resistance to 
apoptosis. Nat Rev Cancer, 2002. 2(4): p. 277-88. 
185 
 
64. Clarke, J., N. Butowski, and S. Chang, Recent advances in therapy for 
glioblastoma. Arch Neurol, 2010. 67(3): p. 279-83. 
65. Huang, T.T., et al., Targeted therapy for malignant glioma patients: lessons 
learned and the road ahead. Neurotherapeutics, 2009. 6(3): p. 500-12. 
66. Mantovani, A., Cancer: Inflaming metastasis. Nature, 2009. 457(7225): p. 36-7. 
67. Seo, N., S. Hayakawa, and Y. Tokura, Mechanisms of immune privilege for tumor 
cells by regulatory cytokines produced by innate and acquired immune cells. 
Semin Cancer Biol, 2002. 12(4): p. 291-300. 
68. Shields, J.D., et al., Induction of lymphoidlike stroma and immune escape by 
tumors that express the chemokine CCL21. Science, 2010. 328(5979): p. 749-52. 
69. Le, D.M., et al., Exploitation of astrocytes by glioma cells to facilitate 
invasiveness: a mechanism involving matrix metalloproteinase-2 and the 
urokinase-type plasminogen activator-plasmin cascade. J Neurosci, 2003. 23(10): 
p. 4034-43. 
70. Leaver, H.A., M.T. Rizzo, and I.R. Whittle, Glioma cell death: cell-cell 
interactions and signalling networks. Mol Neurobiol, 2010. 42(1): p. 89-96. 
71. Zhai, H., F.L. Heppner, and S.E. Tsirka, Microglia/macrophages promote glioma 
progression. Glia, 2011. 59(3): p. 472-85. 
72. Jain, R.K., et al., Angiogenesis in brain tumours. Nat Rev Neurosci, 2007. 8(8): p. 
610-22. 
73. de Waal, R.M. and W.P. Leenders, Sprouting angiogenesis versus co-option in 
tumor angiogenesis. EXS, 2005(94): p. 65-76. 
74. Machein, M.R. and K.H. Plate, Role of VEGF in developmental angiogenesis and 
in tumor angiogenesis in the brain. Cancer Treat Res, 2004. 117: p. 191-218. 
75. Hagedorn, M. and A. Bikfalvi, Target molecules for anti-angiogenic therapy: 
from basic research to clinical trials. Crit Rev Oncol Hematol, 2000. 34(2): p. 89-
110. 
76. Narayana, A., et al., Antiangiogenic therapy using bevacizumab in recurrent high-
grade glioma: impact on local control and patient survival. J Neurosurg, 2009. 
110(1): p. 173-80. 
77. Lamszus, K., P. Kunkel, and M. Westphal, Invasion as limitation to anti-
angiogenic glioma therapy. Acta Neurochir Suppl, 2003. 88: p. 169-77. 
186 
 
78. Barth, R.F. and B. Kaur, Rat brain tumor models in experimental neuro-oncology: 
the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol, 2009. 
94(3): p. 299-312. 
79. Dai, C. and E.C. Holland, Glioma models. Biochim Biophys Acta, 2001. 1551(1): 
p. M19-27. 
80. de Vries, N.A., J.H. Beijnen, and O. van Tellingen, High-grade glioma mouse 
models and their applicability for preclinical testing. Cancer Treat Rev, 2009. 
35(8): p. 714-23. 
81. de Vries, N.A., et al., Rapid and robust transgenic high-grade glioma mouse 
models for therapy intervention studies. Clin Cancer Res, 2010. 16(13): p. 3431-
41. 
82. Sonabend, A.M., I.V. Ulasov, and M.S. Lesniak, Emerging role of new transgenic 
mouse models in glioma research. Expert Rev Anticancer Ther, 2007. 7(12 
Suppl): p. S7-13. 
83. Beckman, G., et al., G-6-PD and PGM phenotypes of 16 continuous human tumor 
cell lines. Evidence against cross-contamination and contamination by HeLa 
cells. Hum Hered, 1971. 21(3): p. 238-41. 
84. Fillmore, H.L., et al., An in vivo rat model for visualizing glioma tumor cell 
invasion using stable persistent expression of the green fluorescent protein. 
Cancer Lett, 1999. 141(1-2): p. 9-19. 
85. Grobben, B., P.P. De Deyn, and H. Slegers, Rat C6 glioma as experimental model 
system for the study of glioblastoma growth and invasion. Cell Tissue Res, 2002. 
310(3): p. 257-70. 
86. Wessels, J.T., et al., In vivo imaging in experimental preclinical tumor research--
a review. Cytometry A, 2007. 71(8): p. 542-9. 
87. Johnson, M., et al., Differential biodistribution of adenoviral vector in vivo as 
monitored by bioluminescence imaging and quantitative polymerase chain 
reaction. Hum Gene Ther, 2006. 17(12): p. 1262-9. 
88. Vilalta, M., et al., Biodistribution, long-term survival, and safety of human 
adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high 
sensitivity non-invasive bioluminescence imaging. Stem Cells Dev, 2008. 17(5): 
p. 993-1003. 
89. de Bouard, S., et al., Antiangiogenic and anti-invasive effects of sunitinib on 
experimental human glioblastoma. Neuro Oncol, 2007. 9(4): p. 412-23. 
187 
 
90. Rehemtulla, A., et al., Rapid and quantitative assessment of cancer treatment 
response using in vivo bioluminescence imaging. Neoplasia, 2000. 2(6): p. 491-5. 
91. Alexiou, G.A., et al., Assessment of glioma proliferation using imaging 
modalities. J Clin Neurosci, 2010. 17(10): p. 1233-8. 
92. Gerstner, E.R., et al., Advances in neuroimaging techniques for the evaluation of 
tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin 
Neurol, 2008. 21(6): p. 728-35. 
93. Harney, A.S. and T.J. Meade, Molecular imaging of in vivo gene expression. 
Future Med Chem, 2010. 2(3): p. 503-19. 
94. Cenic, A., et al., Dynamic CT measurement of cerebral blood flow: a validation 
study. AJNR Am J Neuroradiol, 1999. 20(1): p. 63-73. 
95. Taylor, C.R. and R.M. Levenson, Quantification of immunohistochemistry--issues 
concerning methods, utility and semiquantitative assessment II. Histopathology, 
2006. 49(4): p. 411-24. 
96. Price, S.J., et al., Detecting glioma invasion of the corpus callosum using diffusion 
tensor imaging. Br J Neurosurg, 2004. 18(4): p. 391-5. 
97. Price, S.J., et al., Improved delineation of glioma margins and regions of 
infiltration with the use of diffusion tensor imaging: an image-guided biopsy 
study. AJNR Am J Neuroradiol, 2006. 27(9): p. 1969-74. 
98. Wallner, K.E., et al., Patterns of failure following treatment for glioblastoma 
multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys, 1989. 
16(6): p. 1405-9. 
99. Trehin, R., et al., Fluorescent nanoparticle uptake for brain tumor visualization. 
Neoplasia, 2006. 8(4): p. 302-11. 
100. Jain, R.K., Transport of molecules, particles, and cells in solid tumors. Annu Rev 
Biomed Eng, 1999. 1: p. 241-63. 
101. Jain, R.K., Delivery of molecular and cellular medicine to solid tumors. Adv 
Drug Deliv Rev, 2001. 46(1-3): p. 149-68. 
102. Kim, J.J. and I.F. Tannock, Repopulation of cancer cells during therapy: an 
important cause of treatment failure. Nat Rev Cancer, 2005. 5(7): p. 516-25. 
103. Madani, I., W. De Neve, and M. Mareel, Does ionizing radiation stimulate cancer 
invasion and metastasis? Bull Cancer, 2008. 95(3): p. 292-300. 
188 
 
104. Barcellos-Hoff, M.H. and S.A. Ravani, Irradiated mammary gland stroma 
promotes the expression of tumorigenic potential by unirradiated epithelial cells. 
Cancer Res, 2000. 60(5): p. 1254-60. 
105. Nakamura, J.L., D.A. Haas-Kogan, and R.O. Pieper, Glioma invasiveness 
responds variably to irradiation in a co-culture model. Int J Radiat Oncol Biol 
Phys, 2007. 69(3): p. 880-6. 
106. Park, C.M., et al., Ionizing radiation enhances matrix metalloproteinase-2 
secretion and invasion of glioma cells through Src/epidermal growth factor 
receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling 
pathways. Cancer Res, 2006. 66(17): p. 8511-9. 
107. Gliemroth, J., et al., Proliferation, migration, and invasion of human glioma cells 
exposed to fractionated radiotherapy in vitro. Neurosurg Rev, 2003. 26(3): p. 
198-205. 
108. Tugues, S., et al., Vascular endothelial growth factors and receptors: Anti-
angiogenic therapy in the treatment of cancer. Mol Aspects Med, 2011. 
109. Murphy, E.A., et al., Nanoparticle-mediated drug delivery to tumor vasculature 
suppresses metastasis. Proc Natl Acad Sci U S A, 2008. 105(27): p. 9343-8. 
110. Miller, K.D., et al., Randomized phase II trial of the anti-angiogenic potential of 
doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery 
Laboratory. Breast Cancer Res Treat, 2005. 89(2): p. 187-97. 
111. Gomori, E., et al., Microsatellite analysis of primary and recurrent glial tumors 
suggests different modalities of clonal evolution of tumor cells. J Neuropathol Exp 
Neurol, 2002. 61(5): p. 396-402. 
112. Di Nicolantonio, F., et al., Cancer cell adaptation to chemotherapy. BMC Cancer, 
2005. 5: p. 78. 
113. Eramo, A., et al., Chemotherapy resistance of glioblastoma stem cells. Cell Death 
Differ, 2006. 13(7): p. 1238-41. 
114. Quintana, E., et al., Efficient tumour formation by single human melanoma cells. 
Nature, 2008. 456(7222): p. 593-8. 
115. Borovski, T., et al., Cancer stem cell niche: the place to be. Cancer Res, 2011. 
71(3): p. 634-9. 
189 
 
116. Yamahara, T., et al., Morphological and flow cytometric analysis of cell 
infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging. 
Brain Tumor Pathol, 2010. 27(2): p. 81-7. 
117. Grampa, G. and G. Baroldi, [Glioma with extracranial metastases]. Oncologia, 
1958. 11(1): p. 1-15. 
118. Zeitlhofer, J. and H. Kranus, [Extracranial metastases of glioma]. Zentralbl 
Neurochir, 1952. 12(6): p. 347-56. 
119. Mondin, V., et al., A survey of metastatic central nervous system tumors to 
cervical lymph nodes. Eur Arch Otorhinolaryngol. 267(11): p. 1657-66. 
120. Ellingson, B.M., et al., Spatially quantifying microscopic tumor invasion and 
proliferation using a voxel-wise solution to a glioma growth model and serial 
diffusion MRI. Magn Reson Med, 2011. 65(4): p. 1131-43. 
121. Zhang, X., et al., Experiment and observation on invasion of brain glioma in vivo. 
J Clin Neurosci, 2002. 9(6): p. 668-71. 
122. Winkler, F., et al., Imaging glioma cell invasion in vivo reveals mechanisms of 
dissemination and peritumoral angiogenesis. Glia, 2009. 57(12): p. 1306-15. 
123. Zhang, F., et al., In Vivo MRI Tracking of Cell Invasion and Migration in a Rat 
Glioma Model. Mol Imaging Biol, 2010. 
124. Bernas, L.M., P.J. Foster, and B.K. Rutt, Magnetic resonance imaging of in vitro 
glioma cell invasion. J Neurosurg, 2007. 106(2): p. 306-13. 
125. Szentirmai, O., et al., Noninvasive bioluminescence imaging of luciferase 
expressing intracranial U87 xenografts: correlation with magnetic resonance 
imaging determined tumor volume and longitudinal use in assessing tumor 
growth and antiangiogenic treatment effect. Neurosurgery, 2006. 58(2): p. 365-
72; discussion 365-72. 
126. Zhu, L., et al., Real-Time Video Imaging of Protease Expression In Vivo. 
Theranostics, 2011. 1: p. 18-27. 
127. Lee, S., J. Xie, and X. Chen, Activatable molecular probes for cancer imaging. 
Curr Top Med Chem. 10(11): p. 1135-44. 
128. Pilkington, G.J., et al., In vitro and in vivo models for the study of brain tumour 
invasion. Anticancer Res, 1997. 17(6B): p. 4107-9. 
190 
 
129. Vinader, V., et al., An agarose spot chemotaxis assay for chemokine receptor 
antagonists. J Pharmacol Toxicol Methods, 2011. 
130. Sun, P., et al., DNER, an epigenetically modulated gene, regulates glioblastoma-
derived neurosphere cell differentiation and tumor propagation. Stem Cells, 
2009. 27(7): p. 1473-86. 
131. Albini, A. and D.M. Noonan, The 'chemoinvasion' assay, 25 years and still going 
strong: the use of reconstituted basement membranes to study cell invasion and 
angiogenesis. Curr Opin Cell Biol, 2010. 22(5): p. 677-89. 
132. Albini, A., et al., The "chemoinvasion assay": a tool to study tumor and 
endothelial cell invasion of basement membranes. Int J Dev Biol, 2004. 48(5-6): 
p. 563-71. 
133. Tomei, A.A., et al., Fluid flow regulates stromal cell organization and CCL21 
expression in a tissue-engineered lymph node microenvironment. J Immunol, 
2009. 183(7): p. 4273-83. 
134. Miteva, D.O., et al., Transmural flow modulates cell and fluid transport functions 
of lymphatic endothelium. Circ Res, 2010. 106(5): p. 920-31. 
135. Ohnishi, T., et al., A novel model of glioma cell invasion using organotypic brain 
slice culture. Cancer Res, 1998. 58(14): p. 2935-40. 
136. Yoshida, D., et al., Tracking cell invasion of human glioma cells and suppression 
by anti-matrix metalloproteinase agent in rodent brain-slice model. Brain Tumor 
Pathol, 2002. 19(2): p. 69-76. 
137. Nygaard, S.J., et al., Dynamic determination of human glioma invasion in vitro. J 
Neurosurg, 1998. 89(3): p. 441-7. 
138. Giese, A., et al., Glioma cell adhesion and migration on human brain sections. 
Anticancer Res, 1998. 18(4A): p. 2435-47. 
139. Pedersen, J.A., S. Lichter, and M.A. Swartz, Cells in 3D matrices under 
interstitial flow: effects of extracellular matrix alignment on cell shear stress and 
drag forces. J Biomech, 2010. 43(5): p. 900-5. 
140. Ng, C.P. and M.A. Swartz, Fibroblast alignment under interstitial fluid flow using 
a novel 3-D tissue culture model. Am J Physiol Heart Circ Physiol, 2003. 284(5): 
p. H1771-7. 
141. Haessler, U., et al., An agarose-based microfluidic platform with a gradient buffer 
for 3D chemotaxis studies. Biomed Microdevices, 2009. 11(4): p. 827-35. 
191 
 
142. Griffith, L.G. and M.A. Swartz, Capturing complex 3D tissue physiology in vitro. 
Nat Rev Mol Cell Biol, 2006. 7(3): p. 211-24. 
143. Bajetto, A., et al., Expression of CXC chemokine receptors 1-5 and their ligands 
in human glioma tissues: role of CXCR4 and SDF1 in glioma cell proliferation 
and migration. Neurochem Int, 2006. 49(5): p. 423-32. 
144. Kaczarek, E., et al., Dissecting glioma invasion: interrelation of adhesion, 
migration and intercellular contacts determine the invasive phenotype. Int J Dev 
Neurosci, 1999. 17(5-6): p. 625-41. 
145. Goldbrunner, R.H., J.J. Bernstein, and J.C. Tonn, ECM-mediated glioma cell 
invasion. Microsc Res Tech, 1998. 43(3): p. 250-7. 
146. Gimona, M., The microfilament system in the formation of invasive adhesions. 
Semin Cancer Biol, 2008. 18(1): p. 23-34. 
147. Hao, H., et al., Focal adhesion kinase as potential target for cancer therapy 
(Review). Oncol Rep, 2009. 22(5): p. 973-9. 
148. Courtneidge, S.A., et al., The SRC substrate Tks5, podosomes (invadopodia), and 
cancer cell invasion. Cold Spring Harb Symp Quant Biol, 2005. 70: p. 167-71. 
149. Friedl, P. and K. Wolf, Proteolytic interstitial cell migration: a five-step process. 
Cancer Metastasis Rev, 2009. 28(1-2): p. 129-35. 
150. Nakano, A., et al., Matrix metalloproteinases and tissue inhibitors of 
metalloproteinases in human gliomas. J Neurosurg, 1995. 83(2): p. 298-307. 
151. Chintala, S.K. and J.K. Rao, Invasion of human glioma: role of extracellular 
matrix proteins. Front Biosci, 1996. 1: p. d324-39. 
152. Rubenstein, B.M. and L.J. Kaufman, The role of extracellular matrix in glioma 
invasion: a cellular Potts model approach. Biophys J, 2008. 95(12): p. 5661-80. 
153. Uhm, J.H., et al., Mechanisms of glioma invasion: role of matrix-
metalloproteinases. Can J Neurol Sci, 1997. 24(1): p. 3-15. 
154. Jin, S.G., et al., The effect of hyaluronic Acid on the invasiveness of malignant 
glioma cells : comparison of invasion potential at hyaluronic Acid hydrogel and 
matrigel. J Korean Neurosurg Soc, 2009. 46(5): p. 472-8. 
155. Demchik, L.L., et al., Cathepsin B and glioma invasion. Int J Dev Neurosci, 1999. 
17(5-6): p. 483-94. 
192 
 
156. Goldbrunner, R.H., J.J. Bernstein, and J.C. Tonn, Cell-extracellular matrix 
interaction in glioma invasion. Acta Neurochir (Wien), 1999. 141(3): p. 295-305; 
discussion 304-5. 
157. Tysnes, B.B. and R. Mahesparan, Biological mechanisms of glioma invasion and 
potential therapeutic targets. J Neurooncol, 2001. 53(2): p. 129-47. 
158. Nobes, C.D. and A. Hall, Rho, rac, and cdc42 GTPases regulate the assembly of 
multimolecular focal complexes associated with actin stress fibers, lamellipodia, 
and filopodia. Cell, 1995. 81(1): p. 53-62. 
159. Gimona, M., et al., Assembly and biological role of podosomes and invadopodia. 
Curr Opin Cell Biol, 2008. 20(2): p. 235-41. 
160. Yamaguchi, H. and J. Condeelis, Regulation of the actin cytoskeleton in cancer 
cell migration and invasion. Biochim Biophys Acta, 2007. 1773(5): p. 642-52. 
161. dos Remedios, C.G., et al., Actin binding proteins: regulation of cytoskeletal 
microfilaments. Physiol Rev, 2003. 83(2): p. 433-73. 
162. Yamazaki, D., S. Kurisu, and T. Takenawa, Regulation of cancer cell motility 
through actin reorganization. Cancer Sci, 2005. 96(7): p. 379-86. 
163. Bubb, M.R., et al., Depolymerization of actin filaments by profilin. Effects of 
profilin on capping protein function. J Biol Chem, 2003. 278(27): p. 24629-35. 
164. Kwiatkowski, D.J., Functions of gelsolin: motility, signaling, apoptosis, cancer. 
Curr Opin Cell Biol, 1999. 11(1): p. 103-8. 
165. Bershadsky, A.D., et al., The state of actin assembly regulates actin and vinculin 
expression by a feedback loop. J Cell Sci, 1995. 108 ( Pt 3): p. 1183-93. 
166. Schmitt-Ney, M. and J.F. Habener, Cell-density-dependent regulation of actin 
gene expression due to changes in actin treadmilling. Exp Cell Res, 2004. 295(1): 
p. 236-44. 
167. Lyubimova, A., A.D. Bershadsky, and A. Ben-Ze'ev, Autoregulation of actin 
synthesis requires the 3'-UTR of actin mRNA and protects cells from actin 
overproduction. J Cell Biochem, 1999. 76(1): p. 1-12. 
168. Pendyala, S. and V. Natarajan, Redox regulation of Nox proteins. Respir Physiol 
Neurobiol, 2010. 174(3): p. 265-71. 
169. Brown, D.I. and K.K. Griendling, Nox proteins in signal transduction. Free Radic 
Biol Med, 2009. 47(9): p. 1239-53. 
193 
 
170. Chen, K., S.E. Craige, and J.F. Keaney, Jr., Downstream targets and intracellular 
compartmentalization in Nox signaling. Antioxid Redox Signal, 2009. 11(10): p. 
2467-80. 
171. Li, B., et al., NOX4 expression in human microglia leads to constitutive 
generation of reactive oxygen species and to constitutive IL-6 expression. J Innate 
Immun, 2009. 1(6): p. 570-81. 
172. Sorescu, D., et al., Superoxide production and expression of nox family proteins 
in human atherosclerosis. Circulation, 2002. 105(12): p. 1429-35. 
173. Griffith, B., et al., NOX enzymes and pulmonary disease. Antioxid Redox Signal, 
2009. 11(10): p. 2505-16. 
174. Sorce, S. and K.H. Krause, NOX enzymes in the central nervous system: from 
signaling to disease. Antioxid Redox Signal, 2009. 11(10): p. 2481-504. 
175. Goyal, P., et al., Identification of novel Nox4 splice variants with impact on ROS 
levels in E49 cells. Biochem Biophys Res Commun, 2005. 329(1): p. 32-9. 
176. Wu, W.S., The signaling mechanism of ROS in tumor progression. Cancer 
Metastasis Rev, 2006. 25(4): p. 695-705. 
177. Takada, Y. and B.B. Aggarwal, Flavopiridol inhibits NF-kappaB activation 
induced by various carcinogens and inflammatory agents through inhibition of 
IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, 
cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem, 2004. 279(6): p. 
4750-9. 
178. Shono, T., et al., Enhanced expression of NADPH oxidase Nox4 in human 
gliomas and its roles in cell proliferation and survival. Int J Cancer, 2008. 123(4): 
p. 787-92. 
179. Diaz, B., et al., Tks5-dependent, nox-mediated generation of reactive oxygen 
species is necessary for invadopodia formation. Sci Signal, 2009. 2(88): p. rE3. 
180. Chen, T.C., et al., Green tea epigallocatechin gallate enhances therapeutic 
efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett, 
2011. 302(2): p. 100-8. 
181. Groves, M.D., et al., Phase II trial of temozolomide plus marimastat for recurrent 
anaplastic gliomas: a relationship among efficacy, joint toxicity and 
anticonvulsant status. J Neurooncol, 2006. 80(1): p. 83-90. 
194 
 
182. Groves, M.D., et al., Phase II trial of temozolomide plus the matrix 
metalloproteinase inhibitor, marimastat, in recurrent and progressive 
glioblastoma multiforme. J Clin Oncol, 2002. 20(5): p. 1383-8. 
183. Lettau, I., et al., Matrix metalloproteinase-19 is highly expressed in astroglial 
tumors and promotes invasion of glioma cells. J Neuropathol Exp Neurol, 2010. 
69(3): p. 215-23. 
184. Pullen, N.A. and H.L. Fillmore, Induction of matrix metalloproteinase-1 and 
glioma cell motility by nitric oxide. J Neurooncol, 2010. 96(2): p. 201-9. 
185. Weinstein, I.B. and A. Joe, Oncogene addiction. Cancer Res, 2008. 68(9): p. 
3077-80; discussion 3080. 
186. Weinstein, I.B. and A.K. Joe, Mechanisms of disease: Oncogene addiction--a 
rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol, 2006. 
3(8): p. 448-57. 
187. Di, C., et al., Emerging therapeutic targets and agents for glioblastoma migrating 
cells. Anticancer Agents Med Chem, 2010. 10(7): p. 543-55. 
188. Glover, K.Y., R. Perez-Soler, and V.A. Papadimitradopoulou, A review of small-
molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in 
development for non-small cell lung cancer. Semin Oncol, 2004. 31(1 Suppl 1): p. 
83-92. 
189. de Groot, J.F., et al., Tumor invasion after treatment of glioblastoma with 
bevacizumab: radiographic and pathologic correlation in humans and mice. 
Neuro Oncol, 2010. 12(3): p. 233-42. 
190. Huang, P.H., et al., Quantitative analysis of EGFRvIII cellular signaling networks 
reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci 
U S A, 2007. 104(31): p. 12867-72. 
191. Takahashi, S., et al., Downregulation of uPARAP mediates cytoskeletal 
rearrangements and decreases invasion and migration properties in glioma cells. 
J Neurooncol, 2010. 
192. Zhang, B., et al., Reduction of Akt2 inhibits migration and invasion of glioma 
cells. Int J Cancer, 2009. 125(3): p. 585-95. 
193. Mayer, L.D., et al., Influence of vesicle size, lipid composition, and drug-to-lipid 
ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res, 
1989. 49(21): p. 5922-30. 
195 
 
194. Gabizon, A., et al., Pharmacokinetic and imaging studies in patients receiving a 
formulation of liposome-associated adriamycin. Br J Cancer, 1991. 64(6): p. 
1125-32. 
195. Papahadjopoulos, D., et al., Sterically stabilized liposomes: improvements in 
pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A, 
1991. 88(24): p. 11460-4. 
196. Gabizon, A., et al., Clinical studies of liposome-encapsulated doxorubicin. Acta 
Oncol, 1994. 33(7): p. 779-86. 
197. Ruoslahti, E., S.N. Bhatia, and M.J. Sailor, Targeting of drugs and nanoparticles 
to tumors. J Cell Biol, 2010. 188(6): p. 759-68. 
198. Cho, K., et al., Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer 
Res, 2008. 14(5): p. 1310-6. 
199. Pauwels, E.K. and P. Erba, Towards the use of nanoparticles in cancer therapy 
and imaging. Drug News Perspect, 2007. 20(4): p. 213-20. 
200. Hashizume, H., et al., Openings between defective endothelial cells explain tumor 
vessel leakiness. Am J Pathol, 2000. 156(4): p. 1363-80. 
201. Gulati, M., et al., Study of azathioprine encapsulation into liposomes. J 
Microencapsul, 1998. 15(4): p. 485-94. 
202. Moghimi, S.M., A.C. Hunter, and J.C. Murray, Long-circulating and target-
specific nanoparticles: theory to practice. Pharmacol Rev, 2001. 53(2): p. 283-
318. 
203. Zagzag, D., et al., Molecular events implicated in brain tumor angiogenesis and 
invasion. Pediatr Neurosurg, 2000. 33(1): p. 49-55. 
204. Maeda, H., The enhanced permeability and retention (EPR) effect in tumor 
vasculature: the key role of tumor-selective macromolecular drug targeting. Adv 
Enzyme Regul, 2001. 41: p. 189-207. 
205. Semple, S.C., A. Chonn, and P.R. Cullis, Interactions of liposomes and lipid-
based carrier systems with blood proteins: Relation to clearance behaviour in 
vivo. Advanced Drug Delivery Reviews, 1998. 32(1-2): p. 3-17. 
206. Zalutsky, M.R., Current status of therapy of solid tumors: brain tumor therapy. J 
Nucl Med, 2005. 46 Suppl 1: p. 151S-6S. 
196 
 
207. Bai, X., et al., Honokiol, a small molecular weight natural product, inhibits 
angiogenesis in vitro and tumor growth in vivo. J Biol Chem, 2003. 278(37): p. 
35501-7. 
208. Wolf, I., et al., Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth 
of breast cancer through induction of apoptosis and cell cycle arrest. Int J Oncol, 
2007. 30(6): p. 1529-37. 
209. Shigemura, K., et al., Honokiol, a natural plant product, inhibits the bone 
metastatic growth of human prostate cancer cells. Cancer, 2007. 109(7): p. 1279-
89. 
210. Fried, L.E. and J.L. Arbiser, Honokiol, a multifunctional antiangiogenic and 
antitumor agent. Antioxid Redox Signal, 2009. 11(5): p. 1139-48. 
211. Ahn, K.S., et al., Honokiol potentiates apoptosis, suppresses osteoclastogenesis, 
and inhibits invasion through modulation of nuclear factor-kappaB activation 
pathway. Mol Cancer Res, 2006. 4(9): p. 621-33. 
212. Rayet, B. and C. Gelinas, Aberrant rel/nfkb genes and activity in human cancer. 
Oncogene, 1999. 18(49): p. 6938-47. 
213. Pikarsky, E., et al., NF-kappaB functions as a tumour promoter in inflammation-
associated cancer. Nature, 2004. 431(7007): p. 461-6. 
214. Tertil, M., A. Jozkowicz, and J. Dulak, Oxidative stress in tumor angiogenesis- 
therapeutic targets. Curr Pharm Des, 2010. 16(35): p. 3877-94. 
215. Cooney, R.V., et al., Inhibition of cellular transformation by triphenylmethane: a 
novel chemopreventive agent. Carcinogenesis, 1992. 13(7): p. 1107-12. 
216. Salhia, B., et al., Molecular pathways triggering glioma cell invasion. Expert Rev 
Mol Diagn, 2006. 6(4): p. 613-26. 
217. Karumbaiah, L., et al., Targeted downregulation of N-acetylgalactosamine 4-
sulfate 6-O-sulfotransferase significantly mitigates chondroitin sulfate 
proteoglycan-mediated inhibition. Glia, 2011. 59(6): p. 981-96. 
218. Horowitz, A.T., Y. Barenholz, and A.A. Gabizon, In vitro cytotoxicity of 
liposome-encapsulated doxorubicin: dependence on liposome composition and 
drug release. Biochim Biophys Acta, 1992. 1109(2): p. 203-9. 
219. Broaddus, W.C., et al., Enhanced radiosensitivity of malignant glioma cells after 
adenoviral p53 transduction. J Neurosurg, 1999. 91(6): p. 997-1004. 
197 
 
220. Zhang, W., et al., Inhibition of human malignant glioma cell motility and invasion 
in vitro by hypericin, a potent protein kinase C inhibitor. Cancer Lett, 1997. 
120(1): p. 31-8. 
221. Bello, L., et al., Simultaneous inhibition of glioma angiogenesis, cell 
proliferation, and invasion by a naturally occurring fragment of human 
metalloproteinase-2. Cancer Res, 2001. 61(24): p. 8730-6. 
222. Zagzag, D., et al., Geldanamycin inhibits migration of glioma cells in vitro: a 
potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion. J 
Cell Physiol, 2003. 196(2): p. 394-402. 
223. Central Brain Tumor Registry of the United States Statistical Report: Primary 
Brain and Central Nervouse System Tumors Diagnosed in the United States in 
2004-2006. 2010, Central Brain Tumor Registry of the United States: Hinsdale, 
IL. 
224. Stupp, R., Malignant glioma: ESMO clinical recommendations for diagnosis, 
treatment and follow-up. Ann Oncol, 2007. 18 Suppl 2: p. ii69-70. 
225. Couldwell, W.T. and V.W. Yong, Glioma invasion. J Neurosurg, 2001. 95(3): p. 
379-80. 
226. Noha, M., et al., Suppression of cell invasion on human malignant glioma cell 
lines by a novel matrix-metalloproteinase inhibitor SI-27: in vitro study. J 
Neurooncol, 2000. 48(3): p. 217-23. 
227. Jung, Y.D. and L.M. Ellis, Inhibition of tumour invasion and angiogenesis by 
epigallocatechin gallate (EGCG), a major component of green tea. Int J Exp 
Pathol, 2001. 82(6): p. 309-16. 
228. Larson, D.A., et al., Phase II study of high central dose Gamma Knife 
radiosurgery and marimastat in patients with recurrent malignant glioma. Int J 
Radiat Oncol Biol Phys, 2002. 54(5): p. 1397-404. 
229. Wick, W., et al., Prevention of irradiation-induced glioma cell invasion by 
temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. 
Cancer Res, 2002. 62(6): p. 1915-9. 
230. Immordino, M.L., F. Dosio, and L. Cattel, Stealth liposomes: review of the basic 
science, rationale, and clinical applications, existing and potential. Int J 
Nanomedicine, 2006. 1(3): p. 297-315. 
198 
 
231. Yuan, F., et al., Microvascular permeability and interstitial penetration of 
sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res, 
1994. 54(13): p. 3352-6. 
232. Yuan, F., et al., Vascular permeability in a human tumor xenograft: molecular 
size dependence and cutoff size. Cancer Res, 1995. 55(17): p. 3752-6. 
233. Allen, T.M., Long-circulating (sterically stabilized) liposomes for targeted drug 
delivery. Trends Pharmacol Sci, 1994. 15(7): p. 215-20. 
234. Gabizon, A. and D. Papahadjopoulos, The role of surface charge and hydrophilic 
groups on liposome clearance in vivo. Biochim Biophys Acta, 1992. 1103(1): p. 
94-100. 
235. Gabizon, A., et al., Effect of liposome composition and other factors on the 
targeting of liposomes to experimental tumors: biodistribution and imaging 
studies. Cancer Res, 1990. 50(19): p. 6371-8. 
236. Fierz-David, H.E. and L. Blangey, Fundamental Process of Dye Chemistry. 1979, 
New York: Interscience Publishers. 
237. McNeeley, K.M., et al., Masking and triggered unmasking of targeting ligands on 
nanocarriers to improve drug delivery to brain tumors. Biomaterials, 2009. 
30(23-24): p. 3986-95. 
238. Singla, A.K., A. Garg, and D. Aggarwal, Paclitaxel and its formulations. Int J 
Pharm, 2002. 235(1-2): p. 179-92. 
239. Candolfi, M., et al., Intracranial glioblastoma models in preclinical neuro-
oncology: neuropathological characterization and tumor progression. J 
Neurooncol, 2007. 85(2): p. 133-48. 
240. Ji, Y., et al., Characterization of the tumor invasion area in the rat intracerebral 
glioma. J Neurooncol, 1996. 30(3): p. 189-97. 
241. Greish, K., Enhanced permeability and retention (EPR) effect for anticancer 
nanomedicine drug targeting. Methods Mol Biol, 2010. 624: p. 25-37. 
242. Dams, E.T., et al., Accelerated blood clearance and altered biodistribution of 
repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther, 
2000. 292(3): p. 1071-9. 
243. Kim, M.S., et al., Emodin suppresses hyaluronic acid-induced MMP-9 secretion 
and invasion of glioma cells. Int J Oncol, 2005. 27(3): p. 839-46. 
199 
 
244. Nowicki, M.O., et al., Lithium inhibits invasion of glioma cells; possible 
involvement of glycogen synthase kinase-3. Neuro Oncol, 2008. 10(5): p. 690-9. 
245. Seufert, S., et al., PPAR Gamma Activators: Off-Target Against Glioma Cell 
Migration and Brain Invasion. PPAR Res, 2008. 2008: p. 513943. 
246. Grommes, C., et al., Inhibition of in vivo glioma growth and invasion by 
peroxisome proliferator-activated receptor gamma agonist treatment. Mol 
Pharmacol, 2006. 70(5): p. 1524-33. 
247. Shen, J., et al., Marchantin C: a potential anti-invasion agent in glioma cells. 
Cancer Biol Ther, 2010. 9(1): p. 33-9. 
248. Olson, M.F. and E. Sahai, The actin cytoskeleton in cancer cell motility. Clin Exp 
Metastasis, 2009. 26(4): p. 273-87. 
249. Disanza, A., et al., Actin polymerization machinery: the finish line of signaling 
networks, the starting point of cellular movement. Cell Mol Life Sci, 2005. 62(9): 
p. 955-70. 
250. Hall, A. and C.D. Nobes, Rho GTPases: molecular switches that control the 
organization and dynamics of the actin cytoskeleton. Philos Trans R Soc Lond B 
Biol Sci, 2000. 355(1399): p. 965-70. 
251. Forget, M.A., et al., The expression of rho proteins decreases with human brain 
tumor progression: potential tumor markers. Clin Exp Metastasis, 2002. 19(1): p. 
9-15. 
252. Gebhardt, C., et al., S100A8 and S100A9 in inflammation and cancer. Biochem 
Pharmacol, 2006. 72(11): p. 1622-31. 
253. Hermani, A., et al., S100A8 and S100A9 activate MAP kinase and NF-kappaB 
signaling pathways and trigger translocation of RAGE in human prostate cancer 
cells. Exp Cell Res, 2006. 312(2): p. 184-97. 
254. Yong, H.Y. and A. Moon, Roles of calcium-binding proteins, S100A8 and 
S100A9, in invasive phenotype of human gastric cancer cells. Arch Pharm Res, 
2007. 30(1): p. 75-81. 
255. Kuzumaki, N., et al., [Tumor suppressive function of gelsolin]. Gan To Kagaku 
Ryoho, 1997. 24(11): p. 1436-41. 
256. Demuth, T. and M.E. Berens, Molecular mechanisms of glioma cell migration 
and invasion. J Neurooncol, 2004. 70(2): p. 217-28. 
200 
 
257. Mueller, M.M., T. Werbowetski, and R.F. Del Maestro, Soluble factors involved 
in glioma invasion. Acta Neurochir (Wien), 2003. 145(11): p. 999-1008. 
258. Hoelzinger, D.B., T. Demuth, and M.E. Berens, Autocrine factors that sustain 
glioma invasion and paracrine biology in the brain microenvironment. J Natl 
Cancer Inst, 2007. 99(21): p. 1583-93. 
259. Idani, H., et al., Intra-tumoral injection of doxorubicin (adriamycin) encapsulated 
in liposome inhibits tumor growth, prolongs survival time and is not associated 
with local or systemic side effects. Int J Cancer, 2000. 88(4): p. 645-51. 
260. Sugahara, T., et al., Posttherapeutic intraaxial brain tumor: the value of 
perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor 
recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J 
Neuroradiol, 2000. 21(5): p. 901-9. 
261. Apetoh, L., et al., Toll-like receptor 4-dependent contribution of the immune 
system to anticancer chemotherapy and radiotherapy. Nat Med, 2007. 13(9): p. 
1050-9. 
262. Zhang, H., G. Wang, and H. Yang, Drug delivery systems for differential release 
in combination therapy. Expert Opin Drug Deliv, 2011. 8(2): p. 171-90. 
263. Abe, T., et al., Expression of multidrug resistance protein gene in patients with 
glioma after chemotherapy. J Neurooncol, 1998. 40(1): p. 11-8. 
264. Ogawara, K., et al., In vivo anti-tumor effect of PEG liposomal doxorubicin 
(DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on 
vascular endothelial cells. J Control Release, 2009. 133(1): p. 4-10. 
265. Siegal, T., A. Horowitz, and A. Gabizon, Doxorubicin encapsulated in sterically 
stabilized liposomes for the treatment of a brain tumor model: biodistribution and 
therapeutic efficacy. J Neurosurg, 1995. 83(6): p. 1029-37. 
266. Sakakibara, T., et al., Doxorubicin encapsulated in sterically stabilized liposomes 
is superior to free drug or drug-containing conventional liposomes at suppressing 
growth and metastases of human lung tumor xenografts. Cancer Res, 1996. 
56(16): p. 3743-6. 
267. Tardi, P.G., N.L. Boman, and P.R. Cullis, Liposomal doxorubicin. J Drug Target, 
1996. 4(3): p. 129-40. 
268. Vaage, J., et al., Therapy of mouse mammary carcinomas with vincristine and 
doxorubicin encapsulated in sterically stabilized liposomes. Int J Cancer, 1993. 
54(6): p. 959-64. 
201 
 
269. Wu, J., et al., Reversal of multidrug resistance by transferrin-conjugated 
liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci, 
2007. 10(3): p. 350-7. 
270. Gaber, M.H., et al., Thermosensitive sterically stabilized liposomes: formulation 
and in vitro studies on mechanism of doxorubicin release by bovine serum and 
human plasma. Pharm Res, 1995. 12(10): p. 1407-16. 
271. Lasic, D.D., Doxorubicin in sterically stabilized liposomes. Nature, 1996. 
380(6574): p. 561-2. 
272. Onishi, M., et al., Angiogenesis and invasion in glioma. Brain Tumor Pathol, 
2011. 28(1): p. 13-24. 
273. Cheng, C.K., Q.W. Fan, and W.A. Weiss, PI3K signaling in glioma--animal 
models and therapeutic challenges. Brain Pathol, 2009. 19(1): p. 112-20. 
274. Engelman, J.A., Targeting PI3K signalling in cancer: opportunities, challenges 
and limitations. Nat Rev Cancer, 2009. 9(8): p. 550-62. 
275. Dhillon, A.S., et al., MAP kinase signalling pathways in cancer. Oncogene, 2007. 
26(22): p. 3279-90. 
276. Li, N. and M. Karin, Is NF-kappaB the sensor of oxidative stress? FASEB J, 
1999. 13(10): p. 1137-43. 
277. Tobar, N., et al., NOX4-dependent ROS production by stromal mammary cells 
modulates epithelial MCF-7 cell migration. Br J Cancer, 2010. 103(7): p. 1040-7. 
278. Takada, Y., et al., Flavopiridol suppresses tumor necrosis factor-induced 
activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated 
protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of 
antiapoptotic gene products, and enhances apoptosis through cytochrome c 
release and caspase activation in human myeloid cells. Mol Pharmacol, 2008. 
73(5): p. 1549-57. 
279. Martyn, K.D., et al., Functional analysis of Nox4 reveals unique characteristics 
compared to other NADPH oxidases. Cell Signal, 2006. 18(1): p. 69-82. 
280. von Lohneysen, K., et al., Mutational analysis reveals distinct features of the 
Nox4-p22 phox complex. J Biol Chem, 2008. 283(50): p. 35273-82. 
281. von Lohneysen, K., et al., Structural insights into Nox4 and Nox2: motifs involved 
in function and cellular localization. Mol Cell Biol, 2010. 30(4): p. 961-75. 
202 
 
282. Blouw, B., et al., A role for the podosome/invadopodia scaffold protein Tks5 in 
tumor growth in vivo. Eur J Cell Biol, 2008. 87(8-9): p. 555-67. 
283. Prados, M.D. and V. Levin, Biology and treatment of malignant glioma. Semin 
Oncol, 2000. 27(3 Suppl 6): p. 1-10. 
284. Kim, J.Y., et al., Src-mediated regulation of inflammatory responses by actin 
polymerization. Biochem Pharmacol, 2010. 79(3): p. 431-43. 
285. Manea, A., et al., Transcriptional regulation of NADPH oxidase isoforms, Nox1 
and Nox4, by nuclear factor-kappaB in human aortic smooth muscle cells. 
Biochem Biophys Res Commun, 2010. 396(4): p. 901-7. 
286. Manea, A., et al., Jak/STAT signaling pathway regulates nox1 and nox4-based 
NADPH oxidase in human aortic smooth muscle cells. Arterioscler Thromb Vasc 
Biol, 2010. 30(1): p. 105-12. 
287. Maurer, H.H., Screening procedures for simultaneous detection of several drug 
classes used for high throughput toxicological analyses and doping control. A 
review. Comb Chem High Throughput Screen, 2000. 3(6): p. 467-80. 
288. Terstappen, G.C. and A. Reggiani, In silico research in drug discovery. Trends 
Pharmacol Sci, 2001. 22(1): p. 23-6. 
289. Van Dyke, T. and T. Jacks, Cancer modeling in the modern era: progress and 
challenges. Cell, 2002. 108(2): p. 135-44. 
290. Friedl, P. and K. Wolf, Tumour-cell invasion and migration: diversity and escape 
mechanisms. Nat Rev Cancer, 2003. 3(5): p. 362-74. 
291. Wolf, K., et al., Compensation mechanism in tumor cell migration: mesenchymal-
amoeboid transition after blocking of pericellular proteolysis. J Cell Biol, 2003. 
160(2): p. 267-77. 
292. Liotta, L.A. and E. Kohn, Anoikis: cancer and the homeless cell. Nature, 2004. 
430(7003): p. 973-4. 
293. Mischel, P.S. and T.F. Cloughesy, Targeted molecular therapy of GBM. Brain 
Pathol, 2003. 13(1): p. 52-61. 
294. von Mehren, M., G.P. Adams, and L.M. Weiner, Monoclonal antibody therapy 
for cancer. Annu Rev Med, 2003. 54: p. 343-69. 
203 
 
295. Kinsella, P., M. Clynes, and V. Amberger-Murphy, Imatinib and docetaxel in 
combination can effectively inhibit glioma invasion in an in vitro 3D invasion 
assay. J Neurooncol, 2011. 101(2): p. 189-98. 
296. Raman, K. and B. Kuberan, Click-xylosides mitigate glioma cell invasion in vitro. 
Mol Biosyst, 2010. 6(10): p. 1800-2. 
297. Gessler, F., et al., Inhibition of tissue factor/protease-activated receptor-2 
signaling limits proliferation, migration and invasion of malignant glioma cells. 
Neuroscience, 2010. 165(4): p. 1312-22. 
298. Lim, Y.C., et al., (-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced 
invasion and metastasis in hypopharyngeal carcinoma cells. Cancer Lett, 2008. 
271(1): p. 140-52. 
299. Charrois, G.J. and T.M. Allen, Multiple injections of pegylated liposomal 
Doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther, 
2003. 306(3): p. 1058-67. 
300. Hsu, M.J. and R.L. Juliano, Interactions of liposomes with the reticuloendothelial 
system. II: Nonspecific and receptor-mediated uptake of liposomes by mouse 
peritoneal macrophages. Biochim Biophys Acta, 1982. 720(4): p. 411-9. 
301. Ellens, H., E. Mayhew, and Y.M. Rustum, Reversible depression of the 
reticuloendothelial system by liposomes. Biochim Biophys Acta, 1982. 714(3): p. 
479-85. 
302. Hu, B., et al., Angiopoietin-2 induces human glioma invasion through the 
activation of matrix metalloprotease-2. Proc Natl Acad Sci U S A, 2003. 100(15): 
p. 8904-9. 
303. Netti, P.A., et al., Enhancement of fluid filtration across tumor vessels: 
implication for delivery of macromolecules. Proc Natl Acad Sci U S A, 1999. 
96(6): p. 3137-42. 
304. Zitvogel, L., et al., Immunological aspects of cancer chemotherapy. Nat Rev 
Immunol, 2008. 8(1): p. 59-73. 
305. Baumgartner, G., et al., The impact of extracellular matrix on the 
chemoresistance of solid tumors--experimental and clinical results of 
hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett, 1998. 131(1): 
p. 85-99. 
306. Abstracts from the 15th Annual Meeting of the Society for Neuro-Oncology. in 
Society for Neuro-oncology. 2010. Montreal, Quebec, Canada: Neuro-oncology. 
204 
 
307. Parker, R.J., S.M. Sieber, and J.N. Weinstein, Effect of liposome encapsulation of 
a fluorescent dye on its uptake by the lymphatics of the rat. Pharmacology, 1981. 
23(3): p. 128-36. 
308. Sumer, B. and J. Gao, Theranostic nanomedicine for cancer. Nanomedicine 
(Lond), 2008. 3(2): p. 137-40. 
309. Vajkoczy, P., et al., Microtumor growth initiates angiogenic sprouting with 
simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin 
Invest, 2002. 109(6): p. 777-85. 
310. Forsyth, P.A., et al., Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and 
membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different 
aspects of the pathophysiology of malignant gliomas. British Journal Of Cancer, 
1999. 79(11-12): p. 1828-1835. 
311. Vajkoczy, P., et al., Microtumor growth initiates angiogenic sprouting with 
simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. The 
Journal Of Clinical Investigation, 2002. 109(6): p. 777-785. 
312. Cho, K., et al., Therapeutic Nanoparticles for Drug Delivery in Cancer. Clinical 
Cancer Research, 2008. 14(5): p. 1310-1316. 
313. Kim, K.Y., Nanotechnology platforms and physiological challenges for cancer 
therapeutics. Nanomedicine: Nanotechnology, Biology and Medicine, 2007. 3(2): 
p. 103-110. 
314. Jain, R.K., et al., Angiogenesis in brain tumours. Nat Rev Neurosci, 2007. 8(8): p. 
610-622. 
315. Ghaghada, K.B., et al., New Dual Mode Gadolinium Nanoparticle Contrast Agent 
for Magnetic Resonance Imaging. PLoS ONE, 2009. 4(10): p. e7628. 
316. OGAN, M.D., et al., Albumin Labeled with Gd-DTPA: An Intravascular 
Contrast-Enhancing Agent for Magnetic Resonance Blood Pool Imaging: 
Preparation and Characterization. Investigative Radiology, 1987. 22(8): p. 665-
671. 
317. Daldrup, H., et al., Correlation of dynamic contrast-enhanced magnetic 
resonance imaging with histologic tumor grade: comparison of macromolecular 
and small-molecular contrast media. Pediatric Radiology, 1998. 28(2): p. 67-78. 
318. Woodle, M.C., M.S. Newman, and P.K. Working, Biological Properties of 
Sterically Stabilized Liposomes, in Stealth Liposomes, D.D. Lasic and F. Martin, 
Editors. 1995, Taylor & Francis Inc: Boca Raton. 
205 
 
319. Gossmann, A., et al., Dynamic contrast-enhanced magnetic resonance imaging as 
a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft 
model of glioblastoma multiforme. Journal of Magnetic Resonance Imaging, 
2002. 15(3): p. 233-240. 
320. Kim, M.S., et al., Emodin suppresses hyaluronic acid-induced MMP-9 secretion 
and invasion of glioma cells. International Journal of Oncology, 2005. 27(3): p. 
839-846. 
321. Norden, A.D., et al., Bevacizumab for recurrent malignant gliomas: efficacy, 
toxicity, and patterns of recurrence. Neurology, 2008. 70(10): p. 779-787. 
322. Dunn, J., et al., Extent of MGMT promoter methylation correlates with outcome in 
glioblastomas given temozolomide and radiotherapy. Br J Cancer, 2009. 101(1): 
p. 124-31. 
323. Sadones, J., et al., MGMT promoter hypermethylation correlates with a survival 
benefit from temozolomide in patients with recurrent anaplastic astrocytoma but 
not glioblastoma. Eur J Cancer, 2009. 45(1): p. 146-53. 
324. Kim, K., et al., Epidermal growth factor receptor vIII expression in U87 
glioblastoma cells alters their proteasome composition, function, and response to 
irradiation. Mol Cancer Res, 2008. 6(3): p. 426-34. 
325. Giese, A., Glioma invasion--pattern of dissemination by mechanisms of invasion 
and surgical intervention, pattern of gene expression and its regulatory control by 
tumorsuppressor p53 and proto-oncogene ETS-1. Acta Neurochir Suppl, 2003. 
88: p. 153-62. 
326. Tonn, J.C. and R. Goldbrunner, Mechanisms of glioma cell invasion. Acta 
Neurochir Suppl, 2003. 88: p. 163-7. 
327. Tuettenberg, J., et al., Recurrence pattern in glioblastoma multiforme patients 
treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol, 2009. 
135(9): p. 1239-44. 
328. Giese, A., et al., Migration of human glioma cells on myelin. Neurosurgery, 1996. 
38(4): p. 755-64. 
329. Lazarini, F., et al., Role of the alpha-chemokine stromal cell-derived factor (SDF-
1) in the developing and mature central nervous system. Glia, 2003. 42(2): p. 139-
48. 
330. Teicher, B.A. and S.P. Fricker, CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin 
Cancer Res, 2010. 16(11): p. 2927-31. 
206 
 
331. Ehtesham, M., et al., CXCR4 expression mediates glioma cell invasiveness. 
Oncogene, 2006. 25(19): p. 2801-6. 
332. Salmaggi, A., et al., CXCL12 expression is predictive of a shorter time to tumor 
progression in low-grade glioma: a single-institution study in 50 patients. J 
Neurooncol, 2005. 74(3): p. 287-93. 
333. Woerner, B.M., et al., Widespread CXCR4 activation in astrocytomas revealed by 
phospho-CXCR4-specific antibodies. Cancer Res, 2005. 65(24): p. 11392-9. 
334. Fleury, M.E., K.C. Boardman, and M.A. Swartz, Autologous morphogen 
gradients by subtle interstitial flow and matrix interactions. Biophys J, 2006. 
91(1): p. 113-21. 
335. Shields, J.D., et al., Autologous chemotaxis as a mechanism of tumor cell homing 
to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell, 
2007. 11(6): p. 526-38. 
336. Randolph, G.J., V. Angeli, and M.A. Swartz, Dendritic-cell trafficking to lymph 
nodes through lymphatic vessels. Nat Rev Immunol, 2005. 5(8): p. 617-28. 
337. Shieh, A.C., et al., Tumor cell invasion is promoted by interstitial flow-induced 
matrix priming by stromal fibroblasts. Cancer Res, 2011. 71(3): p. 790-800. 
338. Abbott, N.J., Evidence for bulk flow of brain interstitial fluid: significance for 
physiology and pathology. Neurochem Int, 2004. 45(4): p. 545-52. 
339. Sawamoto, K., et al., New neurons follow the flow of cerebrospinal fluid in the 
adult brain. Science, 2006. 311(5761): p. 629-32. 
340. Rosenberg, G.A., W.T. Kyner, and E. Estrada, Bulk flow of brain interstitial fluid 
under normal and hyperosmolar conditions. Am J Physiol, 1980. 238(1): p. F42-
9. 
341. Reulen, H.J., et al., Clearance of edema fluid into cerebrospinal fluid. A 
mechanism for resolution of vasogenic brain edema. J Neurosurg, 1978. 48(5): p. 
754-64. 
342. Ramnarayan, R., et al., Overall survival in patients with malignant glioma may be 
significantly longer with tumors located in deep grey matter. J Neurol Sci, 2007. 
260(1-2): p. 49-56. 
343. Reiss, K., et al., Stromal cell-derived factor 1 is secreted by meningeal cells and 
acts as chemotactic factor on neuronal stem cells of the cerebellar external 
granular layer. Neuroscience, 2002. 115(1): p. 295-305. 
207 
 
344. Wang, T.W. and M. Spector, Development of hyaluronic acid-based scaffolds for 
brain tissue engineering. Acta Biomater, 2009. 5(7): p. 2371-84. 
345. Saria, A. and J.M. Lundberg, Evans blue fluorescence: quantitative and 
morphological evaluation of vascular permeability in animal tissues. J Neurosci 
Methods, 1983. 8(1): p. 41-9. 
346. do Carmo, A., et al., CXCL12/CXCR4 promotes motility and proliferation of 
glioma cells. Cancer Biol Ther, 2010. 9(1): p. 56-65. 
347. Zhang, J., S. Sarkar, and V.W. Yong, The chemokine stromal cell derived factor-1 
(CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase. 
Carcinogenesis, 2005. 26(12): p. 2069-77. 
348. Rubin, J.B., et al., A small-molecule antagonist of CXCR4 inhibits intracranial 
growth of primary brain tumors. Proc Natl Acad Sci U S A, 2003. 100(23): p. 
13513-8. 
349. Ping, Y.F., et al., [Activation of CXCR4 in human glioma stem cells promotes 
tumor angiogenesis]. Zhonghua Bing Li Xue Za Zhi, 2007. 36(3): p. 179-83. 
350. Yang, S.X., et al., Activation of chemokine receptor CXCR4 in malignant glioma 
cells promotes the production of vascular endothelial growth factor. Biochem 
Biophys Res Commun, 2005. 335(2): p. 523-8. 
351. Ng, C.P. and M.A. Swartz, Mechanisms of interstitial flow-induced remodeling of 
fibroblast-collagen cultures. Ann Biomed Eng, 2006. 34(3): p. 446-54. 
352. Schneider, I.C. and J.M. Haugh, Quantitative elucidation of a distinct spatial 
gradient-sensing mechanism in fibroblasts. J Cell Biol, 2005. 171(5): p. 883-92. 
353. Li Jeon, N., et al., Neutrophil chemotaxis in linear and complex gradients of 
interleukin-8 formed in a microfabricated device. Nat Biotechnol, 2002. 20(8): p. 
826-30. 
354. Hong, X., et al., SDF-1 and CXCR4 are up-regulated by VEGF and contribute to 
glioma cell invasion. Cancer Lett, 2006. 236(1): p. 39-45. 
355. Souza, G.R., et al., Three-dimensional tissue culture based on magnetic cell 
levitation. Nat Nanotechnol, 2010. 5(4): p. 291-6. 
356. Swartz, M.A., J.A. Hubbell, and S.T. Reddy, Lymphatic drainage function and its 
immunological implications: from dendritic cell homing to vaccine design. Semin 
Immunol, 2008. 20(2): p. 147-56. 
208 
 
357. Boardman, K.C. and M.A. Swartz, Interstitial flow as a guide for 
lymphangiogenesis. Circ Res, 2003. 92(7): p. 801-8. 
358. Zhou, Y., et al., CXCR4 is a major chemokine receptor on glioma cells and 
mediates their survival. J Biol Chem, 2002. 277(51): p. 49481-7. 
359. Luetmer, P.H., et al., Measurement of cerebrospinal fluid flow at the cerebral 
aqueduct by use of phase-contrast magnetic resonance imaging: technique 
validation and utility in diagnosing idiopathic normal pressure hydrocephalus. 






Jennifer Megan Munson was born in Marietta, GA on November 17, 1983 to 
Chris and Joan Munson. After completing an International Baccalaureate degree at 
Campbell High School in Smyrna, GA, she attended Tulane University in New Orleans, 
LA. She graduated with a bachelor’s of science in Chemical Engineering and 
Neuroscience in 2006. She then worked at both Genentech in South San Francisco, CA in 
cell culture process development until Fall 2007 when she began attending graduate 
school at Georgia Tech. During her time at Georgia Tech, she spent ten months abroad in 
Lausanne, Switzerland on a Fulbright Fellowship studying the effects of interstitial flow 
on glioma invasion. She currently lives in Atlanta, GA with her two cats, Pie and Bean, 
and her fiancé, Charles. She enjoys swimming, reading children’s novels, and traveling in 
her free time.  
 
 
